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CHAPTER 1 
Introduction 

Introduction 
Background 
Systemic hypertension is one of the most common pathological conditions 
in Westernized societies with an estimated prevalence of up to 25 % !. The 
individual risk of morbidity and mortality associated with hypertension 
increases progressively with higher blood pressure levels, but the main 
burden of this illness arises from the masses of people with only minimally 
elevated blood pressure2. Reduction of the incidence of the sequelae of 
hypertension in individuals will depend mainly on drug treatment, because 
non-pharmacologic interventions appear to be considerably less effective in 
lowering blood pressure3. Over the past 30 years, protective effects of 
antihypertensive drugs have been demonstrated for ever lower diastolic blood 
pressures, the latest trials using 90 mmHg as the threshold for inclusion4,5. A 
growing part of the population thus seems to be eligible for antihypertensive 
treatment, although the individual benefit will be lower at lower blood 
pressure levels. The many possible disadvantages of treatment and even of 
the diagnosis hypertension could thus outweigh the benefits. Kaplan therefore 
broadened a statement of Rose6 for a conceptual definition of hypertension7: 
"that level of blood pressure at which the benefits (minus the risks and costs) 
of action exceed the risks and costs (minus the benefits) of inaction". Thus, 
the more we reduce the disadvantages of treatment, the larger the proportion 
of the population which can have benefit from it. A better understanding of 
the mode of action of specific drugs could lead to more rational choices in 
individual patients and hopefully a better control of side effects. In this 
thesis, we have studied two intriguing and at first sight opposite effects of 
calcium entry blockers, namely their natriuretic action and their propensity to 
cause edema formation. 
General aspects of calcium entry blockers 
Calcium entry blockers are a chemically heterogeneous class of drugs which 
share the ability to inhibit calcium influx into vascular smooth muscle cells, 
myocardial contractile cells, and conducting cells of the heart8. In vitro, the 
effects of these agents could be reversed by calcium ions, which led 
Fleckenstein to propose the term calcium antagonists9. Although this term is 
still widely used, the denomination calcium entry blockers (СЕВ) seems more 
appropriate. Intracellular free calcium plays an essential role in many cell 
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functions including muscle contraction. Its concentration can be increased by 
release from intracellular stores, in particular the sarcoplasmatic reticulum, 
and by calcium influx through special calcium channels in the plasma 
membrane which itself is almost impermeable for calcium ions8. Calcium 
channels can be opened either by depolarisation (voltage operated calcium 
channels) or by hormones such as norepinephrine and angiotensin II (receptor 
operated calcium channels). These calcium channels play an important 
physiologic role in excitation-contraction coupling processes in vascular 
smooth muscle cells and hence regulate vascular tone and peripheral 
resistance. СЕВ block the voltage operated channels and thereby induce 
vasodilation and blood pressure reduction10. The voltage operated calcium 
channel is a protein structure which transverses the lipid bilayer of the 
plasma membrane. It has been isolated from skeletal muscle and appears to 
be composed of four subunits (αϊ ,α2/δ , j3, 7)11· The different classes of 
СЕВ bind to specific receptor domains of the ori-subunit, a 165 kDa protein, 
which by itself is capable of calcium conduction11. However, both binding of 
СЕВ and conduction of calcium are greatly influenced by the other three 
subunits. Calcium channels in heart and vascular smooth muscle cells are less 
accessible than in skeletal muscle, but αϊ and a2 subunits have been iden­
tified in these tissues. Very recently, also β subunits were demonstrated in 
the human heart12. Molecular cloning techniques have revealed a great 
diversity among calcium channels, arising from multiple genes and alternative 
splicing in gene products13. Thus, with the anticipation of specific phenotypes 
of calcium channels in different tissues, it is not surprising that the 
chemically heterogeneous СЕВ and even different drugs within one class 
exhibit a wide variety of affinity for the respective target tissues. Three 
classes of СЕВ, with each their own receptor binding site11, can be used as 
antihypertensive drugs: the dihydropyridines or nifedipine-like drugs, the 
diphenylalkylamines or verapamil-like drugs, and the benzothiazepines or 
diltiazem-like drugs. In contrast to the latter two classes, dihydropyridines do 
not exhibit negative chronotropic or dromotropic effects at the doses that are 
used in humans14. Moreover, nifedipine and particularly the newer 
dihydropyridines such as felodipine have a high vascular selectivity15 and 
hence a more specific vasodilatory action with less negative inotropic effects. 
Such potent arteriolar vasodilators might be ideal antihypertensive drugs 
because they can correct the elevated peripheral resistance which 
characterizes established hypertension16. However, when using the directly 
acting vasodilators such as diazoxide and minoxidil, the decrease in blood 
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pressure is partly offset by both an increase in cardiac output resulting from 
activation of the baroreceptor reflex and renal sodium retention17. 
Dihydropyridine СЕВ also activate the baroreceptor reflex18, but the degree 
of activation appears to be less than with other vasodilators10 and might be 
largely prevented by an administration schedule which results in a slow, 
gradual rise of plasma drug levels19. Chronic treatment with СЕВ even resets 
the baroreceptor reflex within one week, thus allowing sustained blood 
pressure reduction without persistent tachycardia18-20. 
Natriuretic effects of calcium entry blockers 
The compensatory renal sodium retention that is observed during treatment 
with directly acting vasodilators21,22 can be explained, according to Guyton, 
by the pressure-natriuresis relationship which is determined by the kidneys23: 
at a fixed sodium intake, a decrease in blood pressure will lead to sodium 
retention until the equilibrium pressure, which belongs to that sodium intake, 
is restored. In this perspective, only a concomitant influence of an 
antihypertensive drug on the kidneys, which changes the pressure-natriuresis 
relationship, can prevent sodium retention when blood pressure is reduced. 
Directly acting vasodilators apparently lack such an effect. It is therefore 
quite remarkable and of great clinical importance that СЕВ change the 
pressure-natriuresis relationship in such a way that blood pressure is reduced 
without sodium retention24. СЕВ and directly acting vasodilators indeed have 
opposite effects on renal sodium excretion, as has been demonstrated nicely 
in salt-loaded normotensive and hypertensive rats where minoxidil induced 
sodium retention in sharp contrast to the acute natriuresis with equipotent 
hypotensive doses of the dihydropyridine nitrendipine25. In humans, an acute 
natriuretic effect of nifedipine was already demonstrated in 197226, but it took 
10 years before СЕВ received serious attention as effective vasodilators 
devoid of sodium retaining properties27. The acute natriuretic action of СЕВ 
was later confirmed in many studies in healthy volunteers and hypertensive 
patients as reviewed by others28'29. Only very high doses of СЕВ which 
decrease blood pressure more than 20 % can induce sodium retention30,31, 
probably by reducing renal perfusion pressure below the autoregulation limit 
for glomerular filtration. The natriuretic effect of СЕВ thus has been well 
established, but the mechanisms responsible for this effect are still largely 
unknown29. 
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Although СЕВ induce diuresis and natriuresis, they lack all possible side 
effects of diuretics. СЕВ do not cause an increase of urinary potassium 
excretion28, and the use of these drugs is therefore not associated with 
hypokalemia. A possible explanation for this beneficial effect might be that 
СЕВ can inhibit aldosterone release by the adrenal glands32 in contrast to 
most diuretics. СЕВ do not induce hyperuricemia33. They can even increase 
urinary urate excretion27,34 probably as a consequence of decreased proximal 
tubular sodium reabsorption35. The usual clinical dosages of СЕВ also induce 
no or only minor, transient changes of lipid and glucose homeostasis36, 
despite the fact that insulin release partly depends on calcium influx. 
Previous work from our department has demonstrated the effectiveness of 
felodipine in treating hypertension in patients with moderate to severe renal 
insufficiency37. In such patients, most СЕВ can be used without major dose 
adjustments, because degradation of these lipophilic and highly protein bound 
drugs occurs almost exclusively through metabolisation in the liver10·38. 
Clearance of the active drug therefore does not depend on renal function. In 
patients with renal insufficiency, sodium and water retention can be a major 
problem and probably contributes to the occurrence of hypertension as 
indicated by animal studies39. Under these circumstances, a natriuretic effect 
of a vasodilator might be of special value. 
The acute sodium losses with СЕВ appear to be maintained on the long 
term, as indicated by sodium balance studies after initiation or 
discontinuation of these drugs 40,41. This chronic sodium loss has initiated the 
discussion whether sodium restriction and/or diuretics will augment the 
antihypertensive effects of СЕВ42·43. Experimental evidence even supports an 
enhanced antihypertensive effect of СЕВ during high salt intake, which might 
be explained by a greater natriuretic effect44 or an enhanced reactivity of 
smooth muscle cells during high salt intake45. 
Edema formation with calcium entry blockers 
In view of their natriuretic effect, it is quite surprising that ankle edema is 
one of the major side effects of СЕВ with an estimated incidence of up to 
10 % for the dihydropyridines10. The higher incidence with dihydropyridines 
than with other classes of СЕВ suggests a relation with the higher vascular 
selectivity and hence the more pronounced peripheral vasodilating effects of 
this class of СЕВ. Edema formation is also a common side effect of other 
12 
Introduction 
potent arteriolar vasodilators such as minoxidil21 and has there been ascribed 
to renal sodium retention secondary to blood pressure reduction17. However, 
the natriuretic effects of СЕВ have cast doubt on this explanation. Therefore, 
it has been suggested that ankle edema with СЕВ and possibly also with other 
arteriolar vasodilators is a direct, local consequence of the peripheral 
vasodilation and thus precedes sodium retention, if that occurs. 
Outline of the thesis 
In the first part of this thesis (chapters 2-5), we have evaluated several 
possible mechanisms that might explain the natriuretic effect of СЕВ. To that 
end, several renal clearance studies with continuous felodipine infusion were 
performed in healthy volunteers. Chapter 2 discusses the possibility that the 
natriuretic action of felodipine is due to reversal of the sodium retaining 
effect of angiotensin-II. This hypothesis originated from previous work in our 
department that had demonstrated that felodipine prevented the sodium 
retention of exogenous angiotensin-II46. As a logical extension to these 
observations, we have evaluated the possibility of a similar interaction 
between СЕВ and endogenous angiotensin-II. Subsequently, we have studied 
the effects of felodipine on urinary potassium excretion, and more 
specifically the role of aldosterone in the remarkable absence of kaliuresis 
during CEB-induced natriuresis. Finally, the role of the intrarenal natriuretic 
hormone dopamine in the natriuretic action of СЕВ was studied. 
The second part of the thesis (chapters 6 and 7) describes two conditions in 
hypertensive patients in which the natriuretic effects of СЕВ might play a 
special role. First, we studied whether felodipine also induced natriuresis in 
hypertensive patients with renal disease and different degrees of renal 
insufficiency. Next, the value of sodium restriction in the antihypertensive 
treatment with СЕВ was determined in patients with essential hypertension. 
The final part of the thesis (chapters 8 and 9) focuses on the edema 
formation with СЕВ and other vasodilators. A new, accurate method for 
measuring foot volume as an exact measure for the degree of ankle edema is 
described. Subsequently, we studied the acute effects of nifedipine and 
diazoxide on foot volume and natriuresis in healthy volunteers. 
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ABSTRACT 
Felodipine induces natriuresis, possibly by renal hemodynamic 
and/or tubular effects. Theoretically, reversal of the sodium-
retaining effect of angiotensin-II (Ang II) could be involved. 
Therefore, we administered felodipine during Ang II infusion and 
during suppression of endogenous Ang II production in two 
double-blind studies in healthy volunteers. 
First, a gradually increasing dose of Ang II was infused during 
felodipine or solvent infusion. Before starting Ang II, felodipine 
had lowered renal vascular resistance (RVR) and filtration 
fraction (FF), and simultaneously increased ClNa. The Ang II-
induced rise of mean arterial pressure (MAP) and renal 
vasoconstriction was partly antagonized and the falls in 
glomerular filtration rate (GFR) and ClNa completely abolished by 
felodipine. The combination of felodipine and 3.0 ng/kg/min 
Ang II even enhanced natriuresis. 
Second, felodipine or solvent was infused after one week of 
pretreatment with placebo or the angiotensin converting enzyme 
(ACE) inhibitor ramipril, which reduced MAP and induced renal 
vasodilation. Ramipril pretreatment did not influence significantly 
the blood pressure reduction, renal vasodilation, and natriuresis 
caused by felodipine. 
In conclusion, it seems unlikely that the natriuretic effect of 
felodipine is due to interference with renal effects of endogenous 
Ang II. The fact that felodipine reverses sodium retention on 
exogenous Ang II may be explained by interference with 
systemic and renal hemodynamic effects specific of exogenous 
Ang II. 
1Θ 
Angiotensin II and natriuresis onfelodipine 
INTRODUCTION 
Dihydropyridine calcium entry blockers such as felodipine induce vasodilation 
and have a powerful antihypertensive effect1. In contrast to the sodium-retaining 
effect of other vasodilating drugs2, calcium entry blockers of different chemical 
classes all have an acute natriuretic effect3, possibly related to their common 
ability to block the voltage-dependent calcium channel. As this natriuresis is not 
accompanied by consistent changes in glomerular filtration rate (GFR)4, a 
decrease in tubular sodium reabsorption must be assumed. Micropuncture 
studies in whole animals have localized the natriuretic effect of calcium entry 
blockers to the proximal tubule during hydropenia5,6 and the distal tubule during 
salt loading7"9. Clearance studies in humans suggest both a proximal and distal 
tubular site of action1011. Theoretically, a decrease in tubular sodium 
reabsorption on calcium entry blockers could be due to a direct effect on sodium 
transport in tubular cells, an indirect effect mediated through changes in renal 
hemodynamics, or an indirect effect mediated through an interaction with one 
of the sodium-retaining or natriuretic hormones. 
In favor of a direct tubular effect, it has been shown that calcium entry 
blockers decrease proximal tubular fluid reabsorption during microperfusion12 
and also inhibit sodium reabsorption in both isolated perfused proximal tubules 
of rabbits13 and in the isolated toad urinary bladder14,15, a model for distal renal 
tubular function. In accordance with the supposed in vivo site of action of 
calcium entry blockers, this direct effect was more pronounced when the drug 
was given at the peritubular12 and the serosal14 side. However, a direct effect on 
renal tubular cells cannot be understood readily, since voltage-operated calcium 
channels have not, as yet, been identified in renal tubular cells16 and also since 
a decrease in cytosolic calcium is expected to enhance sodium reabsorption17. 
Moreover, the very high doses (10~4 to ΙΟ"5 M) used in these studies make it 
difficult to translate the results to man, where indirect mechanisms could be 
equally or even more important. 
In most studies in man18, renal hemodynamic changes favoring natriuresis 
could explain at least part of the proximal tubular effect. However, in dogs, 
calcium entry blockers also induced natriuresis when an aortic clamp prevented 
any rise in renal blood flow (RBF)6,19, suggesting that changes in renal 
hemodynamics cannot be the only factor responsible for the natriuretic effect. 
Therefore, an interaction of calcium entry blockers with one of the sodium-
retaining or natriuretic hormones could be involved as well. As selective 
administration of a calcium entry blocker into one renal artery increases sodium 
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excretion only in the corresponding kidney20, it seems unlikely that a change in 
systemic secretion of hormones such as ANP plays a major role in the 
natriuretic effect. Thus, interference with the local, intrarenal secretion of a 
hormone such as angiotensin II (Ang II)21·22, or inhibition of the renal effect of 
this hormone could be involved. Blockade of the physiologic effects of Ang II 
results in renal vasodilation and a decrease in proximal and distal tubular sodium 
reabsorption, effects comparable to the renal actions of calcium entry blockers. 
Moreover, many of the physiologic effects of Ang II depend on the availability 
of intracellular free calcium23. In fact, in animals, calcium entry blockers can 
prevent both the decrease in renal blood flow and the sodium retention induced 
by exogenous Ang n14,24"26. Therefore, an antagonism of the renal effects of 
Ang II could be responsible for the natriuretic effect of felodipine. To evaluate 
this hypothesis, we studied the natriuretic effect of felodipine in healthy 
volunteers during concomitant infusion with Ang II and also after pretreatment 
with the angiotensin converting enzyme (ACE) inhibitor ramipril. 
METHODS 
The interactions between felodipine and Ang II (study A) and between 
felodipine and the ACE inhibitor ramipril (study B) were examined in two 
groups of 12 healthy male volunteers, aged 21-35 years. All participants were 
free of medication, had normal kidney function, and had a blood pressure below 
140/90 mm Hg. Dietary sodium intake was restricted to approximately 100 
mmol per day in the week preceding each infusion experiment. 
Study A 
In a double-blind, randomized, crossover fashion, felodipine and placebo 
(solvent) were infused for 300 minutes on two separate days, with an interval 
washout period of three weeks. During ongoing felodipine or solvent infusion, 
a gradually increasing dose of the Ang II analogue va^-angiotensin-II-asp1-/?-
amide (HypertensinR, Ciba Geigy) was given for 120 minutes. Felodipine was 
infused at a rate of 9 /xg/minute for the first 40 minutes followed by 6.75 
/zg/minute for the remaining 260 minutes. One hundred and forty minutes after 
the start of felodipine or solvent, Ang II was given in increasing doses of 0.3, 
1.0 and 3.0 ng/kg/min in periods lasting 40 minutes each. Moderate water 
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diuresis was established by an oral water load of 625 ml before the experiment 
and was maintained by infusion of 400 ml of 0.25 % NaCI in 3.3 % glucose per 
hour. Two urine collections of 40 minutes were made before the Ang II 
infusion, one during each dose of Ang II, and one after stopping the Ang II 
infusion. Blood pressure was measured by Arteriosonde (model 1225). 
Study В 
In a double-blind, randomized, crossover fashion, felodipine was infused for 
200 minutes after seven days of oral pretreatment with ramipril, 5 mg twice 
daily. In two control experiments, felodipine was infused after one week of oral 
placebo and solvent was infused after ramipril. Washout periods lasted at least 
three weeks. Felodipine was infused at a rate of 0.15 μg/kg/min (mean 11 
μg/min) for the first 40 minutes followed by 0.10 ¿ig/kg/min (mean 7.4 /xg/min) 
for the remaining 160 minutes. Maximal water diuresis was induced by an oral 
water load of 25 ml/kg and was maintained by infusion of 400 ml of 0.25 % 
NaCI in 3.3 % glucose per hour and by oral replacement of urinary losses in 
excess of this infusion rate. Two urine collections of 40 minutes were made 
before and five during infusion of felodipine or solvent. Blood pressure was 
measured by Dinamap (model 1846P, Critikon). 
Both studies 
In both studies, subjects were kept fasting during the infusion experiment and 
remained supine except for spontaneous voiding. With a continuous infusion 
technique27, renal plasma flow (RPF) and GFR were estimated by measurement 
of renal clearances of PAH and inulin (laevofructosan, InutestR), respectively. 
PAH, inulin and electrolytes were measured by standard (semi) automated 
techniques, and felodipine plasma levels by gas chromatography28. Clearances 
of various substances (Clx) were calculated by the standard formula 
C1X=(UX*V)/P and fractional excretions (FEX) by C1X/GFR. RBF was 
approximated by RPF/(1-Hct), renal vascular resistance (RVR) by 
1000*MAP/RBF and filtration fraction (FF) by GFR/RPF. 
For statistical analysis, Wilcoxon's rank sum test was used for comparison of 
baseline values, whereas repeated measures analysis of variance (ANOVA) was 
used to compare responses to Ang II in study A and responses to felodipine and 
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solvent infusions in study B. A probability value below 0.05 was considered 
statistically significant. All results are given as means±SEM. 
The study protocol was approved by the hospital Ethics Committee and all 
volunteers gave written informed consent. 
RESULTS 
Study A 
One of the volunteers had problems with spontaneous voiding, resulting in a 
very irregular urinary flow rate. Renal clearances were considered unreliable in 
this subject and his results were excluded from the analysis. All results thus 
concern the remaining 11 subjects (Table 1). The absolute values before start 
of Ang II infusion were measured after 140 minutes of infusion with felodipine 
Table 1. Effects of graded Ang II infusion (in ng/kg/min) during solvent and felodipine 
MAP 
mm H g 
RBF 
ml/min 
GFR 
ml/min 
FF 
% 
RVR 
units 
α* 
ml/min 
FE* 
% 
S 
F 
S 
F 
S 
F 
S 
F 
S 
F 
S 
F 
S 
F 
before Ang II 
abs value 
81 ±3 
75 ± 2 
972 ±43 
1067+42 
108 ± 5 
100±4 
18.8±1.0 
16.2±0.8D 
83 ± 4 
71±4 C 
0.9 ±0.1 
2.8±0.3C 
0.9±0.1 
2.8±0.3C 
0.3 
+2 + 1 
+ 1±2 
-95±32B 
-20 ±61 
-7 ±4 
+ 4 + 5 
+0.7+0.6 
+0.9±0.5 
+ 12±3A 
+ 3 ± 4 
-0.2±0.1B 
+0.1 ±0.2 
-O.l±0.1B 
-0.1+0.1 
1.0 
+5 + I A 
+ 2 ± 1 D 
-150±35A 
-38 ±67 
-5 ±4 
+ 10±6 
+2.2±0.9B 
+2.3±0.7A 
+ 2 2 ± 3 A 
+ 5 ± 5 D 
-0.3±0.1B 
+0.4±0.2 C 
-0.2±0.1B 
+0.1±0.1 c 
3.0 
Δ abs 
+ 11±1 A 
+ 8 ± 1 A 
-305±31A 
-175±54A 
-11±3 A 
+ 5 ± 5 D 
+5.7±0.9 A 
+4.1+0.9* 
+ 5 6 ± 6 A 
+22±5 A - C 
-0.5 ±0. I A 
+ 1.4±0.4A C 
-O.4±0.1A 
+ 1.1±0.3A C 
after Ang II 
+4 + 2 
+ 2 ± 1 
-48±31 
-10+55 
+ 2 ± 3 
+ 7 ± 5 
+ 1.0±0.6 
+ 1.2±0.4B 
+ 9 ± 3 B 
+ 3 ± 3 
+0.2±0.1 B 
+ 1.0±0.2A D 
+0.2±0.1 B 
+0.7±0.2 B 
Abbreviations: abs value, absolute value before start of Ang II infusion; Δ abs, absolute 
change from value before Ang II infusion. S, solvent infusion; F, felodipine infusion. 
A
 Ρ < 0.01 and B Ρ < 0.05 compared to values before Ang II infusion. 
c
 Ρ < 0.01 and D Ρ < 0.05 compared to solvent infusion. 
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or solvent and thus indicate the effects of felodipine without Ang IL Felodipine 
infusion resulted in a slightly, but not significantly lower MAP (P=0.08), a 
lower RVR and a not significantly higher RBF (P=0.10). GFR was not 
changed, whereas FF was decreased. Felodipine infusion was followed by a 
threefold rise in ClNft and FENa. Felodipine plasma levels increased gradually 
from 7.1 ±0.5 nmol/litre at 40 minutes to 11.6+0.4 at 260 minutes after start 
of felodipine infusion. 
Graded Ang II infusion during solvent resulted in a dose-related rise of blood 
pressure, renal vasoconstriction, and sodium retention (Table 1). GFR was 
reduced less than RBF, leading to an increase in FF. The degree of sodium 
retention (ClNa) was associated with the decrease in RBF during the two higher 
doses of Ang II (r=0.72 and r=0.70, respectively, both P<0.02). 
Felodipine infusion partly antagonized these effects of Ang II (Table 1). 
During infusion of 1.0 ng/kg/min Ang II, felodipine prevented the rise in MAP 
and RVR, tended to antagonize the decrease in GFR (P=0.08), and abolished 
the sodium retention caused by Ang II. During infusion of 3.0 ng/kg/min 
Ang II, felodipine did not prevent the rise in MAP and only partly antagonized 
the Ang II-induced rise of RVR and decrease in RBF (P=0.058), but abolished 
the Ang II-induced decrease in GFR. Moreover, at this dose of Ang II, 
felodipine not only prevented the sodium retention by Ang II, but even enhanced 
sodium excretion by 50±13 %. Felodipine infusion did not influence the 
Ang II-induced rise of FF. 
Study В 
After completion of this study, one subject was excluded from the analysis, 
because his serum PAH and inulin levels could not be determined accurately due 
to technical problems. All results thus concern the remaining 11 subjects 
(Table 2). Baseline values were measured before starting felodipine or solvent 
infusion and thus indicate the effect of pretreatment per se. 
After seven days of pretreatment with ramipril, blood pressure reduction, 
renal vasodilation, and a reduction of ACE activity to 11 ± 1 % were observed. 
Comparison of the effects of solvent and felodipine infusions after ramipril 
shows that ramipril pretreatment did not prevent the effects of felodipine on 
renal hemodynamics and sodium excretion. After placebo, but also after ramipril 
pretreatment, felodipine infusion reduced blood pressure, induced renal 
vasodilation, decreased FF, and increased FENa. The felodipine-induced 
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Table 2. Effects of felodipine and solvent infusion after pretreatment with ramipril or placebo 
MAP 
mmHg 
RBF 
ml/min 
GFR 
ml/min 
FF 
% 
RVR 
arbitrary units 
FEH. 
% 
baseline 
Δ abs (inf) 
baseline 
Δ abs (inf) 
baseline 
Δ abs (inf) 
baseline 
Δ abs (inf) 
baseline 
Δ abs (inf) 
baseline 
Δ abs (inf) 
Rami + Sol ν 
86 ±2 
0±1 B 
1108±51 
-58±28A 
107 ±4 
-1±2 
17.0±0.7 
+0.5±0.5A 
68 ±4 
+4±2 A 
0.8±0.l 
+0.2±0.lA 
Rami + Felo 
86+2 
-5±1 
1079 ±46 
+ 126±35 
111 ±2 
+ 3±2 
18.0±0.8 
-1.3+0.4 
71 ±4 
-10±2 
0.6 ±0.1 
+ 1.2 ±0.2 
Plac+Felo 
90±2A 
-7±1 
957±56B 
+ 156±21 
106±3 
+2±1 
19.8±1.3 
-2.4±0.4A 
86±6A 
-18±3B 
0.7+0.1 
+ 1.7±0.2 
Abbreviations: rami and plac, ramipril and placebo pretreatment; solv and felo, solvent and 
felodipine infusions; Δ abs (inf), mean absolute changes from baseline during drug infusions. 
A
 Ρ < 0.01 and B Ρ < 0.05, compared to rami + felo. 
decreases of FF and RVR were significantly diminished by ramipril 
pretreatment. The negative influence of ramipril on felodipine-induced 
natriuresis failed to reach statistical significance (P=0.07) and ramipril had no 
significant effect (P>0.10) on the felodipine-induced decrease in MAP and 
increase in RBF. GFR was not changed by ramipril nor by felodipine. 
Correlation analysis showed that a lower baseline MAP after ramipril was 
associated with a more pronounced inhibition of natriuresis on felodipine 
(r=0.67, P=0.02). Felodipine plasma levels increased gradually from 8.2±3.1 
nmol/litre at 40 minutes to 12.7 ±1.7 at 200 minutes after placebo pretreatment 
and from 7.1 ±2.2 to 12.4±1.6 after ramipril. 
DISCUSSION 
An interaction with the renal tubular effect of Ang II could explain the 
natriuretic action of calcium entry blockers. If such an interaction were present, 
one would expect that calcium entry blockers prevent the sodium retention 
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induced by physiologic amounts of exogenous Ang II and also that suppression 
of endogenous Ang II production prior to treatment with a calcium entry blocker 
would interfere with the acute natriuretic action of this drug. Our two studies 
show that felodipine prevented the sodium retention induced by exogenous 
Ang II, whereas suppression of Ang II production by ramipril had no significant 
effect on the acute natriuresis induced by felodipine. This apparent discrepancy 
cannot be explained by differences in felodipine dose or sodium intake, since 
felodipine plasma levels and daily urinary sodium excretion rates (data not 
shown) were comparable in the two studies. Theoretically, an acute natriuretic 
effect of ramipril29 could have masked an inhibitory influence of ramipril on 
felodipine-induced natriuresis. However, the effects of felodipine were studied 
after one week of pretreatment with ramipril and thus at a time when sodium 
balance should have been restored. Indeed, baseline sodium excretion rate was 
not changed by ramipril and hardly any change in sodium excretion was 
observed during solvent infusion after ramipril. Therefore, we must assume that 
the natriuretic effect of felodipine does not depend mainly on interference with 
the sodium-retaining effect of endogenous Ang II at renal tubular level. 
Moreover, the minor and statistically insignificant negative influence of ramipril 
on felodipine-induced natriuresis was related to the ramipril-mediated reduction 
in baseline blood pressure. This suggests that ramipril might have blunted the 
natriuretic action of felodipine through reduction of renal arterial pressure 
(RAP). In anesthetized dogs, reduction of RAP by an aortic clamp also 
diminished the natriuretic effect of the calcium entry blocker diltiazem19. 
If we assume that natriuresis on felodipine does not depend mainly on the 
presence of endogenous Ang II, the question remains why felodipine not only 
prevented sodium retention by exogenous Ang II, but even enhanced natriuresis 
at the highest dose of Ang II. In this respect, it is important to realize that 
exogenous Ang II does not mimic the effects of Ang II formed intrarenally, 
since relatively high doses of Ang II have to be given systemically in order to 
reach relevant changes in intrarenal levels21. Intravenously administered Ang II 
increases systemic blood pressure and thus RAP. This rise of RAP leads to a 
reflex myogenic preglomerular arteriolar vasoconstriction30"33. Moreover, a 
direct effect of exogenous Ang II on the preglomerular vessel might contribute 
to this constriction32, although Ang II acts preferentially on the postglomerular 
arteriole30. Thus, despite an increase in RAP, Ang II infusion decreases RBF 
due to pre- and postglomerular vasoconstriction, and increases FF. This renal 
vasoconstriction is probably in part responsible for the sodium-retaining effect 
of Ang II, since the decrease in RBF is related to the decrease in sodium 
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excretion during Ang II. In accordance with other studies14'24'25,34'35, we observed 
that felodipine not only attenuated the rise in blood pressure on Ang II, but also 
blunted the rise of RVR. This last effect might explain part of the inhibition of 
the sodium-retaining effect of Ang II by felodipine. Animal studies showed that 
calcium entry blockers prevent pressure-induced vasoconstriction in isolated 
interlobular arteries31 and also in preglomerular arterioles of isolated perfused 
hydronephrotic kidneys36, whereas they do not affect postglomerular resistance37. 
From this, it can be understood that felodipine not only attenuated the rise in 
RVR, but also prevented the fall in GFR at all doses of Ang II. Preferential 
preglomerular vasodilation by felodipine together with the rise in blood pressure 
at the highest dose of Ang II can explain the enhanced natriuresis during the 
combination of Ang II and felodipine. Similar observations of enhanced 
natriuresis during Ang II infusion were made in anesthetized dogs, when blood 
pressure increased and renal vasoconstriction was prevented by simultaneous 
infusion of various vasodilators into the renal arteries38. Therefore, the reversal 
of Ang II-induced sodium retention by felodipine can be explained without 
assuming a specific interaction at renal tubular level. However, in contrast to 
other types of vasodilators, calcium entry blockers also induce natriuresis when 
administered systemically, indicating a specific effect of these drugs on sodium 
excretion. 
In summary, it seems likely that calcium entry blockers interfere with some 
actions of exogenous Ang II, especially the rise in blood pressure and 
preglomerular vasoconstriction. Although we cannot exclude that felodipine 
specifically reverses the sodium-retaining effect of exogenous Ang II at renal 
tubular level, most of our observations on sodium excretion can also be 
explained by an indirect effect of felodipine on the myogenic preglomerular 
vasoconstriction secondary to the Ang II-induced rise in blood pressure. The 
natriuretic effect of felodipine still occurs during ACE-inhibition with ramipril, 
implying that mechanisms other than interference with the tubular effects of 
endogenous Ang II must be involved in the natriuretic action of calcium entry 
blockers. Further studies are needed to elucidate the exact mechanisms involved. 
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ABSTRACT 
The mechanism of natriuresis with calcium entry blockers 
such as felodipine is largely unexplained. As these drugs 
prevent sodium retention following exogenous angiotensin II, 
the natriuretic effect of felodipine might be due to a similar 
interaction with endogenous angiotensin IL In such a case, 
angiotensin converting enzyme inhibition with ramipril should 
prevent natriuresis with felodipine. 
We tested this hypothesis in a randomized, double-blind, 
crossover study in 12 male volunteers by comparing intrave-
nous felodipine after one week of oral ramipril with felodipine 
after placebo and with solvent after ramipril. Ramipril pretre-
atment reduced ACE activity to 11 ±1 %, lowered the blood 
pressure and increased renal blood flow. However, ramipril 
pretreatment did not prevent the pronounced increase in natri-
uresis and diuresis with felodipine. Fractional sodium excre-
tion only tended to increase less during felodipine after rami-
pril than during felodipine after placebo (absolute changes of 
+ 1.2±0.2 % and +1.7±0.2 %, respectively, P=0.07). 
Ramipril did not influence felodipine-mediated blood pressure 
reduction and renal vasodilation. 
In conclusion, ACE inhibition has no significant effect on 
the natriuretic and hemodynamic effects of felodipine, sugge-
sting that mechanisms other than interaction with endogenous 
angiotensin II are involved in these effects of calcium entry 
blockers. 
i n 
Felodipine: effects after ACE inhibition 
INTRODUCTION 
Dihydropyridine calcium entry blockers such as felodipine have proven to 
be effective antihypertensive drugs1. In contrast to other vasodilators, calcium 
entry blockers of different chemical classes all have a natriuretic effect2, 
which possibly contributes to their antihypertensive action3. Micropuncture 
and microperfusion studies have documented inhibition of tubular sodium 
reabsorption in either the proximal4*6 or the distal7"9 renal tubule, but the 
mechanism responsible for these effects remains to be identified. Theoretical­
ly, a direct effect on tubular sodium transport, renal hemodynamic changes 
or an interaction with one of the natriuretic or sodium-retaining hormones 
could be involved. Sodium retention induced by exogenous angiotensin IIю 
can be prevented by calcium entry blockers, both in animals11"14 and in 
humans15. Since endogenous angiotensin II probably has a sodium-retaining 
effect similar to exogenous angiotensin II 16,17, it is possible that the natriure­
tic action of calcium entry blockers is due to an interaction with endogenous 
angiotensin II. Therefore we studied the natriuretic effect of felodipine after 
suppression of angiotensin II production by the angiotensin converting 
enzyme (ACE) inhibitor ramipril. 
METHODS 
Subjects 
Initially, 12 healthy male volunteers were recruited. Because of adverse 
experiences, two of these subjects were replaced during the study. All 
participants were free of medication. Ages ranged from 21 to 35 years (mean 
of 25 years) and all had a blood pressure < 140/90 mm Hg(mean±SD of 
127±ll/80±8 mmHg), and normal length (183±8 cm) and body weight 
(74±8 kg). 
The study protocol was approved by the hospital Ethics Committee and all 
volunteers gave written informed consent. 
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Study protocol 
Each subject received a 200 min infusion with felodipine after 7 days of 
oral pretreatment with the ACE inhibitor ramipril, 5 mg, given twice daily to 
obtain powerful ACE inhibition throughout 24-hours. In two control experi-
ments, each subject received a placebo infusion (solvent) after pretreatment 
with ramipril and a felodipine infusion after pretreatment with oral placebo. 
A double-blind, randomized, two-way crossover design was used with 
felodipine infusion after ramipril always second in order. Treatment periods 
were separated by wash-out intervals of 3 weeks. During treatment a diet 
containing approximately 100 mmol sodium per day was prescribed and 
compliance was tested by measuring creatinine and sodium in 24-hour urine 
samples. The evening preceding each clearance study, 600 mg of lithium 
carbonate (16.2 mmol of lithium) was given orally. Subjects were asked to 
refrain from smoking and the use of alcohol for the last 24 hours preceding 
clearance studies and also from caffeine-containing beverages for the last 
8 hours. 
On the eighth day of oral pretreatment, 1 hour after a light breakfast, 
infusion experiments took place between 8.30 h and 16.30 h. Upon arrival, 
body weight was measured and the last ramipril or placebo capsule was 
given. Maximal water diuresis was induced by an oral water load of 
25 ml/kg of body weight, resulting in a urinary osmolality of 65 mOsm/kg 
(range of 51 to 89 mOsm/kg) and a urinary flow rate of 14 ml/min (range of 
9 to 19 ml/min). Thereafter, 0.25 % sodium chloride in 3.3 % glucose was 
infused at a rate of 400 ml/hr to maintain diuresis and to compensate for 
sodium losses observed during placebo18. Urinary volume losses in excess of 
400 ml/hr were replaced orally by tap water. Subjects remained supine 
except for spontaneous voiding. With a continuous infusion technique15, the 
renal plasma flow (RPF) and glomerular filtration rate (GFR) were estimated 
by measurement of renal clearances of p-aminohippuric acid (PAH) and 
inulin (laevofructosan, Laevosan-Gesellschaft, Linz, Austria), respectively. 
After 90 min of equilibration, two baseline urine collections of 30 min were 
made before starting felodipine or solvent infusion. To obtain stable plasma 
levels in the therapeutic range, 0.15 /ig/kg/min of felodipine was infused for 
the first 40 min followed by 0.10/xg/kg/min for the remaining 160 min15 
(cumulative dose 1.60±0.15 mg, mean±SD). Five further urine collections 
of 40 min were made with blood samples drawn at the beginning and the end 
of each urine collection period. In blood and urine samples, PAH, inulin, 
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sodium, potassium, chloride, urate, and phosphate concentrations were 
measured by standard (semi)automated techniques, whereas lithium was 
determined by atomic absorption spectrophotometry and osmolality by 
freezing point depression. In blood samples hematocrit (Ht) was determined 
by routine Coulter counter, ACE activity by a colorimetrie method (ACE-
color, Fujirebio, Tokyo, Japan)19 and plasma renin activity (PRA) and plasma 
aldosterone concentration (PAC) by radioimmunoassay20,21. Felodipine was 
determined by gas chromatography22 and ramiprilat, the active metabolite of 
ramipril, by radioimmunoassay23. Blood pressures and pulse rates were 
recorded at 2 min intervals by an automatic device (Dinamap model 1846P, 
Critikon, Tampa, FL, USA), which directly measures the mean arterial 
pressure (MAP). 
For blood pressure data, the mean values of ten consecutive readings in the 
middle of each urine collection period were calculated. Of the various 
substances (s), clearances (Cls) and fractional excretions (FEç) were calcula-
ted according to the standard formulas24. The renal blood flow (RBF) was 
approximated by RPF/(1-Ht) (ml/min), the renal vascular resistance (RVR) 
by 1,000*MAP/RBF (arbitrary units) and the filtration fraction (FF) by 
(GFR/RPF)*100 (%). The GFR, RPF, and RBF were adjusted to a standard 
body surface area of 1.73 m2. In the absence of renal vein samples, we could 
not correct the RPF and RBF for changes in the extraction ratio's of PAH. 
The free water clearance (C1H20) was calculated as urinary flow rate (V) 
minus the osmolal clearance (Cl0ßm). The fractional proximal sodium reab-
sorption (FPRNa) and fractional distal sodium reabsorption (FDRNa) were 
calculated as follows: 
a) by the lithium clearance method25: 
FPRNa(Li) = (l-ClLl/GFR)*100 (%). 
FDRNa(Li) = (l-ClNa/ClLl)*100 (%). 
b) by the free water clearance method24: 
FPRNa(H20) = (l.(UNft+K*V/PNa+ClH2O)/GFR)*100 (%). 
FDRNa(H20) = ClH2O/(Clcl+ClH2O)*100(%). 
Statistical analysis 
For evaluation of the influence of pretreatment per se on baseline values 
measured just before starting felodipine or solvent infusion, only ramipril 
preceding felodipine infusion was compared to oral placebo. 
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For evaluation of the effect of ramipril on felodipine-induced changes, 
felodipine infusion after ramipril was compared, on the one hand, to solvent 
infusion after ramipril and, on the other hand, to felodipine infusion after 
placebo. Absolute changes from baseline were compared, except for hormo-
nal parameters, where percentage changes were used. For the pharmacokine-
tic parameters, areas under the curve were compared. 
Statistics were performed with SAS (statistical analysis system) software 
using two tailed Wilcoxon's test for paired data and repeated measures 
analysis of variance (ANOVA). Correlation coefficients were calculated 
according to Spearman. A probability value less than 0.05 was considered 
statistically significant. Results are given as means±SEM. 
RESULTS 
As indicated earlier, two subjects withdrew because of adverse experien-
ces: one because of fainting on the second day of ramipril treatment and the 
other because of vomiting during felodipine infusion. Because of technical 
problems, serum inulin and PAH levels of one subject could not be determi-
ned. Therefore, data analysis was restricted to the remaining 11 subjects. 
On the last 2 days of oral pretreatment, urinary sodium excretions during 
Table 1. Systemic hemodynamic parameters after oral pretreatment and 
during drug infiisions. 
Baseline values after pretreatment 
Placebo 
Ramipril 
Mean values during drug infusions 
Ramipril + solvent 
Ramipril + felodipine 
Placebo + felodipine 
Blood 
Systolic 
121 ±2 
115±2A 
116±2 
114+2 
117+2 
pressure {mm 
Diastolic 
72 ±3 
67±3A 
66 + 3c 
62 ±2 
64+2B 
Hg) 
MAP 
90±2 
86±2A 
86+2 c 
81 ±2 
83+2B 
HR 
(beats/min) 
53 ±2 
53 ±2 
53+2 e 
60±2 
62+3 
MAP=mean arterial pressure; HR=heart rate. 
AP<0.01 compared to oral placebo; BP<0.05 and CP<0.0\ compared to ramipril + 
felodipine 
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ramipril (81 ± 7 mmol/day) and 
placebo (77 ±12) did not differ, 
indicating a good adherence to the 
diet. Also, potassium excretion was 
the same during ramipril (94 ± 7 
mmol/day) and placebo (94 ±5). 
Body weight was unchanged by 
pretreatment with ramipril (72.8 ± 
2.1 kg) compared to placebo (72.9± 
2.2). 
Systemic hemodynamics 
The baseline blood pressure was 
lower after ramipril than after oral 
placebo, whereas the heart rate was 
the same (Table 1). Feiodipine 
infusion caused a significant decre­
ase in the MAP when compared to 
solvent infusion (Fig. 1). The de­
creases in MAP with feiodipine 
were similar after pretreatment with 
either ramipril or placebo (-5±1 and 
-7±1 mmHg, respectively, P= 
Mean Arterial Pressure 
90 H 
85-
80 
65 
R + S -
P + Ρ - 0.02 
0.J3 
R+F= 
Heart Rate 
60 
3 
55 
50 
0.0S 
Figure 1. Systemic hemodynamics before 
(baseline) and during drug infusions. 
P=placebo; R=ramipril; R+S=ramip-
ril followed by solvent (o); P+F=pla­
cebo followed by feiodipine ( • ) ; 
R+F'= ramipril followed by feiodipine 
(m); ρ values on the left: comparison of 
baseline values; Ρ values on the right: 
comparison of absolute changes from 
baseline induced by drug infusion. 
0.13). Ramipril had only a minor, 
statistically insignificant effect on the felodipine-induced increase in heart rate 
(Fig. 1, + 7 ± 1 compared to + 1 0 ± 1 beats/min on feiodipine after placebo, 
P=0.08). 
Renal hemodynamics 
Ramipril pretreatment increased the RBF, but did not change the GFR and 
FF (Table 2). In comparison to solvent infusion, feiodipine infusion increased 
the RBF and decreased the RVR (both Ρ<0.01; Fig. 2 and Table 2). The 
increases in RBF during feiodipine after either ramipril or placebo were 
comparable (+126±35 compared to +156±21 ml/min/1.73 m2; P=0.20). 
However, the decrease in RVR was less pronounced during feiodipine after 
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ramipril than during felodipine after 
placebo (-10±2 and -18 ± 3 arbitrary 
units, respectively; P=0.02). The 
GFR did not change during felodi­
pine and solvent inftisions (Fig. 2). 
In comparison to solvent infusion, 
felodipine infusion after ramipril 
lowered the FF (+0.5±0.5 and 
- 1 . 3 ± 0 . 4 %, r e s p e c t i v e l y ; 
An even larger decrease 
in FF was found on 
after placebo (-2.4 ± 
P<0.01). 
(P<0.01) 
felodipine 
0.4 %). 
^^afelodjmneo^Qlrent Diuresis and electrolyte excretions 
-40 0 40 120 
Time (min) 
200 
Figure 2. Renal hemodynamics before 
and during drug infusions. See Figure 1 
for abbreviations and explanation of 
symboh. 
The baseline urinary flow rate and 
fractional excretions of sodium, 
chloride and potassium were similar 
after ramipril and placebo pretreat­
ment (Table 3). After ramipril pre-
treatment, felodipine infusion still 
induced a pronounced increase of natriuresis and diuresis when compared to 
solvent infusion (Fig. 3). Moreover, the natriuretic and diuretic effects of 
felodipine after either ramipril or placebo did not differ significantly (P=0.07 
and P=0.46, respectively; Fig. 3 and Table 3). A positive correlation 
(r=0.67, Ρ=0.02) was found between the ramipril-mediated reduction in 
baseline MAP and the ramipril-induced change in natriuresis with felodipine. 
Changes in FEC1 paralleled changes in FEN a and only small and insignificant 
changes in FEK were observed (Table 3). 
Table 4 gives data on segmental tubular sodium reabsorption. FEp^ 
increased to the same extent during solvent and the two felodipine infusions. 
Compared to the solvent infusion, felodipine infusion induced an increase in 
FEU R A and decreases in FPRNa as well as FDRNa. Calculated by the ClLi 
method, FPRNa decreased less during felodipine after ramipril than during 
felodipine after placebo, but this difference was not found with FPRNa 
calculated by C1H 2 0 method (f=0.09). Similar decreases in FDRNa were 
observed during felodipine infusions after ramipril and placebo. 
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Table 2. Renal hemodynamic parameters after oral pretreatmem and during drug infusions 
Baseline values after pretreatment 
Placebo 
Ramipril 
Mean values during drug infusions 
Ramipril + solvent 
Ramipril + felodipine 
Placebo + felodipine 
RBF 
ml/min 
(1.73 m2) 
957 ±56 
1,079 ±46A 
1,050±52D 
1,205 ±58 
1,113±50 
GFR 
ml/min 
(1.73 m2) 
106±3 
111 ± 2 
106±4 
114±2 
108+4 
FF 
% 
19.8±1.3 
18.0±0.8 
17.5±0.9 
16.8±0.8 
17.4±1.1 
RVR 
units 
86 ± 6 
71±4 B 
72±4 D 
60±3 
68±4 C 
See text for abbreviations 
AP<0.05 and BP<0.01 compared to oral placebo. 
CP<0.05 and DP<0.01 compared to ramipril + felodipine 
Table 3. Urinary flow rate and fractional electrolyte excretions, baseline values 
and absolute changes from baseline during drug infusions. 
Pretreatment: 
Infusion: 
Rami 
Solv 
Rami 
Felo 
Plac 
Felo 
Ρ values 
FEN. (%) 
Baseline 
Δ abs (inf) 
FEK (%) 
Baseline 
Δ abs (inf) 
FEC1 (%) 
Baseline 
Δ abs (inf) 
Urinary flow rate (ml/min) 
Baseline 
Δ abs (inf) 
0.8±0.1 
+0.2±0.0 
9.8±1.4 
-2.1 ±0.8 
0.7 ±0.1 
-0.1 ±0.0 
14.6±0.8 
-0.6±0.5 
0.6±0.1 
+ 1.2±0.2 
9.8±1.6 
-0.3±1.0 
0.6±0.1 
+ 1.1 ±0.3 
14.5±0.8 
+4.8±0.7 
0.7+0.1 
+ 1.7±0.2 
11.2 + 1.6 
+0.2±0.9 
0.5 ±0.1 
+ 1.7±0.3 
13.8±0.8 
+5.6±0.8 
<0.01 
0.15 
<0.01 
<0.01 
0.97 
0.07 
0.37 
0.15 
0.52 
0.12 
0.20 
0.46 
Rami=ramipril; Felo=felodipine; Plac=oral placebo; Solv=solvent infusion; Δ abs 
(inf)=absolute changes from baseline during drug infusions. 
See text for other abbreviations. 
Ρ values A: comparison of ramipril+solvent to ramipril + felodipine. 
Ρ values B: comparison of placebo+felodipine to ramipril+felodipine. 
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Ramipril reduced ACE-activity to 
11 ± 1 % before and to 13±1 % of 
pretreatment level during drug infu­
sions. The baseline PRA was higher 
after ramipril pretreatment (5.6±0.6 
compared to 1.1 ±0.1 nmol/L/h 
after placebo; P<0.01). The base­
line PAC was not changed by pre-
treatment (0.43 ±0.05 nmol/L after 
ramipril and 0.55 ±0.07 nmol/L 
after placebo; />=0.41). As obser­
ved in the course of similar clea­
rance studies without any drugs 
(personal observations), the PRA 
and PAC decreased during solvent 
infusion by 36 ± 4 and 30 ± 7 %, 
respectively. During felodipine after 
ramipril PRA decreased only by 
15± 8 %, i.e., significantly less 
(P<0.01) than during solvent infu­
sion. During felodipine after place­
bo, the PRA even increased by 16±10 % (P<0.01 compared to felodipine 
after ramipril). The decrease of PAC observed during solvent was also found 
during felodipine after ramipril (-30 ±5 %) and during felodipine after 
placebo (-38±4 %), thereby leading to comparable values for PAC during 
felodipine infusions (0.30±0.03 and 0.33 ±0.04 nmol/L, respectively; 
P=0.59). 
-40 о 40 120 
Time (mm) 
200 
Figure 3. Nairiuresis and diuresis before 
and during drug infusions. See Figure 1 
for abbreviations and explanation of 
symbols. 
Pharmacokinetics 
There was no difference in ramiprilat plasma levels during felodipine and 
solvent infusions (Fig. 4). Also, felodipine plasma levels after ramipril and 
after placebo pretreatment were comparable (P=0.11). Both felodipine and 
ramiprilat plasma levels were in the therapeutic range26,27. 
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Table 4· Segmental tubular sodium reabsorption, base-line values and absolute changes 
from baseline during drug injusions. 
Pretreatment: 
Infusion: 
FEURA (%) 
Baseline 
Δ abs (inf) 
FEpo, (%) 
Baseline 
Δ abs (ini) 
FPRNe (Cl J (%) 
Baseline 
Δ abs (inf) 
FDRN. (CIJ (%) 
Baseline 
Δ abs (inf) 
FPRN, (C1H20) (%) 
Baseline 
Δ abs (inf) 
FDRN. (C1H2O) (%) 
Baseline 
Δ abs (inf) 
Rami 
Solv 
7.8 ±0.7 
-0.2+0.3 
9.8±1.1 
+5.5±1.1 
72.8 ±1.2 
-0.9 ±0.6 
97.1 ±0.3 
-0.6 ±0.1 
89.6 ±0.4 
+0.2 ±0.4 
93.4 ±0.9 
+0.2±0.3 
Rami 
Felo 
6.4 ±0.4 
+2.0±0.3 
8.7Ц.2 
+5.8±1.0 
74.9 ±0.6 
-5.4 ±0.4 
97.6±0.2 
-3.6±0.7 
90.3 ±0.5 
-3.3 ±0.3 
93.6±0.9 
-6.8 ±1.4 
Plac 
Felo 
6.9 ±0.6 
+ 2.4±0.4 
8.5±0.9 
+ 7.2±1.2 
72.9 + 1.8 
-8.1 ±0.9 
97.7 ±0.3 
-4.4+0.6 
90.1 ±0.7 
-4.6±0.5 
94.7 ±0.9 
-9.8 ±1.5 
Ρ values 
A 
<0.001 
0.34 
<0.001 
0.001 
<0.001 
<0.001 
в 
0.52 
0.44 
0.76 
0.34 
0.41 
0.02 
0.64 
0.27 
0.83 
0.09 
0.37 
0.11 
See Table 3 and the text for abbreviations. 
DISCUSSION 
This study deals with the influence of ACE inhibition on the natriuretic 
effect of a calcium entry blocker. Similar to the interaction between calcium 
entry blockers and exogenous angiotensin IIй"15, an interaction with the 
sodium-retaining effect of endogenous angiotensin II could be present and 
could explain the natriuretic action of these drugs. If this hypothesis were 
true, suppression of angiotensin II production should inhibit this natriuresis. 
However, chronic ACE inhibition with ramipril did not abolish the natriuresis 
caused by felodipine and also did not influence felodipine-induced diuresis 
and renal vasodilation. Although angiotensin II plasma levels were not 
measured, the ramiprilat plasma levels and the 90 % ACE inhibition indicate 
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powerful suppression of endogenous 
angiotensin II production26,28 during 
felodipine and solvent infusions. 
Therefore, we must assume, in con­
trast to our starting hypothesis, that 
the natriuretic and renal hemody­
namic effects of dihydropyridine 
calcium entry blockers such as 
felodipine depend mainly on other 
factors than interaction with endo­
genous angiotensin II. 
Our data do not exclude the possi­
bility that ACE inhibition slightly 
inhibits felodipine-induced natriure-
sis, as the observed Ρ value of 0.07 
could indicate a statistical type II 
error. However, ramipril pretreat­
ment per se had lowered the blood 
pressure and had induced renal 
vasodilation before the start of 
felodipine. Moreover, the ramipril-
induced reduction in baseline blood 
pressure was positively correlated to the ramipril-mediated change of felodi­
pine-induced natriuresis. Therefore, if ramipril has any effect on the natriu­
retic action of felodipine, such an effect could be ascribed to the blood 
pressure-lowering effect of ramipril and does not necessarily indicate a 
specific interaction between endogenous angiotensin II and felodipine at the 
renal tubular level. 
The question remains why ACE inhibition has no significant influence on 
felodipine-induced natriuresis and renal vasodilation, whereas the interaction 
between exogenous angiotensin II and felodipine had been so prominent in 
our previous study15. This discrepancy cannot be explained by differences in 
felodipine dose or sodium intake, since felodipine plasma levels and daily 
urinary sodium excretion rates are comparable in the two studies. It is 
unlikely that an acute natriuretic effect of ramipril16 masked an inhibitory 
influence of ramipril on felodipine-induced natriuresis, since sodium excre­
tion hardly changed during solvent infusion after ramipril. As ACE inhibition 
not only suppresses angiotensin II production but also retards degradation of 
15 
в 
>10 
15 
J 10 
о 
Ramiprilat plasma levels 
0.66 
ι ι τ I I I I 
-40 0 40 120 200 300 360 
Time (min) 
Figure 4. Plasma drug levels during and 
after drug infusions, the first ramiprilat 
level measured 150 min after the last 
gift of ramipril Ρ values: comparison of 
area under curve 0-200 min. See Figu­
re 1 for abbreviations and explanation 
of symbols. 
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bradykinin, increased bradykinin levels could have influenced our results. 
Bradykinin has a natriuretic effect29 and inhibition of bradykinin production 
by aprotinin prevents natriuresis on calcium entry blockers in animals30 but 
not in humans31. Thus, theoretically, increased bradykinin levels after 
ramipril could have facilitated natriuresis on felodipine and thereby could 
have overridden an inhibitory effect of lowering the levels of endogenous 
angiotensin II on the natriuretic action of felodipine. In this respect, the use 
of a specific angiotensin II inhibitor could have provided more definitive 
answers. Alternatively, the discrepancy between our present results and our 
previous study15 could be explained by the differences in effects of intrave-
nous exogenous angiotensin II as opposed to endogenous angiotensin II. 
Besides the physiologic effects on proximal tubular sodium reabsorption and 
postglomerular vasoconstriction, intravenously administered angiotensin II 
might induce an increase in systemic blood pressure, leading to autoregula-
tory preglomerular vasoconstriction. In the isolated perfused kidney model, 
calcium entry blockers effectively antagonize such a myogenic preglomerular 
vasoconstriction32, whereas they have much less of an effect on postglomeru-
lar vasoconstriction induced by angiotensin II33. Therefore, it is possible that 
no specific direct interaction exists between calcium entry blockers and 
angiotensin II in the kidney. The results obtained in previous studies could be 
due to an influence of calcium entry blockers on the indirect renal effects of 
exogenous angiotensin II, i.e., an interaction with the myogenic preglomeru-
lar vasoconstriction induced by a rise in blood pressure. 
Felodipine infusion increased lithium and urate excretions and decreased 
the calculated FPRNa, thereby suggesting an inhibition of proximal tubular 
sodium reabsorption by felodipine. Since lithium and free water clearance 
methods led to conflicting results regarding an effect of ramipril on the 
felodipine-induced decrease in FPRNft, our data do not allow firm conclusions 
on this subject. 
Ramipril pretreatment did not influence the blood pressure-lowering effect 
of felodipine, but tended to blunt the felodipine-induced tachycardia, as has 
been observed with other combinations of calcium entry blockers and 
ACE inhibitors34~36. Possibly, this inhibitory effect failed to reach statistical 
significance because of the only modest increase in heart rate, related to the 
relatively slow rise in plasma drug levels37. 
In conclusion, ACE inhibition with ramipril does not prevent the natriure-
sis and diuresis on felodipine, suggesting that mechanisms other than interfe-
rence with the effects of endogenous angiotensin II are involved in the 
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natriuretic action of dihydropyridine calcium entry blockers. Further studies 
are needed to elucidate the exact mechanisms involved in the natriuretic 
effect of calcium entry blockers. 
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Exogenous aldosterone antagonizes the distal tubular effects 
of the calcium entry blocker felodipine 
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ABSTRACT 
Calcium entry blockers such as felodipine increase natriuresis 
without increasing kaliuresis. Since these drugs acutely increase 
plasma renin activity without a concomitant change of 
aldosterone, inhibition of aldosterone release might explain the 
absence of kaliuresis. 
In a randomized, crossover study in 12 male volunteers we 
compared the effects of simultaneously administered exogenous 
aldosterone and felodipine with the effects of either felodipine or 
aldosterone alone. Felodipine infusion decreased blood pressure, 
increased renal plasma flow and induced natriuresis without 
kaliuresis. Aldosterone alone reduced sodium excretion and 
increased potassium excretion without influencing 
hemodynamics. Addition of aldosterone to felodipine attenuated 
its natriuretic effect, and induced a kaliuresis, which clearly 
exceeded the rise of potassium excretion during aldosterone alone 
(Δ% FEK +42 + 12 and + 7 ± 8 % , respectively, means±SEM, 
Ρ < 0.02). 
Our data suggest that felodipine-mediated inhibition of 
aldosterone release is essential for the absence of kaliuresis with 
felodipine. In addition, the pronounced kaliuresis with 
aldosterone during felodipine is in keeping with increased distal 
sodium delivery due to a proximal tubular action of felodipine. 
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INTRODUCTION 
Calcium entry blockers, especially dihydropyridines such as felodipine, are 
powerful drugs for the treatment of most forms of hypertension. In contrast to 
other vasodilating drugs1, calcium entry blockers induce a diuresis and 
natriuresis2 which may contribute to their antihypertensive action. The 
mechanisms which are responsible for this natriuretic effect remain to be 
identified. Also the renal tubular site of action is still debated, since 
micropuncture and microperfusion studies in animals have documented inhibition 
of sodium reabsorption in either the proximal3*5 or the distal6"8 renal tubule. 
Clearance studies in humans have suggested a proximal as well as a distal 
tubular site of action9"13. In most studies in humans2,12"15, the natriuretic effect 
of calcium entry blockers is not accompanied by a rise in potassium excretion, 
which favours an effect on the distal tubules and especially the cortical 
collecting ducts where potassium secretion is regulated16. In this respect, it is of 
interest that calcium entry blockade induces a rise of plasma renin activity 
(PRA) which is not followed by an increase of plasma aldosterone concentration 
(РАС)2,17. Therefore, the absence of kaliuresis during calcium entry blockers 
could be related to blockade of aldosterone secretion. In addition, inhibition of 
aldosterone action, or a direct effect on distal tubular sites might be involved. 
We evaluated these possibilities in healthy volunteers by studying the effects of 
exogenous aldosterone during infusion of the calcium entry blocker felodipine. 
METHODS 
Subjects 
Initially, twelve healthy male volunteers were recruited. During the study, 
two of them were replaced because of adverse experiences. All participants were 
free of medication. Ages ranged from 23 to 36 years (mean 28) and all had a 
blood pressure below 140/90 (ranges, systolic 108 to 134 and diastolic 68 to 84 
mm Hg), normal length (range, 174 to 190 cm), and body weight (range, 62 to 
86 kg). 
The study protocol was approved by the hospital Ethics Committee and all 
volunteers gave written informed consent. 
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Study protocol 
Each subject was studied three times in order to compare the simultaneous 
administration of aldosterone and felodipine with both the administration of 
aldosterone alone and of felodipine alone. In three clearance experiments 
separated by washout periods of one week, subjects received combined 
intravenous infusions of felodipine and aldosterone, of felodipine and placebo 
(dextrose 5%), and of placebo (solvent) and aldosterone. A randomised, single 
blind, crossover design was used with the combination of felodipine and 
aldosterone always second in order and randomisation balanced in blocks of six. 
Subjects were advised to keep their sodium intake constant and to refrain from 
licorice on the last three days preceding clearance experiments. Dietary intake 
was checked by measuring creatinine, sodium and potassium in 24-hour urine 
samples collected on the last two days preceding clearance studies. Sodium and 
potassium excretions were corrected for individual mean 24-hour creatinine 
excretions. On the eve of each clearance study, 600 mg lithium carbonate (16.2 
mmol lithium) was given orally. Subjects were asked to refrain from smoking 
and the use of alcohol for the last 24 hours and from caffeine-containing 
beverages for the last eight hours preceding the clearance studies. 
On study days, the subjects consumed a light breakfast and drank 375 ml tap 
water. One hour thereafter, clearance experiments took place between 8.30 hr 
and 15.30 hr. Upon arrival, body weight was measured and water diuresis was 
induced by an additional oral water load of 15 ml/kg body weight, resulting in 
a mean urinary osmolality of 66 mOsm/kg (range, 42 to 127). During the whole 
experiment, 0.25 % sodium chloride in 3.3 % dextrose was infused at a rate of 
400 ml/hr to maintain diuresis and to compensate for sodium losses observed 
previously during similar experiments with placebo18. Urinary volume losses in 
excess of 400 ml/hr were replaced orally by tap water. Subjects remained supine 
except for spontaneous voiding. With a continuous infusion technique described 
elsewhere15 renal plasma flow (RPF) and glomerular filtration rate (GFR) were 
estimated by measurement of renal clearances of para-aminohippuric acid (PAH) 
and inulin (polyfructosan, InutestR, Laevosan-Gesellschaft, Linz, Austria), 
respectively. After 60 min equilibration, two baseline urine collections of 40 
min were made immediately before starting felodipine or solvent infusion. To 
obtain stable plasma levels in the therapeutic range10, 0.175 /xg/kg/min of 
felodipine (PlendilR) was infused for the first 40 min, followed by 0.075 
μg/kg/min for the remaining 200 min (cumulative dose 1.63±0.15 mg, 
mean±SD). Forty minutes after starting felodipine or solvent infusion and after 
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collection of the third 40 min urine sample, infusion of aldosterone (Aldocor-
tenR, Ciba Geigy, Basel, Switzerland) in 5% dextrose (0.01 mg aldosterone/ml) 
or 5 % dextrose alone was started through a separate intravenous cannula in the 
upper arm. After an intravenous bolus of 100 μg of aldosterone in 10 min, 0.83 
/¿g/min was infused for the remaining 190 min (cumulative dose 258 /ig in 200 
min). Five further urine collections of 40 min were made during aldosterone or 
dextrose infusions. Blood samples were drawn at the beginning and the end of 
each urine collection period. In blood and urine samples, PAH, inulin, sodium, 
potassium and chloride concentrations were measured by standard (semi)auto-
mated techniques, whereas lithium was determined by atomic absorption 
spectrophotometry. In blood samples PRA and PAC were determined by 
radioimmunoassay19,20 and plasma felodipine levels by gas chromatography21. 
Blood pressures and pulse rates were recorded at four min intervals with an 
automatic device (Dinamap model 1846P, Critikon, Florida, USA), which 
directly measures mean arterial pressure (MAP). The mean values of five 
consecutive readings in the middle of each urine collection period were used for 
analysis. 
Of the various substances (x), clearances (Clx), urinary excretions (UXV) and 
fractional excretions (FEX) were calculated according to standard formulas22 
(Ux representing the urinary concentration and V the urinary flow rate). 
Filtration fraction (FF) was calculated as (GFR/RPF)xl00 (%). GFR and RPF 
were adjusted to a standard body surface area of 1.73 m2. UK/U(Na+K) was used 
as a measure of sodium-potassium exchange in the distal tubule23. Fractional 
proximal sodium reabsorption (FPRNa) and fractional distal sodium reabsorption 
(FDRNa) were calculated by the lithium clearance method24: 
FPRNa = (l-ClLi/GFR)xl00 (%). 
FDRNa = (l-ClNa/ClLi)xl00 (%). 
Statistical analysis 
Since it takes a latency period of 60-90 min before the effects of aldosterone 
administration can be observed25, only the last three urine collection periods 
were used for evaluation of the effects of aldosterone. For baseline levels, mean 
values of the first two urine collection periods were calculated. Unless stated 
otherwise, absolute values and absolute changes from baseline levels were 
compared. Simultaneous infusion with felodipine and aldosterone was compared 
to felodipine alone on one hand and to aldosterone alone on the other hand. 
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Statistics were performed with SAS (Statistical Analysis System) software, 
using two tailed Wilcoxon's test for simple pairwise comparisons and repeated 
measures analysis of variance (ANOVA) for all other comparisons. A 
probability value less than 0.05 was considered statistically significant. Results 
are presented as means±SEM. 
RESULTS 
Two volunteers withdrew, one because of personal reasons and the other 
because of vomiting at the end of felodipine infusion. In total, 12 volunteers 
completed the whole study protocol. 
Baseline data 
Body weights and 24-hour urinary water and potassium excretions were 
comparable preceding the three clearance experiments (Table 1). The 24-hour 
urinary sodium excretion was lower before infusion of felodipine alone than 
before simultaneous infusion of felodipine and aldosterone (Table 1), but 
baseline UNftV and FENa measured just before felodipine infusions did not differ 
significantly (UNeV: 138 + 19 and 158+24 /xmol/min, P=0.62, Table 2 and 
FENa: 0.8±0.1 and 0.9±0.1%, P=0.56, Fig. 2). Baseline excretions of other 
electrolytes, and baseline levels of systemic and renal hemodynamics were com-
parable in all three experiments. 
Table 1. Steady state data before clearance studies. 
Body weight (kg) 
Urinary volume (ml/24 hr) 
Urinary sodium (mmol/24 hr) 
Urinary potassium (mmol/24 hr) 
Aldo 
73.5±1.9 
1612+165 
163±14 
84 + 6 
Felo+Aldo 
73.4±2.0 
1707±122 
182±14 
80±6 
Felo 
73.3 ± L 9 
1447+123 
139 ±10* 
76±4 
means±SEM. Felo=felodipine; Aldo=aldosterone. 
* P<0.02 compared to Felo+Aldo. 
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Systemic and renal hemodynamics 
MAP, RPF and GFR are presented in 
Figure 1. Infusion of felodipine alone 
lowered MAP by 7 + 1 %, increased 
heart rate by 13 ± 3 % and induced 
renal vasodilation with a 24±4 % rise 
in RPF (all Ρ < 0.01 compared to 
baseline). Felodipine alone did not 
change GFR ( + 3 ± 2 %, Ρ=0Λ5), 
whereas it decreased FF by 16 ± 3 % 
(P<0.01). Aldosterone alone had no 
effect on systemic and renal hemo­
dynamics. Addition of aldosterone to 
felodipine did not change the systemic 
and renal hemodynamic effects of 
felodipine (all Ρ > 0.10 compared to 
felodipine alone). Although GFR 
increased only during simultaneous 
infusion of felodipine and aldosterone 
( + 7 ± 2 %, P<0.01 compared to 
baseline), this felodipine-mediated 
change in GFR did not differ signifi­
cantly (P=0.16) from the change du­
ring felodipine alone ( + 3 ± 2 %). 
95-
90-
85 
o sotv+ aldo 
800-j afelo+dext 
ι felo+ aldo 
Mean Arterial Pressure 
? 
<0 05 
Renal Plasma Flow 
-40 0 80 160 
Time (in mm) 
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Figure 1. Systemic and renal hemody­
namics before (baseline) and during drug 
and placebo infusions. Felo=felodipine; 
Solv=solvent; Aldo=aldosterone; Dext= 
dextrose. Ρ values on the right: compari­
son of mean absolute changes from 
baseline during the last three clearance 
periods. 
Diuresis and urinary electrolyte excretions 
Felodipine alone had a distinct diuretic and natriuretic effect with a 38 ± 3 % 
increase in urinary flow rate, a 210±42 % increase in FEN a, and a 208±42 % 
increase in FEC1 (all Ρ < 0.001 compared to baseline, Fig. 2). UNftV increased 
from 138±19 to 435±70 /¿mol/min and UC,V from 102 + 13 to 312±53 
μπιοΐ/min (both P<0.001 compared to baseline, Table 2). In line with our pre­
vious observations, the natriuretic effect was not accompanied by changes of 
UKV and FEK (Р>0Л09 Table 2 and Fig. 2). UK/U ( N a + K ), FPRNa and FDRNa de­
creased by 57±4, 11 ± 2 , and 5 ± 1 % during felodipine (all Ж 0 . 0 0 1 compa 
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Figure. 2. Diuresis, natrìuresis and 
kahuresis before (baseline) and during 
drug and placebo infusions. Felo-fe-
lodipine; Solv ^solvent; Aldo-aldos-
terone; Dext= dextrose. P-values on the 
right: comparison of mean absolute 
changes from baseline during the last 
three clearance periods. 
red to baseline, Fig. 3). 
Infusion of aldosterone alone indu-
ced sodium and chloride retention 
(Table 2 and Fig. 2). Probably due to 
a steadily decreasing potassium ex-
cretion before aldosterone infusion, 
FEK during aldosterone infusion did 
not differ from baseline level. How-
ever, as can be seen in Fig. 2, FEK 
gradually increased above the level 
measured just before starting aldoste-
rone infusion (P<0.01). FDRNa and 
UK/U(Na+K) were increased by 
aldosterone, whereas FPRNa was not 
changed (Fig. 3). 
Adding aldosterone to the ongoing 
felodipine infusion attenuated the 
natriuretic effect of felodipine and 
counteracted the felodipine-mediated 
decreases of UK/U(Na+K) and FDRNa 
(Fig. 2 and 3). However, UNaV du-
ring simultaneous infusion of felodi-
pine and aldosterone clearly remained 
above baseline level (261 ±34 and 
158±24 μιηοΐ/min, P<0.01, Ta­
ble 2). Compared to felodipine alone, 
combined infusion of felodipine and 
aldosterone induced a sharp increase 
in FEK, which clearly exceeded the 
kaliuretic effect of aldosterone alone 
(+42±12 and + 7 ± 8 % compared to baseline, P<0.02, Fig. 2). As expected, 
aldosterone had no effect on the felodipine-mediated increase of diuresis and 
decrease of FPRNa (Fig. 2 and 3). 
On all three study days, similar small but significant (all Ρ< 0.02 compared 
to baseline) decreases of serum potassium were observed (-0.3 ±0.1 with 
felodipine alone, -0.2±0.1 with aldosterone alone, and -0.3±0.1 mmol/L with 
the combination, P=0.94). 
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Infusion: 
UNaV (μ/nol/min) 
baseline 
infusion 
UKV (μτηοΐ/min) 
baseline 
infusion 
U
a
V (μχηοΜηύη) 
baseline 
infusion 
Cl
u
 (ml/min) 
baseline 
infusion 
Table 2. Electrolyte 
Aldo 
156 ±24 
64+9Ϊ 
89+7 
88 + 8 
131 ±21 
56 ±8* 
29 ±2 
30±1 
excretions and lithium clearances. 
Felo+Aldo 
158 ±24 
261 ± 34t 
87 ±10 
114±8* 
126±19 
236±30 f 
31±2 
4 4 ± 3 t 
Felo 
138±19 
435 ±70+ 
75 ±10 
66±8 
102 ±13 
312±53 t 
29±1 
4 0 ± 3 f 
Ρ values 
A В 
<0.001 <0.01 
0.01 <0.01 
< 0.001 0.03 
<0.001 0.76 
Values are means±SEM. Felo=felodipine; Aldo = aldosterone. 
Ρ values: comparison of absolute changes from baseline induced by infusion; Ρ value A: 
felo+aldo vs aldo alone; Ρ value B: felo + aldo vs felo alone. 
t Ρ < 0.01 and * Ρ < 0.02 compared to baseline. 
Hormones and plasma drug levels 
PRA and РАС were measured for the first time 40 minutes after the start of 
felodipine or solvent, i.e. just before starting aldosterone or dextrose. These 
values as well as the means of the three values obtained thereafter are presented 
in Figure 4. Prior to the start of aldosterone, felodipine had resulted in a higher 
PRA than solvent, but this rise in PRA was not accompanied by a rise in РАС. 
Consequently, the PAC/PRA ratio was significantly lower 40 minutes after start 
of felodipine than after solvent (0.33±0.07 and 0.61 ±0.13, P<0.03). During 
continued infusion of felodipine alone, PRA did not change (Δ PRA -15 ±9 %, 
P=0.15), whereas РАС decreased by 26+8 % (P<0.03). PAC/PRA ratio 
remained suppressed (0.31 ±0.07). Exogenous aldosterone either added to 
felodipine or solvent increased РАС approximately tenfold, but the levels were 
somewhat lower during combined infusion with felodipine (P<0.01, Fig. 4). 
53 
Chapter 4 
"Proximal" Sodium Reabsorption 
Ч 
.J 
и 
0 78-
0 74-
0 70-
0.66-
0 991 
0.96 
o f ¿lo + dexí 
a 5o/v+ aldo 
ш/elo * aldo 
Ζ. 
Ч 
Π 0 93-
У: 
ί 
ρ 
Ρ 
0 90" 
0 ? 
0 5-
оз-
0 1-
"Distal" Sodium Reabsorption 
<0 01 
<0 01 
"Sodium-Potassium Exchange" 
Plasma felodipine levels were com­
parable before the start of aldosterone 
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DISCUSSION 
This study in healthy volunteers 
deals with the effects of exogenous 
aldosterone added to an ongoing 
felodipine infusion. As in our previ­
ous studies10,15, felodipine infusion 
had a distinct natriuretic and diuretic 
effect without increasing kaliuresis. 
Although infusion of calcium entry 
blockers into the renal artery may 
lead to some kaliuresis in animals27,28, 
in most clearance studies in humans 
felodipine and related dihydropyridine 
calcium entry blockers fail to increase 
urinary potassium excretion despite a 
clearcut rise in sodium excretion2,1214. This suggests that calcium entry blockers 
somehow act on the distal tubule. Theoretically, calcium entry blockers could 
inhibit potassium secretion by a direct effect on electrolyte transport at these 
distal tubular sites. Alternatively, they could specifically counteract the local 
action of aldosterone, or they could inhibit aldosterone release by the adrenal 
glands. In the present study, administration of exogenous aldosterone reduced 
sodium excretion and increased potassium excretion, especially when it was 
added to the ongoing felodipine infusion. Although the PACs during infusion 
were in the high physiological range29,30, our results demonstrate that felodipine 
Figure 3. Fractional proximal and distal 
tubular sodium reabsorption and sodium-
potassium exchange in the distal tubule 
before (baseline) and during drug and 
placebo infusions. Felo =felodipine; 
Solv=solvent; Aldo—aldosterone; Dext= 
dextrose. P-values on the right: compari­
son of mean absolute changes from base-
Une during the last three clearance 
periods. 
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is certainly not capable of fully bloc­
king the effects of aldosterone. Mo­
reover, the fact that aldosterone in­
duced a larger kaliuresis during com­
bined infusion with felodipine despite 
a somewhat lower PAC could suggest 
that the effect of aldosterone was 
even more pronounced during felodi­
pine. However, the effects of aldos­
terone on FDRNa and UK/U(Na+K) 
during felodipine and solvent are 
difficult to compare because the 
felodipine-induced changes could have 
influenced the effects of subsequent 
aldosterone infusion. Therefore, we 
cannot exclude with certainty that 
felodipine has any inhibitory effect on 
the local action of aldosterone (vide 
infra). 
Our data indicate that calcium entry 
blockers induce kaliuresis if sufficient 
amounts of aldosterone are present 
during treatment. In this respect, it is 
of interest that felodipine induced a 
rise of PRA without a concomitant 
increase of PAC, a dissociation that 
has been reported frequently2,17. Such 
a rise in PRA is observed only with 
dihydropyridine calcium entry bloc­
kers and is most likely due to sym­
pathetic stimulation and/or a decrease 
in renal perfusion pressure secondary to blood pressure reduction27. The absence 
of a concomitant rise in PAC could be due to inhibition of aldosterone secretion. 
In isolated bovine and human adrenal glomerulosa cells, calcium entry blockers 
and calmodulin inhibitors attenuate the aldosterone release in response to both 
ANG II and potassium31"33. However, although nanomolar concentrations of 
calcium entry blockers are sufficient to inhibit the effect of potassium32·34, 
micromolar concentrations are necessary to attenuate ANG II mediated aldoste-
d uring 
aldo or dext 
Figure 4. Plasma renin activity (PRA) and 
plasma aldosterone concentration (PAC) 
before and during aldosterone (aldo) or 
dextrose (dext) infusion. Values measured 
before aldo or dext were determined 40 
minutes after starting felodipine or solvent 
and indicate the acute effect of felodipine 
on PRA and PAC. The approximately 
tenfold increases in PAC during both 
infusions of exogenous aldosterone were 
also significant compared to values before 
aldo infusion (not indicated in the Figure) 
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rone release, possibly because T-type calcium channels are involved in this latter 
response35. In humans, calcium entry blockers blunted ANG II mediated 
aldosterone release in some15,36"38, but certainly not all studies11,39"41. Therefore, 
in humans it is uncertain whether the dissociation between PRA and aldosterone 
is due to direct inhibition of aldosterone release by glomerulosa cells. Alterna-
tively, this dissociation could be the consequence of either increased renal42 or 
hepatic clearance of aldosterone secondary to increases in renal and hepatic 
blood flow43 induced by calcium entry blockade. Of note, PACs during combi-
ned infusion of felodipine and aldosterone were lower than during aldosterone 
alone, possibly due to such an increased hepatic or renal clearance. Regardless 
of the mechanism actually involved, our data suggest that calcium entry blockers 
fail to induce excess urinary potassium loss at least partly because of their in-
trinsic ability to prevent a rise in PAC. 
The effects of exogenous aldosterone on potassium excretion were more 
pronounced during concomitant infusion of felodipine. At a fixed plasma 
aldosterone level, potassium excretion will depend on the electrochemical 
gradient across the apical tubular membrane in the cortical collecting ducts44 and 
thus on both distal tubular sodium reabsorption as well as distal tubular flow 
rate16. Therefore, the difference in kaliuretic effect of aldosterone during felodi-
pine and solvent is most readily explained by a felodipine-mediated increase in 
sodium and fluid delivery to distal tubular sites. It thus supports a proximal 
tubular site of action of calcium entry blockers, as already suggested by 
micropuncture studies in animals3"5 and by clearance studies in humans9,11"13. 
In view of such an effect of calcium entry blockers on proximal tubular 
sodium reabsorption, the question remains why the resulting increase of distal 
tubular sodium and fluid load does not lead to increased potassium excretion 
when these drugs are given alone, because calcium entry blockers do not 
actually decrease PAC in placebo controlled studies2,11,14,15'1M2.The fall of PAC 
that we observed during felodipine is not specific for this drug, because a 
similar decrease has been observed during placebo infusion (unpublished 
observations). However, it is possible that our methods are not sensitive enough 
to detect small but physiologically important decreases of PAC. Alternatively, 
calcium entry blockers could still have some inhibitory effect on the local action 
of aldosterone or could decrease distal tubular sodium reabsorption by some 
other mechanism. However, increasing PAC can apparently overrule possible 
other effects of calcium entry blockade on distal tubular sodium reabsorption 
and the ability of these drugs to prevent a rise of PAC seems essential for the 
absence of increased kaliuresis. 
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Some factors might have confounded the results of our study. First, 24-hour 
sodium excretion was lower before felodipine alone, suggesting a somewhat 
lower sodium intake in this period, which could have blunted the natriuretic 
effect on felodipine alone. However, during combined infusion of felodipine and 
aldosterone natriuresis was still much lower than during felodipine alone, 
thereby giving even more support to our conclusions. Second, during combined 
infusion with felodipine and aldosterone, a slight but significant increase in GFR 
was observed. We cannot exclude that this rise in GFR, although it did not 
differ from the change observed during felodipine alone, has contributed to an 
increased tubular sodium and fluid load and has favoured potassium secretion 
in this period. Third, it could be questioned whether physiologic amounts of 
aldosterone were administered. The infusion rate we used (0.83 μg/min = 1200 
/ig/day) approximately equals the maximum aldosterone secretion rate in healthy 
volunteers30. Endogenous aldosterone levels as high as the values that we 
observed during the infusion of exogenous aldosterone have been reached in 
ambulatory subjects only by combining a sodium restricted diet with high 
potassium intake or with diuretics29,30. Thus, our results should be confirmed in 
future studies using a model with a modest increase of endogenous aldosterone 
prior to infusion of felodipine. 
In conclusion, administration of exogenous aldosterone during felodipine 
attenuates its natriuretic effect and leads to a more pronounced kaliuresis than 
during aldosterone alone. Our data suggest that felodipine-mediated inhibition 
of aldosterone release plays an essential role in prevention of increased 
potassium excretion and also contributes to the natriuretic effect of this type of 
drug. Moreover, the pronounced kaliuresis during combined infusion of 
felodipine and aldosterone indicates increased distal delivery of sodium by 
felodipine and thus supports a proximal tubular site of action of felodipine. 
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Metoclopramide stimulates kaliuresis during felodipine 
without affecting its natriuresis 
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ABSTRACT 
Calcium entry blockers (СЕВ) such as felodipine induce an 
acute natriuresis without a parallel rise of potassium excretion. 
Previous studies with exogenous aldosterone and felodipine have 
suggested that the absence of kaliuresis might be explained by a 
CEB-induced inhibition of aldosterone release. The natriuresis 
with СЕВ could not be attributed to a similar mechanism, but 
might be due to stimulation of intrarenal natriuretic systems such 
as the dopaminergic system. We therefore studied whether the 
dopamine antagonist metoclopramide could prevent the 
natriuresis with low and therapeutic doses of felodipine and 
whether metoclopramide-induced aldosterone release promoted 
kaliuresis with felodipine. 
Twelve healthy male volunteers participated in a randomized, 
placebo-controlled, crossover study comparing felodipine infusion 
during metoclopramide (10 mg/hr) with felodipine alone. 
Metoclopramide per se induced a slight renal vasoconstriction. 
However, metoclopramide had no significant influence on the 
pronounced and dose-dependent increases of renal plasma flow 
and urinary sodium excretion with felodipine. Metoclopramide 
increased plasma aldosterone concentration (PAC) from 
0.17+0.03 to 0.60±0.14 nmol/L and subsequent felodipine 
infusion clearly increased urinary potassium excretion by 23 ± 6 
and 35 + 8 μπιοΐ/min (low and therapeutic doses). In contrast, 
potassium excretion remained stable with felodipine alone 
( + 5 + 4 and + 7 + 5 /miol/min, both P<0.01 compared to 
felodipine during metoclopramide). 
In conclusion, the natriuretic action of СЕВ cannot be 
explained by stimulation of the dopaminergic system. This 
natriuresis is accompanied by kaliuresis only in the presence of 
elevated endogenous PACs. The ability of СЕВ to prevent a rise 
of РАС thus seems essential for the prevention of urinary 
potassium losses. 
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INTRODUCTION 
Calcium entry blockers (СЕВ), especially dihydropyridines such as felodipine 
(PlendilR), are powerful vasodilating drugs useful for the treatment of 
hypertension1. These drugs have acute diuretic and natriuretic effects2, which 
may contribute to their antihypertensive action. Clearance studies in humans3"6 
and some micropuncture studies in animals7"9 have indicated that СЕВ decrease 
proximal tubular sodium reabsorption. However, the mechanisms responsible 
for CEB-mediated natriuresis remain unknown. Since selective administration 
of а СЕВ into the renal artery stimulates natriuresis10 an interaction with 
intrarenal natriuretic systems such as the dopaminergic system11 could be 
involved. 
We and others have observed that the increased sodium excretion during 
calcium entry blockade is not accompanied by a parallel increase of potassium 
excretion2,3,6'12. This is rather surprising in view of the aforementioned CEB-
mediated decrease of proximal tubular sodium reabsorption. We have previously 
demonstrated that simultaneous administration of exogenous aldosterone and 
felodipine was followed by a large increase of kaliuresis13. Therefore, the 
attenuation of potassium excretion during СЕВ might be explained by the well-
known CEB-mediated inhibition of aldosterone release14. 
Dopamine exerts its biological effects through occupation of the DA, and DA2 
receptor subtypes15. Stimulation of DA! receptors induces renal vasodilation and 
natriuresis11,16, whereas activation of the DA2 receptors leads to inhibition of 
norepinephrine and of aldosterone release11'17,18. Therefore, DA, receptor 
stimulation should be considered as a possible mechanism mediating natriuresis 
with СЕВ, especially since DA, receptor blockade attenuated the natriuretic 
effect of СЕВ in spontaneously hypertensive rats19. 
Since selective DA, receptor antagonists are not available for human studies, 
we used metoclopramide to delineate the role of the dopaminergic system in the 
natriuretic effect of different doses of felodipine. Metoclopramide also increases 
plasma aldosterone concentration (РАС)20 and thus enabled us to study the 
relation between CEB-induced natriuresis, endogenous aldosterone, and 
potassium excretion. In our previous study with exogenous aldosterone, this 
infusion resulted in relatively high РАС above 2.5 nmol/L. We therefore 
questioned whether an increase of endogenous aldosterone within the normal 
physiological range would also increase potassium excretion during CEB-
mediated natriuresis. 
63 
Chapter 5 
METHODS 
Subjects 
Twelve healthy male volunteers participated in this study. All participants 
were free of medication. Ages ranged from 20 to 33 years (mean 26) and all 
had a blood pressure below 140/90 (ranges, systolic 102 to 140 and diastolic 66 
to 86 mmHg), normal length (range, 172 to 191 cm) and body weight (range, 
64 to 81 kg). 
The study protocol was approved by the hospital ethics committee and all 
volunteers gave written informed consent. 
Study protocol 
The effects of felodipine during metoclopramide were compared to felodipine 
alone. As control, also placebo infusions were given. Thus, in three clearance 
experiments separated by washout periods of one week, all subjects received 
combined intravenous infusions of metoclopramide and felodipine, of placebo 
(5% dextrose) and felodipine, and of two placebos (5% dextrose and solvent). 
A randomised, single blind, two-way crossover design was used with the 
combination of metoclopramide and felodipine in order always immediately 
following dextrose and felodipine. Randomisation was balanced in blocks of 
two. Subjects were advised to keep their sodium intake constant on the last three 
days preceding clearance experiments. Dietary intake was checked by measuring 
creatinine, sodium and potassium in 24-hour urine samples collected on the last 
two days preceding clearance studies. On the eve of each clearance study, 600 
mg lithium carbonate (16.2 mmol lithium) was given orally. Subjects were asked 
to refrain from smoking and the use of alcohol for the last 24 hours and from 
caffeine-containing beverages for the last eight hours preceding clearance 
studies. 
On study days, the subjects consumed a light breakfast and drank 375 ml tap 
water. One hour thereafter, clearance experiments took place between 9.00 hr 
and 16.00 hr. Upon arrival, body weight was measured and water diuresis was 
induced by an additional oral water load of 15 ml/kg body weight, resulting in 
a urinary osmolality of 79 mosmol/kg (range, 48 to 122). During the whole 
experiment, 0.25 % sodium chloride in 3.3 % dextrose was infused at a rate of 
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400 ml/hr to maintain diuresis and to compensate for sodium losses observed 
previously during similar experiments with placebo21. Urinary volume losses in 
excess of 400 ml/hr were replaced orally by tap water. Subjects remained supine 
except for spontaneous voiding. With a continuous infusion technique described 
elsewhere12 renal plasma flow (RPF) and glomerular filtration rate (GFR) were 
estimated by measurement of renal clearances of para-aminohippuric acid (PAH) 
and inulin (polyfructosan, InutestR, Laevosan-Gesellschaft, Linz, Austria), 
respectively. After 90 min equilibration, two baseline urine samples of 30 min 
were collected. Thereafter, metoclopramide (PrimperanR, Delagrange, Chilly-
Mazarin, France) in 5% dextrose (1 mg of metoclopramide/ml) or 5% dextrose 
alone was infused through a separate intravenous cannula in the upper arm at 
an infusion rate of 20 ml/hr for the first 30 min and 10 ml/hr until the end of 
the experiment (cumulative dose 45 mg metoclopramide in 240 min). During 
metoclopramide and dextrose, two 30 min urine collections were made before 
felodipine or solvent was started in order to study the effect of pretreatment per 
se. Based on earlier studies3, we used a felodipine infusion schedule aiming at 
stable, subtherapeutic levels for the first 90 min (low dose) and therapeutic 
levels22 for the last 90 min (therapeutic dose). To reach this, 0.10 /xg/kg/min of 
felodipine (PlendilR) was infused for the first 30 min, followed by 0.04 
μg/kg/min for the following 60 min (cumulative dose 0.39±0.04 mg in 90 min, 
mean±SD). Thereafter, the infusion rate was increased to 0,14 μg/kg/min for 
another 30 min and 0.08 μg/kg/min for the last 60 min (cumulative dose 
0.66±0.05 mg in the last 90 min). Six additional 30 min urine samples were 
collected during felodipine and solvent infusions. Blood samples were drawn at 
the beginning and the end of each urine collection period. In blood and urine 
samples, PAH, inulin, sodium, potassium and chloride concentrations were 
measured by standard (semi)automated techniques, whereas lithium was 
determined by atomic absorption spectrophotometry. In blood samples, 
hematocrit (Ht) was determined by routine Coulter Counter, plasma renin 
activity (PRA) and PAC by radioimmunoassay23,24, and plasma felodipine levels 
by gas chromatography25. Blood pressures and pulse rates were recorded at three 
min intervals by an automatic device (Dinamap model 1846P, Critikon, Florida, 
USA), which directly measures mean arterial pressure (MAP). The mean values 
of five consecutive readings in the middle of each urine collection period were 
used for analysis. 
Of the various substances (x), clearances (Cl
x
), urinary excretions (UXV) and 
fractional excretions (FEX) were calculated according to standard formulas26 (Ux 
representing the urinary concentration and V the urinary flow rate). Filtration 
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fraction (FF) was calculated by (GFR/RPF)xlOO (%) and renal blood flow 
(RBF) by RPF/(1-Ht) (ml/min). GFR and RPF were adjusted to a standard body 
surface area of 1.73 m2. Renal vascular resistance (RVR) was calculated by 
1000xMAP/RBF (arbitrary units). Fractional proximal sodium reabsorption 
(FPRNa) and fractional distal sodium reabsorption (FDRNa) were calculated by 
the lithium clearance method27: 
FPRNe = (l-ClLi/GFR)xlOO (%). 
FDRNa = (l-ClNa/Clu)xlOO (%). 
Statistical analysis 
For baseline levels, means of the first two urine collection periods were 
calculated. The fourth urine collection period, measured just before starting 
felodipine or solvent, was used as pretreatment level. For the low and the 
therapeutic felodipine doses, mean values of the last two urine collections of 
each 90 min period were calculated, i.e. mean values of the sixth and seventh 
and mean values of the ninth and tenth clearance period were used, respectively. 
The effects of metoclopramide pretreatment perse were evaluated by comparing 
absolute changes from baseline level. The responses to felodipine infusions were 
evaluated by comparing absolute changes from pretreatment levels as measured 
just before starting felodipine or solvent. Infusion of felodipine alone was 
compared on the one hand to placebo infusion and on the other hand to 
felodipine during metoclopramide. 
Statistics were performed with SAS (Statistical Analysis System) software, 
using two tailed Wilcoxon's test for simple pairwise comparisons and repeated 
measures analysis of variance (ANOVA) for comparison of baseline data. 
Probability values below 0.05 were considered statistically significant. Results 
are presented as means±SEM. 
RESULTS 
All 12 volunteers completed the three clearance experiments. The most 
common side effects were restlessness during or after metoclopramide infusion 
(6/12) and self-limiting headache during felodipine infusion (4/12 compared to 
2/12 with solvent). One volunteer complained of drowsiness during felodipine 
infusion. 
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Table 1. Steady state data before clearance studies 
Body weight (kg) 
Urinary volume (ml/24 hr) 
Urinary sodium (mmol/24 hr) 
Urinary potassium (mmol/24 hr) 
Dext+Solv 
73.1 ±1.5 
1315±83 
135±10 
75 ±5 
Dext+Felo 
72.9 + 1.6 
1488 + 104 
139 ±9 
77+7 
Meto + Felo 
72.9 + 1.6 
1424 ±134 
156 ±20 
80±8 
Values are means±SEM. Dext=dextrose used as placebo; Solv=solvent used as 
placebo; Felo=felodipine; Meto=metoclopramide. 
Table 2. Baseline values of electrolyte excretions and systemic 
and renal hemodynamics 
MAP (mm Hg) 
Heart rate (beats/min) 
RPF (ml/min/1.73m2) 
GFR (ml/min/L73 m2) 
FF (%) 
Urinary flow (ml/min) 
FE,* (%) 
FEK (%) 
FE
a
 (%) 
FDR* (%) 
PRA (nmol/L/hr) 
PAC (nmol/L) 
Dext+Solv 
91±2 
58+2 
641+30 
126±5 
20±1 
15±1 
0.9+0.1 
17±2 
L0±0.2 
97 ±0 
0.66±0.13 
0.34+0.15 
Dext+Felo 
91+3 
55 + 2 
632 ±39 
125 ±4 
21 ±1 
15±1 
0.8 ±0.1 
13±2 
0.9±0.1 
97 ±0 
0.79+0.07 
0.28 ±0.09 
Meto+Felo 
88+21" 
54±2 
586±31 
122+6 
22 ±2 
16±1 
1.0 ±0.2 
16±2 
1.1+0.2 
96±1 
0.76±0.14 
0.17 ±0.03 
P-values 
0.02 
0.18 
0.10 
0.69 
0.52 
0.56 
0.25 
0.08 
0.25 
0.30 
0.61 
0.32 
Values are means±SEM. Baseline values were measured before starting drugs. 
Dext=dextrose used as placebo; Solv=solvent used as placebo; Felo=felodipine; 
Meto=metoclopramide. For other abbreviations see text. 
* Overall P-values for comparison of the three treatment periods by repeated measures 
analysis of variance, t Ρ < 0.05 compared to dext+felo. 
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Δ MAP Baseline data 
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Body weights and 24-hour urinary 
water, sodium, and potassium 
excretions were comparable before 
the three clearance experiments 
(Table 1). Baseline electrolyte excre­
tions, and baseline levels of systemic 
and renal hemodynamics did not 
differ between the three experimental 
periods except for the baseline MAP, 
which was slightly lower preceding 
metoclopramide infusion (Table 2). 
Systemic and renal hemodynamics 
Infusion of low dose felodipine 
decreased MAP from a pretreatment 
level of 89 ± 3 to 86 ± 2 mmHg 
(Fig. 1) and increased heart rate from 
55 ±2 to 60+2 beats/min (both 
Ρ < 0.05 compared to changes with 
solvent). Therapeutic dose felodipine 
increased heart rate further to 65 ± 3 
beats/min (Ж0.01), whereas the 
change of MAP no longer differed 
from the change with solvent 
(P>0.10, Fig. 1). Metoclopramide 
pretreatment did not change blood 
pressure or heart rate and did not 
influence the felodipine-mediated 
blood pressure changes. During simultaneous infusion of metoclopramide and 
therapeutic dose felodipine, the rise of heart rate was more pronounced than 
with felodipine alone ( + 1 6 ± 3 and + 1 0 ± 1 beats/min, respectively, P<0.05). 
Felodipine infusion alone induced a dose related increase of RPF (Fig. 1) and 
a decrease of FF (-2.3±0.4 and -3.7±0.5 % at low and therapeutic dose, both 
P<0.05 compared to solvent). Felodipine did not change GFR (Fig. 1). 
pretr 
60 
low-F 
180 
ther-F 
Figure 1. Changes of sytemic and renal 
hemodynamics. (O) =dextrose (dext) 
followed by solvent (solv); (Ώ) =dextrose 
followed by felodipine (felo); (Ш) -meto­
clopramide (meto) followed by felodipine. 
Pretr—pretreatment; Low-F and ther-F= 
low and therapeutic doses of felodipine; 
Ρ < 0.05 for comparison of dext + felo to 
meto4felo (changes from baseline); 
§P<0.05 and §§P<0.01 for comparison 
of dext4felo to dext-\-solv (changes from 
pretreatment). 
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Metoclopramide infusion per se had 
no influence on GFR and FF, but 
induced a slight renal vasoconstric­
tion. RPF decreased from 586±31 to 
568 ±29 ml/min/1.73 m2 (Δ RPF 
-18 ±7 compared to + 1 4 ± 11 ml/min/ 
1.73 m2 with dextrose, Ρ< 0.02, 
Fig. 1) and RVR increased from 
91 ± 6 to 94±5 units (Δ RVR + 3 ± 2 
compared to -3±2 units with 
dextrose, Ρ < 0.02). However, 
felodipine infusion induced the same 
r e n a l v a s o d i l a t i o n d u r i n g 
metoclopramide as during dextrose 
with comparable decreases of RVR 
(data not shown) and increases of 
RPF (low dose -f68 ±14 and 
+74± 16 ml/min/1.73 m2; therapeutic 
dose +128±15 and +152±27, 
P>0.10 for both doses, Fig. 1). 
- § § -
- § § -
+ 2% 
- § § -
J Meto or Dext L 
-60 
pretr 
60 
low-F 
120 180 
ther-F 
Diuresis and natriuresis 
Figure 2. Changes of urinary flow rate 
(V) and fractional sodium excretion 
(FEfJ; (O) =dextrose followed by 
solvent; (Ώ) = dextrose followed by 
felodipine; (Ш) = metoclopramide folio-
Felodipine infusion alone had a ^ b? ß^ine See Figure 1 for 
,. . j j , , _. abbreviations. P<0.05 and P<0.01 
distinct and dose-dependent diuretic for comparison of dext+felo to meto+felo 
and natriuretic effect with parallel (changes from baseline); ^P<0.01 for 
changes of chloride excretion (Fig. 2 comparison of dext+felo to dext+solv 
and Table 3). Metoclopramide per se W«»ses from pretreatment). 
induced a decrease of urinary flow 
rate and a minor decrease of sodium excretion which was only significant 
compared to dextrose preceding felodipine (Table 3 and Fig. 2). During ongoing 
metoclopramide infusion, felodipine still induced pronounced increases of 
natriuresis and diuresis, which were comparable to the responses with felodipine 
alone. Only the increase of UNaV induced by low dose felodipine tended to be 
attenuated by metoclopramide (+136+29 /¿mol/min compared to +171 ±26 
with felodipine alone, P=0.06). 
Both doses of felodipine significantly increased C1LÌ (Table 3) and decreased 
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-60 0 60 120 180 
pretr Ïow-F ther-F 
Figure 3. Changes of plasma aldosteron 
e concentration (РАС), fractional 
potassium excretion (FE^ and calculate 
d distal sodium reabsorption (FDRfJ; 
(O) -dextrose followed by solvent; 
(Ώ) -dextrose followed by felodipine; 
(Ш) ^metoclopramide followed by 
felodipine. See Figure 1 for abbreviation 
s. Ρ< 0.05 and *P<0.01 for 
comparison of dext+felo to meto+felo 
{changes from baseline); ^P<0.05 and 
" P < 0.01 for comparison of dext+felo to 
dext+solv (changes from pretreatment). 
calculated FPRNa (data not shown) 
and FDRNa (Fig. 3). Metoclopramide 
per se induced a slight decrease of 
CILi (Table 3) and tended to increase 
calculated FPRNâ (P=0.08 compared 
to dextrose preceding felodipine). 
However, metoclopramide did not 
affect the large felodipine-mediated 
increase of ClLi and decrease of 
FPRNa. Only the decrease of FDRNa 
induced by low dose felodipine was 
blunted by metoclopramide (-1.8±0.5 
compared to -2.6±0.3 % with 
felodipine alone, Ρ < 0.05). 
Kaliuresis 
On placebo days, potassium 
excretion steadily decreased with time 
(Fig. 3 and Table 3). In contrast, no 
such decrease of kaliuresis was 
observed with felodipine alone, thus 
suggesting that felodipine caused a 
slight relative increase of potassium 
excretion. Metoclopramide per se had 
no significant effect on potassium 
excretion, but adding felodipine to 
metoclopramide resulted in a prompt 
and clearcut increase of kaliuresis 
(Table 3 and Fig. 3). FEK thus 
increased from 1 3 ± 2 % t o l 8 ± 2 a t 
low and 20 ± 2 % at therapeutic dose 
felodipine (Δ FEK + 5 ± 1 % and 
+ 8±2 % compared to + 1 ± 1 and 
+ 2 ± 1 % with felodipine alone, both 
P<0.01). 
Felodipine and the dopaminergic system 
Hormones and plasma drug levels 
PRA gradually decreased during combined placebo infusion from a baseline 
level of 0.66+0.13 to 0.46+0.14 nmol/L/hr at the end of the experiment. On 
the other two experimental days, similar decreases of PRA were observed 
without any significant influence of metoclopramide nor of either dose of felo­
dipine. PRA decreased by 0.20+0.08 nmol/L/hr with felodipine alone and by 
0.07+0.11 with felodipine during metoclopramide. 
PAC also steadily decreased on placebo days and with felodipine alone 
Table 3. Electrolyte excretions before and during drug and placebo infusions. 
UNaV (μ/nol/min) 
UKV (μ/nol/min) 
U
a
V (vmollmin) 
С1
ь
 (ml/min) 
Dext+Solv 
Dext+Felo 
Meto+Felo 
Dext+Solv 
Dext+Felo 
Meto+Felo 
Dext+Solv 
Dext+Felo 
Meto+Felo 
Dext+Solv 
Dext+Felo 
Meto + Felo 
Baseline 
155 ±20 
142 ±17 
171 ±27 
91±9 
70±8 
84±11 
129±18 
115±16 
143 ±23 
32 ±2 
31 ± 2 
29 ±2 
Before F 
134 + 14 
141 ±21 
139 ±22 
70 ±4 
t 
63 ±7 
66±9 
100±11 
98 ±14 
114±16 
31 ±2 
31±2 
t 
27 ±2 
Low-F 
167 ±20 
312±37 
275 ±38 
58 ± 4 
68 ±8 
t 
88±12 
110±16 
226 ±24 
239 ±35 
31 ± 2 
38 ±2 
36±3 
Ther-F 
175 ±19 
* 
537 ±65 
489±81 
50+4 
70±7 
100±10 
101 ±13 
423 ±54 
430±71 
31±2 
43 ± 2 
44±4 
Values are means±SEM. Baseline values were measured before starting drugs. 
Before F=before starting felodipine or solvent, effect of pretreatment; Iow-F and 
ther-F=low and therapeutic doses of felodipine; Dext=dextrose used as placebo; Solv=solvent 
used as placebo; Felo=felodipine; Meto=metoclopramide. For other abbreviations see text. 
Baseline values were comparable (ANOVA). * Ρ < 0.01 and ^ Ρ < 0.05 compared to 
dext+felo, comparison of absolute changes from baseline level for pretreatment effect and 
absolute changes from pretreatment level for responses to felodipine infusion. 
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Felodipine (Fig. 3). However, metoclopramide 
per se induced a large rise of PAC 
from 0.17±0.03 to 0.60±0.14 
nmol/L (P<0.01 compared to 
dextrose) and PAC remained clearly 
higher during subsequent felodipine 
infusion than during felodipine alone 
(low dose 0.47 ±0Л0 vs 0.12±0.02 
nmol/L, P< 0.001 and therapeutic 
dose 0.32±0.08 vs 0.13 ±0.04, 
P=0.02, Fig. 3). 
Infusion of low dose felodipine led 
to stable, subtherapeutic plasma levels 
of approximately 4 nmol/L. Increa­
sing the dose more than doubled the 
drug levels to a therapeutic level22 of 
9 nmol/L (Fig. 4). Felodipine plasma 
levels were slightly but significantly higher during concomitant metoclopramide 
infusion (low dose 4.8±0.3 compared to 3.9±0.3 nmol/L with felodipine 
alone; therapeutic dose 9.3±0.4 vs 9.0±0.3, Ρ<0.05 for area under curve). 
-60 60 
Time (min) 
120 180 
Figure 4. Plasma felodipine (felo) levels 
during concomitant dextrose (dext, Ώ) 
and metoclopramide (meto, Ш) infusion. 
Ρ value for comparison of area under the 
curves (AUC). 
DISCUSSION 
In the present study in healthy volunteers, the aselective dopamine antagonist 
metoclopramide had no significant influence on the natriuretic and diuretic effect 
of either the low or the therapeutic dose of felodipine. Only the natriuretic effect 
of low dose felodipine was slightly, but insignificantly attenuated by 
metoclopramide. Thus, our data suggest that the natriuretic and diuretic effects 
of СЕВ cannot be explained by an interaction with the intrarenal dopaminergic 
system. 
Metoclopramide exhibits a preferential DA2 receptor selectivity
28,29
, however, 
at high dose also DA, receptors are blocked30. Thus, the question arises whether 
the dose in our study was high enough to block the tubular ΌΑ{ receptors, 
which mediate dopamine-induced natriuresis11,16,31. Studies in healthy volunteers 
have demonstrated that the same metoclopramide infusion schedule as used in 
our study inhibited the natriuretic action of a low dose of dopamine32 and also 
the natriuretic response to the selective DAj agonist fenoldopam33. These data 
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indicate that our metoclopramide dose is indeed capable of blocking DA, 
receptor mediated natriuresis. The use of a selective DA, receptor antagonist 
would of course have allowed more definitive conclusions, but such compounds 
are not available for human studies. 
Our data seem to be in contrast to animal studies, because the selective DA, 
antagonist SCH-23990 prevented the natriuretic effect of nitrendipine and 
diltiazem in spontaneously hypertensive ratsï9. However, it is difficult to 
translate these data to the human situation because very high drug doses were 
used and, consequently, very large changes of blood pressure were observed. 
Of note, in these rats indomethacin also attenuated the natriuresis with 
diltiazem19, whereas such an effect could not be confirmed in humans34. 
Our results do not exclude the possibility that metoclopramide slightly 
attenuates the natriuretic effect of low doses of СЕВ. Although the effects of 
metoclopramide on felodipine-induced natriuresis failed to reach statistical 
significance, sodium excretion tended to be lower. Plasma felodipine levels 
were, however, higher during concomitant metoclopramide infusion, possibly 
due to a decreased metabolic clearance of felodipine. As the natriuretic effects 
of СЕВ appear to be dose dependent35, one might have expected higher rates of 
sodium excretion in this period with higher felodipine levels. Our data are thus 
in line with observations in hypertensive patients, where metoclopramide largely 
prevented the natriuresis of a very low dose of nicardipine, but did not affect 
the natriuretic action of a therapeutic dose36. Taken together, these data might 
suggest a, albeit limited, role for the dopaminergic system in CEB-induced 
natriuresis. However, the attenuation of the natriuretic effect of low doses of 
СЕВ could easily be explained by other effects of metoclopramide, which are 
not mediated through blockade of DA, receptors. Indeed, metoclopramide 
induced a large increase of РАС, which might have attenuated the natriuresis 
with felodipine comparable to the attenuation of natriuresis in our study with 
exogenous aldosterone and felodipine13. This possibility is further supported by 
the results of the present study where metoclopramide attenuated the felodipine-
mediated decrease of distal and not of proximal tubular sodium reabsorption. 
In the setting of elevated PAC during metoclopramide infusion, felodipine 
induced an immediate increase of potassium excretion. This observation is 
noteworthy, since we and others have observed that the natriuresis of СЕВ is 
usually not accompanied by an increase of kaliuresis2,3,612. This absence of 
kaliuresis is surprising in view of the fact that clearance studies in humans4"6 and 
some micropuncture studies in animals7"9 have indicated that СЕВ decrease 
proximal tubular sodium reabsorption. Such a decrease in proximal sodium 
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reabsorption and the subsequent increase of distal tubular sodium and fluid load 
should normally enhance potassium excretion, as is observed with diuretics such 
as furosemide37. Thus, it seems likely that СЕВ also act at a distal tubular site. 
In this respect, it is of interest that dihydropyridine СЕВ can induce a rise of 
PRA without a parallel increase of РАС214, possibly due to direct inhibition of 
aldosterone release by adrenal glomerulosa cells38,39. We suggest that this 
inhibition of aldosterone release is essential for the dissociation between the 
natriuretic and kaliuretic effect of СЕВ. In a previous study, we demonstrated 
that adding exogenous aldosterone to a felodipine infusion resulted in a major 
increase of potassium excretion that was more pronounced than with aldosterone 
alone. However, definite conclusions could not be drawn since РАС were 
relatively high ( > 2.5 nmol/L). Our present findings now confirm that elevated 
endogenous aldosterone levels within the physiological range, as induced by 
metoclopramide, also enabled felodipine to induce kaliuresis. It should be noted 
that it is unlikely that metoclopramide administration per se is the cause of the 
increased potassium excretion, because others have not observed such kaliuretic 
effects of metoclopramide40"42. 
In conclusion, dopaminergic receptor blockade with metoclopramide does not 
prevent the natriuretic effect of low and therapeutic doses of felodipine, thereby 
indicating that the dopaminergic system does not play a major role in the 
natriuretic action of СЕВ. In contrast to felodipine alone, simultaneous infusion 
of metoclopramide and felodipine led to a marked kaliuresis as a consequence 
of the metoclopramide-mediated rise of aldosterone. This confirms earlier 
findings with exogenous aldosterone and indicates that СЕВ will induce 
kaliuresis if sufficient amounts of aldosterone are available. The inhibitory effect 
of СЕВ on aldosterone release thus prevents urinary potassium losses despite an 
increase of natriuresis and diuresis. 
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ABSTRACT 
In contrast to other types of directly acting vasodilators, cal-
cium entry blockers promote sodium excretion. It is not well 
established, however, whether these drugs also induce natriu-
resis in hypertensive patients with renal disease. 
Therefore, we studied the acute effects of the dihydropyri-
dine calcium entry blocker felodipine in nine such patients 
(CCr 68 ±19 ml/min) and 12 healthy normotensive subjects. In 
both the hypertensive patients and the normotensive subjects 
total and fractional sodium excretion rose during the first 40 
minutes of intravenous felodipine infusion: in the hypertensive 
patients this rise of sodium excretion was positively correlated 
to the initial glomerular filtration rate (GFR) (r=0.87, 
P<0.01). In the patients, during ongoing felodipine infusion, 
natriuresis was attenuated in the setting of a large continuing 
decrease of blood pressure. In contrast, in the normotensive 
subjects, in whom blood pressure did not fall any further, a 
steady rise of sodium excretion was observed. In both the 
hypertensive patients and the normotensive subjects GFR 
remained unchanged and renal vascular resistance decreased, 
whereas renal plasma flow increased only in the latter group. 
Changes in sodium excretion were not correlated to changes in 
renal hemodynamic parameters. 
It is concluded, that also in hypertensive patients with 
diminished renal function felodipine exerts a potentially advan-
tageous natriuretic effect. However, this natriuretic effect is 
possibly less at lower GFR and seems to be attenuated by 
blood pressure reduction. The mechanism of this natriuretic 
effect as well as its contribution to the antihypertensive effect 
of felodipine still has to be clarified. 
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INTRODUCTION 
Calcium entry blockers are effective antihypertensive agents with few side 
effects1. In contrast to other vasodilators23, they have a diuretic and natriure-
tic effect in both healthy volunteers and patients with essential hyperten-
sion4"6. It has been suggested that this natriuretic effect contributes to the 
antihypertensive effects of these drugs4,7. It is not well established, whether 
calcium entry blockers also induce natriuresis in hypertensive patients with 
renal disease. In such patients a natriuretic effect of a vasodilator might be of 
specific value, since in many of them sodium and water retention is directly 
involved in inducing and sustaining hypertension2. Therefore, we studied the 
influence of the dihydropyridine calcium entry blocker felodipine on sodium 
excretion, blood pressure, and renal hemodynamics in hypertensive patients 
with renal disease. 
PATIENTS AND METHODS 
We studied the acute effects of an intravenous felodipine infusion in nine 
patients, five men and four women, mean age (±SD) 40±14 years, and 
endogenous creatinine clearance (CCr) 68±19 ml/min (expressed per 1.73 m2 
BS A, like glomerular filtration rate, GFR and renal plasma flow, RPF). 
Three patients had essential hypertension and a CCr below 100 ml/min and six 
had hypertension complicating renal disease (three chronic glomerulonephri-
tis, two chronic pyelonephritis, and one polycystic kidney disease). Antihy-
pertensive drugs were discontinued for at least two days. After an oral water 
load of 800 ml they received 400 ml of fluid and 17 mmol sodium chloride 
per hour intravenously during five hours; urinary volume losses in excess of 
the infusion rate were compensated for by oral water intake. After 2.5 hours 
of equilibration felodipine was infused at a constant rate of 0.01 mg/min for 
two hours (total dose 1.2 mg). Blood pressure was recorded automatically 
(Arteriosonde 1225) every two min. GFR and RPF were estimated at 40-
minute intervals by measuring the renal clearance of continuously infused 
inulin (laevofructosan,InutestR) and PAH as described previously8; in the 
same periods renal clearances of sodium were determined. During felodipine 
infusion blood samples were taken for the determination of plasma drug 
levels by gas chromatography9. For comparison, using the same protocol we 
also studied the effects of felodipine infusion in 12 healthy male volunteers, 
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age 28±4 years, CCr 134± 12 ml/min. However, they received felodipine at a 
rate of 0.012 mg/min during the first 40 min, and at a rate of 0.005 mg/min 
thereafter, resulting in a mean total dose of 0.088 mg. 
Mean arterial blood pressure (MAP) was defined as the diastolic plus one 
third of the pulse pressure. Filtration fraction (FF) was calculated as GFR/ 
RPF. Renal vascular resistance (RVR) was calculated as 1000*MAP/RPF, 
expressed in arbitrary units. Because of the wide range of RVR values a 
logarithmic scale was used for graphical presentation. FENa was expressed as 
a percentage of GFR. 
For statistical analysis of changes of renal clearances and hemodynamic 
parameters mean values of the last two 40-minute periods preceding felodi­
pine infusion were used as baseline levels. Relative changes from these 
baseline levels in the three 40-minute periods during felodipine infusion were 
analyzed by Wilcoxon's rank sum test for paired observations. Correlations 
were calculated according to Spearman. A P-value of 0.05 was considered as 
the level of statistical significance. All results are given as means+SEM. The 
study protocols were approved by the Ethics Committee of the University 
Hospital Nijmegen. 
RESULTS 
The influence of felodipine infusion on urinary sodium excretion and on 
renal and systemic hemodynamics is shown in Figures 1 and 2. In the 
hypertensive patients absolute and fractional sodium excretions during 
felodipine infusion were 93±54 % and 100±54 % above pretreatment level, 
respectively. The mean level of MAP throughout the whole period of 
felodipine infusion was 12 ±1 % (/><0.01) below and that of heart rate 
18 ±5 % (P<0.01) above baseline level. In the last period of felodipine 
infusion blood pressure had decreased by 17±2 % from an initial level of 
171±11/110±4 to 145±9/86±3 mmHg. GFR and RPF did not change 
significantly. The mean decrease of FF was 10±3 % (Ж0.02) and that of 
RVR 15±4 % (P<0.01). In the last two periods of felodipine infusion 
urinary sodium excretion did not rise further, whereas a steady decrease of 
blood pressure and RVR was observed (Fig. 1 and 2). Plasma felodipine 
levels increased gradually in each patient during infusion. The correlation 
between basal GFR and the increase of sodium excretion throughout the 
whole period of felodipine infusion failed to be significant (r=0.53). How-
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ever, as shown in Figure 3, the rise of 
sodium excretion in the first 40 min of 
felodipine infusion was positively 
correlated to the initial GFR level 
(r=0.87, Ж0.01) . We found no 
significant correlations between chan­
ges in total or fractional sodium ex­
cretion on the one hand and changes in 
systemic or renal hemodynamics on 
the other hand. 
In the healthy volunteers absolute 
and fractional sodium excretions were 
169±28 % (P<0.01) and 161 ±25 % 
(P<0.01) above baseline level, respec­
tively. The difference in sodium ex­
cretion between normotensive and 
hypertensive subjects may seem more 
striking as shown in Figure 1 than as 
suggested by the percentage changes; 
however, it should be realized, that 
graphically the means of absolute 
values of sodium excretion instead of 
relative changes are presented. Heart 
rate was 15±2 % above (P<0.01) and 
MAP only 5 ± 1 % (/><0.01) below 
pretreatment level. Blood pressure 
decreased from an initial level of 
121±3/74±3 to 119±3/70±3 mmHg 
at the end of felodipine infusion. Also 
here, GFR did not change. During the 
whole period of felodipine infusion 
RPF rose by 13±4 % (P<0.02), 
accompanied by decreases of FF 
(-8±3 %, P<0.02) and RVR (-14±3 
%, /><0.01). Figure 1 shows that in 
the healthy volunteers sodium excreti­
on rose continuously during felodipine 
infusion. This steady rise coincided 
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Figure L Total (U^V) and fractional 
(FEfiJ sodium excretion, mean 
arterial pressure (MAP), and plasma 
felodipine levels (plasma F) in 12 
normotensive volunteers (O) and 
nine hypertensive patients with renal 
disease (Ш) before and during 
felodipine infusion. *P<0.05 and 
m
*P<0.01, compared to baseline 
values. 
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with an ongoing rise of RPF and a 
further decrease of RVR, but without a 
further decrease of blood pressure 
(Fig. 1 and 2). Also in the healthy 
volunteers we found no correlations 
between the rise of sodium excretion 
and the changes of systemic and renal 
hemodynamic parameters. Due to the 
slightly different infusion protocol the 
plasma felodipine levels were about 
constant throughout the felodipine infu­
sion period. 
DISCUSSION 
In contrast to the experience with 
other types of directly acting vasodila­
tors2,3 we observed a distinct natriure­
tic effect of the calcium entry blocker 
felodipine, also in hypertensive pa­
tients with renal disease. It is very 
improbable that the observed increase 
of sodium excretion has to be attribu­
ted to factors other than the adminis­
tration of felodipine, since sodium 
excretion was stable in the last two 
periods before felodipine infusion and 
increased already in the first period 
after the start of felodipine. The in­
crease of sodium excretion on felodi­
pine administration in the normoten-
sive volunteers was of about the same 
magnitude as in comparable stu­
dies5,8,10,11, where also no large decreases of blood pressure after felodipine 
administration were observed. In comparison to the effects in the normoten-
sive subjects, the natriuresis on felodipine in the hypertensive patients in the 
present study was not very large and possibly less at lower levels of GFR, 
0 40 80 
Time (min) 
120 
Figure 2. GFR, RPFt FF, and RVR 
in 12 normotensive subjects (O) and 
nine hypertensive patients with renal 
disease (Ш) before and during 
felodipine infusion, *P<0.05 and 
**P<0.01, compared to baseline 
values. 
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despite comparable initial so­
dium excretion rates in patients 
and volunteers. Moreover, in 
the hypertensive patients sodi­
um excretion did not gradually 
increase during ongoing felodi­
pine infusion. Theoretically, the 
small differences in infusion 
rates of felodipine between the 
two groups could be responsi­
ble for differences in the course 
of sodium excretion. However, 
it is clear from Figure 1, that 
the absence of a further rise of 
sodium excretion during on­
going felodipine infusion in the 
hypertensive patients cannot be 
ascribed to lower plasma felo­
dipine levels in these patients 
than in the normotensive sub­
jects. The finding that sodium 
hypertensive patients could very well be related to the large decrease of 
blood pressure and hence of renal perfusion pressure at gradually rising 
plasma felodipine levels in the hypertensive patients10,12. This explanation is 
in agreement with observations in patients with essential hypertension, where 
acute felodipine administration induced a somewhat less impressive increase 
of sodium excretion accompanied by a more distinct decrease of blood 
pressure than in the normotensive subjects in our study13,14. 
In normotensive subjects and in patients with essential hypertension 
calcium entry blockers generally induce an acute increase or no change in 
GFR and RPF and a decrease of RVR, accompanying the rise of sodium 
excretion15"18. After acute administration of felodipine in patients with 
essential hypertension, rises of renal perfusion without changes in GFR have 
been observed13,14. In the normotensive volunteers we observed a rise of RPF 
and a decrease of RVR, without a change of GFR, as we have seen before8. 
In accordance with some19"21, but not all16 studies concerning the renal effects 
of calcium entry blockers in patients with kidney disease, we saw no signifi­
cant increase of RPF, and also no change of GFR in our patients. Yet, 
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Figure 3. Correlation between baseline GFR 
and the increase of sodium excretion during 
the first 40 min of felodipine infusion (AU^V) 
in nine hypertensive patients with renal 
disease. 
excretion did not increase further in the 
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calculated RVR decreased, which may be the consequence of a direct effect 
of felodipine in the kidney or merely of adaptive autoregulation due to the 
reduction of systemic blood pressure. The absence of a rise of GFR and the 
observed increase of fractional sodium excretion indicates that the natriuresis 
on felodipine is a consequence of a decrease of tubular sodium reabsorption. 
As others15, we cannot readily explain the natriuretic effect of felodipine 
from changes in RPF, FF or RVR, since we found no correlations between 
changes in these parameters of renal hemodynamics and the increase of 
sodium excretion on felodipine. As will be discussed in more detail elsewhere 
in this issue, the mechanism of the natriuretic effect of felodipine still 
remains unclear. Whatever the mechanism may be, it might contribute to the 
chronic antihypertensive effect of calcium entry blockers as suggested before, 
since sodium balance remains negative during long term administration of 
dihydropyridine calcium entry blockers4,7. In the hypertensive patients with 
renal disease the role of the natriuretic capacity of felodipine in its antihyper-
tensive effect may be more prominent than suggested by the relatively small 
increase of sodium excretion in this study, since at this level of blood 
pressure reduction through peripheral vasodilation sodium retention was to be 
expected2,3. Such sodium retention, observed during the use of directly acting 
vasodilators other than calcium entry blockers, is supposed to antagonize the 
antihypertensive effect of these drugs2,3. Finally, the natriuretic effect of 
felodipine might reduce the incidence of edema formation, often observed 
during the administration of vasodilating agents3,22. 
In conclusion, felodipine has an acute natriuretic effect in hypertensive 
patients with renal disease, albeit possibly less at lower GFR. The very 
effective blood pressure reduction by felodipine probably attenuated the 
natriuretic effect of this drug in our patients. Conversely, it is not clear to 
what extent this natriuretic effect contributes to blood pressure lowering by 
felodipine. The felodipine-induced increase in sodium excretion is accompa-
nied by decreases of FF and RVR and, in healthy volunteers, by an increase 
of RPF. However, the natriuretic effect cannot readily be explained by these 
changes in renal hemodynamics and needs further elucidation. 
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Influence of salt intake on the hypotensive and natriuretic 
responses to felodipine 
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ABSTRACT 
Calcium entry blockers (СЕВ) such as felodipine are powerful 
arteriolar vasodilators which also induce natriuresis. Several 
studies have suggested that СЕВ reduce blood pressure more 
effectively at higher salt intakes, which might be due to a larger 
natriuretic effect. 
We therefore studied the hypotensive and natriuretic responses 
to felodipine during low salt (LS, 50 mmol NaCl/day) and high 
salt diet (HS, 300 mmol NaCl/day) in 12 hypertensive 
outpatients. Placebo was given the first week of randomly 
allocated diet periods. The acute effects of felodipine oral 
solution 5 mg were studied on the eighth day. During the second 
week of each diet, felodipine 5 mg bid was given to study its 
chronic effect. 
At the end of the placebo period, mean arterial pressure 
(MAP, Dinamap) was higher during HS than during LS (120 ± 4 
and 115±2 mm Hg, P<0.02). Felodipine oral solution induced 
comparable hypotensive responses during HS (-12 ± 1 %) and LS 
(-11 ±1 %) despite a greater sodium loss during HS (+288 ±54 
μπίθΐ/min above baseline compared to +108±15 during LS, 
P<0.01). Also chronic felodipine decreased MAP to the same 
degree during HS (-10±2 %) and LS (-9±1 %). The lowest 
MAP was thus reached when using felodipine during LS (103 ± 2 
vs. 109±3 mm Hg at HS, P<0.02). During both diets, chronic 
felodipine decreased body weight (-0.5 ±0.2 kg) and increased 
foot volume (+1.7±0.8 %). The highest foot volumes and 
visible edema were observed with felodipine at HS. Felodipine 
did not change plasma volume, ANP, or serum albumin, but the 
diet-induced differences in these parameters had disappeared after 
felodipine. 
In conclusion, felodipine induced comparable hypotensive 
responses during different salt intakes despite a larger natriuretic 
effect at HS. The combination of LS and felodipine resulted in 
the lowest blood pressure and the least edema. We therefore 
would not advise unrestricted salt intake during treatment with 
СЕВ. 
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INTRODUCTION 
Calcium entry blockers (СЕВ), especially dihydropyridines such as felodipine, 
are effective antihypertensive drugs with few side effects1. In contrast to the 
sodium retaining effect of other vasodilators2, СЕВ have a well established acute 
natriuretic effect in both normotensive volunteers and hypertensive patients3. 
Although it has been questioned whether this acute sodium loss is maintained in 
the long term, most sodium balance studies performed after initiation4 6 or 
discontinuation of а СЕВ7 9 favour a long term reduction in sodium balance. It 
is still unclear, however, whether the natriuretic effect contributes to the 
hypotensive response to СЕВ. It is also a matter of discussion whether dietary 
sodium intake influences the antihypertensive effect of these drugs10,11. 
Several5,12,13, but not all14 studies have indicated that the hypotensive response 
to СЕВ is larger during a salt supplemented diet than during dietary salt 
restriction. Theoretically, such an enhanced hypotensive response during high 
salt intake might be explained by a larger natriuretic effect12 or, alternatively, 
to an enhanced reactivity of vascular smooth muscle cells15. In the present study 
in hypertensive patients, we evaluated the influence of dietary salt intake on the 
acute and chronic hypotensive and natriuretic responses to felodipine. Several 
indices of intravascular volume were measured to estimate the long term 
changes in sodium balance. 
METHODS 
Patients 
For this study, we selected patients with established hypertension and a 
diastolic blood pressure above 95 mm Hg without antihypertensive treatment. 
Patients with signs of secondary hypertension, ischemic heart disease, 
cerebrovascular disease, diabetes mellitus or renal failure (endogenous creatinine 
clearance below 80 ml/min/1.73 m2) were excluded. One female with essential 
hypertension and coexisting benign glomerular haematuria was included. The 
study protocol was approved by the hospital Ethics Committee. 
Twelve white patients (three women) who gave written informed consent 
entered the study at least two weeks after withdrawal of all antihypertensive 
drugs. On entry, blood pressure was 167/103 (SD 19/5) mm Hg by mercury 
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sphygmomanometry. Mean age was 50 years (range 36-65) and mean body mass 
index 26 kg/m2 (range 21-32). Nine patients were free of medication, whereas 
two patients continued the use of diazepam and allopurinol, respectively. 
Another patient using low dose phentolamine for urologie problems was later 
excluded from data analysis because of non-compliance with the sodium 
restricted diet (see results). Three patients occasionally used acetaminophen for 
headache. 
Study protocol 
In random sequence, a low salt (LS, 50 mmol NaCl/day) and a high salt diet 
(HS, 300 mmol NaCl/day) was prescribed for periods of two weeks, separated 
by an interval of at least four weeks. LS intake was reached by dietary advise 
and HS intake by adding on average 15 Slow Sodium tablets daily (Ciba Geigy, 
Basel, CH, 10 mmol NaCl/tablet) to a sodium constant diet. Adherence to the 
diets was tested by measuring creatinine, sodium and potassium concentrations 
in 24-hour urine collections. Urine sodium and potassium excretions were 
adjusted to individual mean 24-hour creatinine excretions. 
In a single blind manner, placebo was given the first week and felodipine the 
second week of each diet period. Felodipine extended release 5 mg (PlendilR) 
was given twice daily in order to obtain stable plasma drug levels throughout 24 
hours16. The influence of the diet per se and the acute effects of felodipine oral 
solution 5 mg were determined on the eighth day, whereas the chronic effects 
of felodipine were measured on the fifteenth day of both diets. On the eve of all 
measurements, 600 mg of lithium carbonate (16.2 mmol Li2+) was given orally. 
Patients were asked to refrain from smoking and the use of alcohol for the last 
24 hours and from caffeine-containing beverages for the last eight hours 
preceding measurements. 
On the eighth and the fifteenth day, patients consumed a light breakfast, drank 
250 ml of tap water and took their last placebo or felodipine tablet one hour 
before arrival at the ward, where measurements were performed always in the 
same room and at the same time of the day. Upon arrival, foot volume was 
recorded with a recently developed, accurate method using a sensitive balance 
to measure the water displacement induced by immersion of the foot (intra-
individual coefficient of variation 1.31 % for day to day variability). Body 
weight was measured after voiding and diuresis was induced by a fixed water 
intake of 375 ml in 60 min. A baseline blood sample was collected and supine 
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blood pressures and pulse rates were recorded at two min intervals for 30 min 
with an automatic device (Dinamap model 1846P, Critikon, Tampa, Florida, 
USA). The mean values of the last 10 recordings were used for analysis. 
Immediately after the supine rest, another blood sample was taken for 
determination of hormones. Subsequently, plasma volume was measured by 
standard isotope dilution technique17: 2 /¿Ci of radioiodinated human serum 
albumen (,25I-HSA) was injected intravenously. Before injection and four times 
at five min intervals thereafter, blood samples were collected from the 
contralateral arm for determination of plasma 125I concentrations. Another blood 
and urine sample was collected for estimation of renal clearances. 
Only on the eighth day, the experiment continued with the gift of felodipine 
5 mg oral solution and an additional oral water load of 450 ml in 60 min. 
Supine blood pressures and heart rates were recorded at two min intervals 0-60 
and 120-150 min after felodipine. At the end of these supine recordings, blood 
and urine samples were collected for measurement of renal clearances. Foot 
volume, body weight and hormones were measured 150 min after felodipine oral 
solution. 
In blood and urine samples, creatinine, sodium, potassium, chloride, urate, 
and phosphate concentrations were measured by standard (semi)automated 
techniques and lithium by atomic absorption spectrophotometry. Hemoglobin 
and hematocrit (Ht) were determined by routine Coulter Counter, serum albumin 
by an automated bromine cresol green method, and plasma renin activity (PRA) 
with the Phadebas angiotensin I test (Pharmacia Diagnostics, Sweden). Atrial 
natriuretic peptide (ANP) and plasma aldosterone concentration (PAC) were 
measured by radioimmunoassays18,19 and plasma felodipine levels by gas 
chromatography20. 
Urinary excretions (UXV), clearances (CIJ, and fractional excretions (FEX) 
were calculated according to standard formulas21, using Clcrcat as an estimate of 
glomerular filtration rate. Fractional proximal sodium reabsorption (FPRNa) and 
fractional distal sodium reabsorption (FDRNJ were calculated by the lithium 
clearance method22: 
FPRNft = (l-FELl)xl00 (%). 
FDRNa = (l-ClNa/ClLl)xl00 (%). 
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Statistical analysis 
Statistics were performed with SAS (Statistical Analysis System) software. 
The possibility that the order of the diets influenced various parameters was 
tested by standard two-sample T-tests23. Two tailed Wilcoxon's rank sum test 
was used for all pairwise comparisons. Probability values below 0.05 were 
considered statistically significant. Results are presented as means ± SEM and 
"NSH indicates Ρ values above 0.10. 
RESULTS 
Side effects and compliance 
The most common side effect of felodipine oral solution was headache (10 
patients during either diet), whereas dizziness (2) and flushing (1) were noted 
in the HS period. The only side effect that was reported more frequently with 
chronic felodipine than with placebo was edema in the HS (3), but not in the LS 
period. 
All participants completed the study protocol. However, one male subject was 
excluded from data analysis because of noncompliance with the sodium 
restricted diet (average urine Na+ 252 mmol/day). The 11 remaining patients all 
had a urinary sodium excretion below 100 mmol/day with LS and above 200 
Table L Steady state 24 hour urinary excretions during placebo and during felodipine. 
Urinary volume (ml/24 h) 
Urinary Na+ (mmol/24 h) 
Urinary K+ (mmol/24 h) 
Plac 
Felo 
Plac 
Felo 
Plac 
Felo 
Low salt 
1634 ±136 
1737 ±182 
51 ±7 
69 ±8 
78 ±5 
81 ±6 
High salt 
1833 ±116 
2043 ±100 
279 ±22 
301 ±20 
75 ±5 
80 ±5 
Ρ value 
NS 
NS 
<0.01 
<0.01 
NS 
NS 
Values (means ± SEM) are averages for the last two days of placebo (plac) and the last 
two days of felodipine (felo). 
Ρ values for differences between low and high salt diet. 
None of the differences between felodipine and placebo reached significance (P>0.10). 
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eighth day 
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Figure 1. Course of mean arterial pressure (MAP) and heart rate (HR) 
on two different diets. Baseline values (-70 min) were measured after 
one week of placebo (plac, eighth day). Acute effect offelodipine 
(felo) oral solution 5 mg (eighth day) and chronic effect of one week 
felodipine 5 mg bid (15th day) are illustrated. NS (P>0.10) or 
numbers regard differences between low and high salt diets. Ρ< 0.05 
and Ρ< 0.01 compared to baseline values. Error bars indicate SEM. 
mmol/day with HS. Compliance to both diets was as good during felodipine as 
during placebo (Table 1). Daily urinary volumes and urinary potassium 
excretions did not differ between LS and HS (Table 1). 
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Table 2. Effect of placebo and chronic felodipine on body weights, foot volumes 
and indices of intravascular volume. 
Body weight (kg) 
Foot volume (ml) 
Plasma volume (ml) 
Serum albumin (gfl) 
Hematocrit (%) 
Plac 
Felo 
Plac 
Felo 
Plac 
Felo 
Plac 
Felo 
Plac 
Felo 
Low salt 
76.6+2.6 
76.1 ±2.5"^ 
1213+44 
1232+40 
2800 + 111 
2928 ±129 
45.8+0.6 
44.7+0.7 
43.3 + 1.0 
41.8+0.8 
High salt 
77.9 ±2.7 
77.4±2.7t 
1237 ±43 
1258 ±43* 
3034 ±133 
2977 ±142 
44.5 ±0.8 
45.1 ±0.6 
41.6±0.9 
41.4±0.8 
Ρ value 
0.02 
<0.01 
<0.01 
<0.01 
<0.01 
NS 
0.03 
NS 
0.08 
NS 
Values are expressed as means ± SEM. Plac=pi acebo; Felo=fel od ip ine. 
Ρ values for differences between low and high salt diet. 
tp<0.05 for the difference between placebo and felodipine. 
Effects of salt intake 
The order of the two diets appeared to change their effect on hemoglobin and 
Clercs (both Ρ<0.05 for period effect), implicating that the influence of the diet 
on these parameters could not be evaluated. 
On the eighth day after one week of placebo, supine mean arterial pressure 
(MAP) was higher during HS than during LS (120±4 and 115+2 mm Hg, 
respectively, Ρ<0.02, Fig. 1), whereas heart rates did not differ. In four 
patients, the MAP was at least 5 (range 7-25) mm Hg higher during HS than 
during LS. Body weight, plasma volume, and also foot volume were higher 
during HS, whereas serum albumin was lower in this period (Table 2). As 
expected, PRA and PAC were lower and ANP was higher during HS than 
during LS (PRA: 0.63±0.16 vs. 1.47±0.28 nmol/l/h; PAC: 0.19±0.02 vs. 
0.56±0.11 nmol/1; ANP: 12.1 ±1.7 vs. 8.0±1.0 pmol/1, all differences 
P<0.01, Fig. 2). 
94 
Sodium intake and effects of felodipine 
1 °·4" 
á 0.2-
^ 
I 1.0-
< 
o- 0.5-
S 12-
g 10-
PS S" 
5 6-
plac 
rk 
< 0.01 
-r 
Π 
<o.o; 
r: 
<ö.o; 
^ ^ 
/e/o acute 
α low salt 
•high salt 
-4 
eighth day 
felo chronic 
* 
0.02 
Σ -
1 
Τ л$ 
Τ ns 
15th day 
-60 150 
Time (min) 
Figure 2. Acute and chronic effects of felodipine on plasma 
aldosterone concentrations (PAC), plasma renin activity (PRA), and 
atrial natriuretic peptide (ANP) on two different diets. For farther 
details see Figure 1. 
Acute effects of felodipine 
Felodipine oral solution induced a rapid fall of MAP accompanied by a rise 
of heart rate during both diets (Fig. 1). The maximal antihypertensive effect was 
observed 30 min after felodipine administration and was comparable during the 
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two diets (HS -12 ± 1 % and LS 
-11 ± 1 %, Fig. 3). Also, the maximal 
increases of heart rate did not differ (HS 
+ 2 0 ± 6 % and LS + 1 5 ± 4 %). 
Felodipine induced similar and short 
lasting increases of Cl
creat during HS and 
LS ( + 2 7 ± 8 % and + 2 2 ± 8 %) in the 
period that acute increases of urinary 
flow rate were observed. This diuretic 
effect was accompanied by acute 
increases of ClNa and FENft during both 
diets (Fig. 4). Felodipine induced a 
greater sodium loss during HS 
( + 2 8 8 ± 54 /шюі/min above baseline 
compared to + 1 0 8 + 15 μπιοΐ/min 
during LS, P < 0 . 0 1 ) . The relative 
increase of FEN a, however, was larger 
during LS ( + 1 6 9 + 48 % vs . 
+ 8 9 + 2 0 % with HS, Ρ<0.05). The 
changes of FEC1 parallelled the changes 
of FEN a (data not shown). Felodipine 
induced no significant changes of 
potassium excretion during either diet 
(Fig. 4). Pretreatment urate, phosphate, 
and lithium clearances fitted a more 
pronounced proximal as well as distal 
sodium reabsorption during LS 
(Table 3). During the two diets, 
felodipine induced comparable increases 
of FEpo4 and decreases of FDRNa. The 
felodipine-induced increase of FE
urfttc, 
however, was blunted during LS and also the decrease of FPRNa tended to be 
less during LS than during HS (Table 3). 
In accordance with a larger total urinary volume loss during HS 
(1158±106 ml vs. 8 8 1 ± 4 6 ml during LS, P < 0 . 0 1 ) , a larger decrease of body 
weight was observed after felodipine in this period (-1,0±0.1 kg vs. -0.7+0.0 
during LS, Р<0Л\). Felodipine did not change foot volume during the period 
of supine rest in the experiment. There were no significant changes of Ht or 
5% 10% 15% 20% 
Δ MAP low 
b) Felodipine chronic 
20%-
5 15%-
0-, 
g 10%-
< 
5%-
• 
• 
уГШ 
5% 
• ^r 
• У 
A • m • /• • 
10% 15% 20% 
Δ MAP low 
Figure 3. Comparison of individual 
changes of mean arterial pressure 
during low (A MAP low) and high salt 
(A MAP high) diets after acute (a) and 
chronic (b) felodipine administration. 
Oblique lines indicate line of identity. 
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serum albumin with felodipine. ANP and PRA also did not change in contrast 
to the fall of PAC (Fig. 2). 
Plasma felodipine levels were comparable during LS and HS (Fig. 5). 
Chronic effects of felodipine 
One week of oral felodipine resulted in the same blood pressure decrease 
during LS and HS (-9±1 % compared to -10±2 %, P=NS, Fig. 3). The diet-
induced difference in blood pressure persisted during felodipine and the lowest 
level of MAP was thus reached with felodipine at LS (103±2 compared to 
109±3 mm Hg during felodipine at HS, P<0.02, Fig. 1). Heart rate was 
slightly higher on felodipine than on placebo, but the difference was only 
significant during HS (Fig. 1). 
Felodipine decreased body weight by 0.5 ±0.2 kg in both diet periods and at 
the same time increased foot volume, although during LS this increase failed to 
reach significance (+19±9 ml, P=0.08, Table 2). During LS, but not during 
HS, felodipine tended to increase plasma volume (+128+55 ml, P=0.07) and 
decrease serum albumin (-1.1+0.5 g/1, P=0.08) and hematocrit (-1.6±0.6 %, 
P=0.05). Thus, the diet-induced differences in plasma volume, serum albumin, 
Table 3 . Acute effects offelodipine oral solution on several parameters of 
segmental tubular sodium reabsorption. 
F E ^ (%) 
FE™ (%) 
FPRJ (%) 
FÜR J (%) 
Baseline 
Felo 
Baseline 
Felo 
Baseline 
Felo 
Baseline 
Felo 
Low salt 
7.1+0.7 
+0.7+0.5 
8.8±1.7 
+5.3+0.9* 
81.2±1.1 
-3.0±0.8* 
97.8+0.3 
-2.8+0.5* 
High salt 
8.8 + 1.2 
+2.1 ±0.6t 
10.8±2.1 
+6.0+0.9* 
74.7 ±2.7 
-5.2 ±1.0* 
92.5 ±1.0 
-3.9 ±0.8* 
Ρ value* 
0.02 
0.01 
0.04 
NS 
0.01 
0.07 
<0.01 
NS 
Values are expressed as means ± SEM. Basel ine=values measured on the eighth day at the 
end of placebo and just before felodipine administration; Felo = mean change in the first Vh 
hours after felodipine oral solution. 
Ρ values for differences between low and high salt diet. 
*P<0.05 and *P<0.01 for the acute effect of felodipine oral solution. 
δ FPRN, and FDRN. concern nine patients. 
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Figure 4. Acute and chronic effects offelodipine on urinary flow rate (V), fractional 
sodium excretion (FEfJ, and fractional potassium excretion (FE^ on two different diets. 
For further details see Figure 1. 
and hematocrit were no longer demonstrable after felodipine (Table 2). Also the 
diet-induced differences in ANP and PRA had disappeared (Fig. 2). Felodipine 
increased PRA during HS and decreased PAC during LS. 
Plasma felodipine levels were within the therapeutic range (4-14 nmol/1) and 
comparable during LS and HS (Fig. 5). 
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120150 
Time (mm) 
Figure 5. Plasmafelodipine levels after 
acute and chronic felodipine 
administration on two different diets. 
P-value on the 8th day for area under 
the curve on the 15th day for mean 
values. For further details see 
Figure 1. 
DISCUSSION 
It has been claimed that СЕВ, unlike 
most other antihypertensive drugs, 
reduce blood pressure more effectively 
at high than at low salt intake5,12,13. Such 
an effect might be ascribed to a larger 
natriuretic effect of СЕВ in the salt 
loaded state. We therefore studied the 
hypotensive and natriuretic effects of the 
dihydropyridine СЕВ felodipine during 
different dietary salt intakes. In our 
outpatients with essential hypertension, 
felodipine oral solution induced 
comparable acute hypotensive responses 
during high and low salt intakes. Also 
one week of continued felodipine 
treatment resulted in similar reductions of blood pressure in both dietary 
periods. Since the different salt intakes had resulted in a moderate difference in 
blood pressure before the administration of felodipine, the lowest blood pressure 
was achieved using felodipine during dietary salt restriction. Therefore, at first 
sight, our data seem to contrast with previous claims of a larger antihypertensive 
effect at high salt intake512,13. However, these claims were based on the acute 
hypotensive responses to the dihydropyridine nifedipine, whereas the studies 
addressing the more chronic effect of СЕВ during different salt intakes are more 
in line with our observations. In hospitalized patients, several СЕВ induced a 
comparable chronic antihypertensive effect at extremes of salt intake24,25, 
whereas only nifedipine caused a slightly, but not significantly smaller 
hypotensive response during severe sodium restriction5. Moreover, in one of 
these studies, the lowest blood pressure was reported with the dihydropyridine 
nisoldipine at low salt intake25. In contrast, Luft et al could not demonstrate an 
additional hypotensive effect of moderate sodium restriction in patients already 
treated with nifedipine9. However, in this study, sodium restriction was applied 
for six days only, whereas we have prescribed diets for two weeks. Possibly, 
such a longer period of moderate sodium restriction is needed to achieve 
maximal effect on blood pressure. Because of the fixed order of placebo and 
felodipine in our study, we cannot exclude that the dietary salt intake had 
additional effects on blood pressure during the second week of each diet period 
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when felodipine was used. Part of the observed difference in final blood 
pressure during chronic felodipine might thus be ascribed to a late effect of the 
diets, but this does not weaken our conclusion that the most favourable blood 
pressure is reached with felodipine and moderate dietary salt restriction. 
The discrepancies between our study and the aforementioned acute studies 
with nifedipine51213 might be explained by differences in study protocols, patient 
populations, or dose and type of drug used. In only four of our patients, mean 
arterial pressure was more than five mm of mercury higher during high salt than 
during low salt intake. In contrast, in the studies with nifedipine, a rigorous 
sodium depletion512 and/or inclusion of more so called sodium sensitive 
patients12,13 had resulted in more pronounced differences in blood pressure 
between high and low salt intake. Under such circumstances, differences in 
antihypertensive response are to be expected since the fall in blood pressure with 
any antihypertensive agent depends directly on the pretreatment level26,27. In this 
respect it is rather surprising that a relatively high dose of the dihydropyridine 
СЕВ nicardipine induced similar acute hypotensive responses at extremes of salt 
intake in markedly sodium sensitive Japanese patients14. 
We clearly demonstrated that felodipine acutely increases diuresis and 
natriuresis despite the simultaneous reduction of blood pressure, thereby 
confirming previous observations with other СЕВ3. It has been suggested that 
this natriuresis might contribute to the blood pressure lowering action of СЕВ28, 
but our data do not substantiate this idea. First, during high salt intake 
felodipine induced a larger sodium and weight loss than during low salt intake, 
but this was not reflected in a larger reduction of blood pressure in the high salt 
period. Also the time course of blood pressure and sodium excretion (Fig. 1 and 
4) argue against a major role for the natriuretic effect in the acute hypotensive 
response to СЕВ. Furthermore, it has been shown that nifedipine reduces blood 
pressure during severe, diuretic-induced sodium depletion, a condition where 
nifedipine no longer exerts a natriuretic effect12. 
Our data on segmental tubular sodium reabsorption indicate that dietary salt 
restriction enhances proximal and distal sodium reabsorption. Under these 
circumstances felodipine had a smaller natriuretic effect than on the high salt 
diet, which appeared to be mainly due to less inhibition of proximal reabsorption 
on the low salt diet. Somewhat in contrast, felodipine had comparable effects on 
distal tubular sodium reabsorption and urinary potassium excretion, which is 
surprising in view of the differences in plasma aldosterone levels before 
administration of felodipine oral solution. However, plasma aldosterone levels 
were no longer different after felodipine due to a pronounced fall of aldosterone 
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in especially the low salt period. Also the smaller distal tubular sodium load 
after felodipine in the low salt period might have been responsible for the 
absence of a difference in distal tubular effects of felodipine between the two 
diets. 
After one week of continued treatment with felodipine, body weight was 
0.5 kg lower than after placebo in both diet periods. This decrease of body 
weight corresponds with a sodium loss of approximately 75 mmol, which is in 
agreement with the data from sodium balance studies during calcium entry 
blockade6"8. These data imply that treatment of hypertension with СЕВ is clearly 
not associated with sodium retention, a well known side effect of other arteriolar 
vasodilators. Both in the acute and the chronic phase, the reduction of body 
weight by felodipine was not reflected in significant changes of plasma volume 
or the other indirect indices of intravascular volume. From this we must 
conclude that fluid and sodium losses are mainly derived from the extravascular 
compartment. Interestingly, the diet-induced differences in plasma volume, 
serum albumin, hematocrit, ANP, and PRA had disappeared after continued 
felodipine administration, although the difference in body weight was 
maintained. This effect of felodipine appeared to be due to a slight rise in 
plasma volume during the low salt diet rather than a decrease in plasma volume 
during the high salt diet. This suggests that at different salt intakes СЕВ have 
different effects on the distribution of fluid between the intra- and extravascular 
compartment. Although there is no ready explanation for such an effect of СЕВ, 
we would suggest that the lower blood pressure level with felodipine at low salt 
intake favours a shift of fluid into the intravascular compartment which 
apparently does not occur at the somewhat higher blood pressure level observed 
with felodipine at high salt intake. 
Felodipine induced a comparable degree of edema formation during high and 
low salt intake, but the additive effects of felodipine and high salt diet resulted 
in the largest foot volume. Accordingly, clinical ankle edema with felodipine 
was noted in three patients during the high salt period. The edema formation 
with felodipine was not accompanied by any other sign of sodium retention and 
occurred despite a simultaneous reduction in body weight. These data support 
the hypothesis that edema formation with СЕВ is a local phenomenon at the site 
of vasodilation: preferential dilation of small, precapillary arterioles29,30 
presumably leads to an increase in intracapillary hydrostatic pressure which 
explains the observed increase of transcapillary fluid filtration in skeletal 
muscles31,32. In the present study, felodipine did not induce acute changes of foot 
volume in the supine patients in contrast to our observations with nifedipine in 
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healthy sedentary volunteers33. This discrepancy may be explained by 
interference of nifedipine with the increase in vascular resistance which 
normally protects capillaries against an orthostatic load31. The edema formation 
in the depending legs also implies a larger decrease of extravascular volume in 
the other parts of the body than already assumed in the previous paragraph. 
Because dihydropyridines preferentially increase skeletal muscle, coronary, and 
cerebral blood flow34, a decrease of extravascular volume in the other organs 
might be assumed. 
Although we did not observe renal sodium retention after one week of 
felodipine, it is possible that long-term administration would have led to ongoing 
edema formation followed by renal sodium retention. Such a mechanism could 
explain the observation of an increase of exchangeable sodium without a change 
of plasma volume after eight weeks of nifedipine35. With a high dose of a 
thiazide diuretic, leg edema disappeared and exchangeable sodium normalized 
at the cost of a considerable reduction in plasma volume35. Our results show that 
the incidence of edema can also be reduced by restricting dietary salt intake. 
Both measures are probably less effective than in other edematous states because 
the edema with СЕВ is not primarily due to sodium retention. 
In conclusion, felodipine induced comparable acute and chronic hypotensive 
responses during different salt intakes despite a somewhat larger natriuretic 
effect with the high salt diet. The combination of modest sodium restriction and 
felodipine resulted not only in the lowest blood pressure but also in less edema. 
We therefore would not advise unrestricted salt intake for patients on СЕВ. 
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À new method for measuring human foot volume: 
accuracy and biological variation 
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ABSTRACT 
In pathological conditions mainly characterized by ankle 
edema, regular and reliable estimates of foot volume are needed 
for follow-up, especially after therapeutic interventions. Most 
available devices are inaccurate or not suited for long-term 
studies. 
We describe a new method that uses a sensitive balance to 
measure the force needed for immersion of the foot in a water-
bath. The degree of filling of this water-bath is controlled with 
the same balance, which enables refreshing of the water with 
only minimal errors (coefficient of variation (CV)=0.09 % for 
standard measure). Accuracy of the method was demonstrated by 
repeated measurements of foot volume in volunteers 
(CV=0.32 %, n=27) and in patients with various renal diseases 
(CV=0.28 %, n=22). Foot volume remained stable during at 
least 10 minutes in water of room temperature, which makes a 
heating device unnecessary. Biological changes were 
demonstrated easily: foot volume was increased by 15 minutes 
sedentary rest (+1.0+0.2 %, η=9), and in the course of the day 
( + 1.2+0.5 %, η =12). It was also higher premenstrually 
( + 1.2±0.5 %, n=7). Day to day variation, measured at the 
same points of time, was considerable (CV= 1.31 %) and should 
be taken into account in long-term studies. 
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INTRODUCTION. 
Ankle edema is a common symptom in several pathological states such as 
chronic venous insufficiency, congestive heart failure, and the nephrotic 
syndrome. In conditions where the amount of edema is the only available 
parameter for evaluation of the course of the disease and the effect of 
therapeutic interventions, it is important to have an accurate and simple method 
to quantitate the volume of the foot. Most available methods estimate foot 
volume by recording water displacement after immersion of the foot. Some 
methods measure water overflow1'3, whereas others determine the rise of the 
water-level on a calibrated scale4,5 or with more sophisticated devices67. Yet 
another method uses the principle of Archimedes, i.e. upward force equals the 
weight of the displaced water, and determines the water pressure at a fixed point 
in the foot-bath8. All these methods have important disadvantages: some lack 
accuracy whereas the others are not suited for measurements over a prolonged 
period of time. Here, we describe a new, accurate, sensitive, and simple method 
which also uses the principle of Archimedes and is suited for repeated 
measurements of foot volume. We have tested the accuracy of this method and 
have evaluated the influence of biological variables on measured foot volumes. 
METHODS 
Apparatus and procedure 
Similar to the other methods for measuring foot volume, our new method 
(LM. Valk) uses the principle of water displacement, but records it in a new, 
indirect and precise way. As shown in Figure 1, a perspex water-bath with a 
maximal capacity of 201 is placed on a sensitive electronic balance (Mettier PM 
34, Mettler Instrumente AG, Greifensee, Switzerland). A specially constructed 
stainless steel foot support is suspended in the foot-bath, but rests fully on the 
floor on both sides of the balance. The water-bath is filled with tap water until 
the balance indicates exactly 15,000 g, thereafter the balance is tared to zero. 
Subsequent immersion of the foot induces water displacement that is perceived 
by the balance as an increase in weight, which equals the immersed volume 
multiplied by the relative weight of water at a specific temperature (0.998 g/ml 
at 22 °C). Stated differently, the balance perceives the force that is necessary 
1 0 7 
Chapter 8 
a) Foot volume recorder 
foot support 160 
257 
water-
bath 
143 
balance 
415 
to immerse the foot and which 
depends solely on the volume of the 
foot (Archimedes' principle). In order 
to reach a fixed and reproducible 
degree of immersion of the foot and 
lower leg, a stable chair with 
adjustable height is used and a rigidly 
standardized seated position is 
pursued with the thigh horizontal, 
lower leg vertical, and left foot 
resting on the foot support with the 
heel against the niche in the back and 
the fore-foot against the left side of 
the foot support (see Figure lb). 
Moreover, to minimize errors due to 
different degrees of immersion, three 
or four successive foot placements 
and recordings are made without 
actually removing the foot from the 
water-bath: if less than three 
recordings are within a 5 g range, the 
foot is withdrawn and the whole 
procedure is repeated. However, this 
proved to be seldom necessary and in 
most persons foot volume can be 
measured within one minute. 
Removal of the foot from the 
water-bath and evaporation cause 
water losses between experiments. Such losses are easily corrected for by adding 
water to the bath until the balance indicates again exactly zero. Thus, the same 
water-level is reached before each measurement. Unless stated otherwise, water 
of room temperature was used (20-24 °C). Because the relative volume of water 
closely approaches 1 at room temperature (1.00223 ml/g at 22 °C), the simple 
conversion of 1 g to 1 ml can be used since it systematically underestimates 
volume by only 0.2 %. 
floor 
b) Bottom of foot support (immersed part) 
143 
left 
elevated support 
with niche ^y~ 
330 
back 
Figure 1. Side view (a) and top view (b) 
of foot volume recorder. Measures of foot 
support (in mm) are indicated. Perspex 
water-both measunng 388x208x250 mm 
had a maximal capacity of 20 litres. Left 
foot of the subject is placed on the bottom 
of the foot support with the heel against 
the niche in the back. 
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Subjects 
Fifty-seven healthy volunteers (15 F), aged 19-34 years, participated in one 
or more of the substudies. All subjects were without signs of venous 
insufficiency and had a normal length (range, 1.62 to 1.97 m) and body weight 
(range, 49 to 95 kg). Additionally, 22 patients (6 F) with a mean age of 49 
years (range, 17 to 83 years) were selected from our out-patient department to 
test the reproducibility of the method. Most patients had chronic renal diseases 
and three of them had large amounts of edema due to either a nephrotic 
syndrome (2) or fluid overload caused by advanced renal failure (1). Mean 
length was 1.76 m (range, 1.60 to 1.96 m) and mean body weight was 73 kg 
(range, 59 to 97 kg). 
The study protocol was approved by the Hospital Ethics Committee and 
informed consent was obtained from all participants. 
Reproducibility 
Refilling the water-bath. The maximal error induced by refreshing the water 
in the water-bath was estimated by refilling the water-bath 10 times and 
subsequently measuring the water displacement of a standard measure (a bottle). 
Foot volume. To estimate the error of the method for measuring foot volume, 
three successive recordings were made within approximately five minutes 
immediately after arrival at the ward in 27 volunteers (9 F) and in all 22 
patients. The foot was withdrawn from the water-bath between recordings and 
carefully dried. The water lost by removal of the foot was substituted before the 
next recording as indicated above. 
Biological variation 
Sedentary rest. Foot volumes were measured in 9 male volunteers 
immediately after arrival at the ward and after 15 and 30 minutes of sedentary 
rest. 
Water temperature. Changes of foot volume were studied in cold water (14.7 
to 16.5 °C), water of room temperature (lukewarm, 20.9 to 23.1 °C), and 
warm water (33.9 to 37.4 °C) in three groups of 10, 9 and 11 volunteers, 
respectively. Foot volume was first recorded in water of room temperature in 
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all subjects immediately after arrival at the ward. During a subsequent sedentary 
rest of at least 15 min, the water-bath was refilled with water of the desired 
temperature. Thereafter, subjects immersed their foot for 10 min and foot 
volume was recorded immediately, and after one, five and ten minutes of 
immersion. Foot volumes were calculated by multiplying the recorded weight 
with the relative volume of water at that temperature (1.00090 for cold, 1.00223 
for lukewarm, and 1.00600 ml/g for warm water)9. 
Time of the day. Foot volumes were measured in the course of a usual week-
day in 12 students (6 F). Recordings were made without a preceding sedentary 
rest in the morning (range, 8.18 to 10.30 hr), at noon (range, 12.00 to 
14.05 hr), and in the afternoon (range, 15.45 to 17.47 hr). Additionally, foot 
volume was measured after 20 min supine rest following the recording in the 
afternoon. 
Exercise. Immediately after arrival at the ward, 14 volunteers (6 F) performed 
a 15 min bicycle exercise at 75 % of the estimated maximal capacity (range, 
132 to 190 Watt) which was followed by a 15 min sedentary rest. Foot volumes 
were recorded before and immediately after the exercise and also after the 
sedentary rest following the exercise. 
Menstrual cycle. Foot volumes were determined twice in seven females which 
had a regular cycle (3) or used oral contraceptives (4). Foot volume was 
recorded at the same time of the day 0-5 days before and 12-15 days after 
menstruation. 
Day to day variability. Foot volumes were measured in the course of several 
weeks in 23 volunteers. In 12 of them (2 F), foot volumes were recorded five 
times in two to five weeks, always at the same time of the day (five in the 
morning) after a sedentary rest of 30 min. In 11 other male volunteers, foot 
volumes were measured three times in the course of two to seven weeks without 
a preceding sedentary rest, but always in the morning within two hours of 
rising. 
Statistical analysis 
Statistics were performed with SAS (Statistical Analysis System) software. 
Coefficients of variation (CV) for reproducibility were calculated by one way 
analysis of variance10,11. The influence of biological variation was evaluated by 
Wilcoxon's rank sum test for pairwise comparisons and Tukey's studentized 
range test for multiple comparisons. Probability values below 0.05 were 
considered statistically significant and results are presented as means±SEM. 
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RESULTS 
Reproducibility 
Refilling the water-bath. The 
recorded volume of the standard 
measure varied only slightly with 
repeated filling of the water-bath: the 
CV was 0.09 % at a mean volume of 
1111 ml. The actual error induced by 
refreshing the water will be smaller, 
because placement of the bottle (the 
standard measure) on the foot support 
is also a source of variation in this 
experiment. 
Foot volume. Our method proved 
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Figure 2. Individual coefficients of 
variation (CV) for foot volume recordings 
repeated within a few minutes in 22 
patients with various renal diseases. 
There was no indication that the method 
was less accurate in older patients or in 
patients with massive edema. 
to be accurate with a CV of 0.30 % for measurements repeated within a few 
minutes. The procedure itself did not influence measured foot volume, because 
there was no significant difference between the three subsequent recordings. 
Accuracy of the method was as good in patients as in volunteers with а С V of 
0.28 % and 0.32 % at mean foot volumes of 1292 and 1234 ml, respectively. 
There was no indication that the method was less accurate in patients above 60 
years (n=7) or in patients with edema (n=3) (Fig. 2). 
Biological variation 
Sedentary rest. Resting in the sitting position induced an increase of foot 
volume from 1305±54 ml on arrival at the ward to 1317±55 ml after 15 min 
sitting (+1.0±0.2 %, P<0.01). Foot volume did not increase further in the 
subsequent 15 min of sedentary rest (+0.1 ±0.2 %, P>0.10). 
Water temperature. In the three temperature groups, comparable increases of 
foot volume were observed during the 15 minutes sedentary rest preceding the 
10 minutes immersion (+0.7±0.3 %, + 1.0±0.2 %, and + 1.1±0.1 % in the 
groups assigned to cold, lukewarm and warm water, respectively, differences 
NS with Tukey's test). During immersion, foot volume remained stable in 
lukewarm water, whereas it decreased slightly in cold water (-0.3 ±0.1 % after 
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Figure 3. Relative changes of foot volume 
during 10 minutes continuous immersion in 
water of different temperatures. Ρ < 0.05 and 
Ρ < 0.01 compared to start of immersion. The 
change in warm water was different from the 
change in cold water (1, 5 and 10 min), and 
from the change in lukewarm water (5 and 10 
min) (Ρ<0.05 with Tukey's test). 
10 minutes, Fig, 3). The most 
prominent change, however, was 
the increase of foot volume in 
warm water (+0.9±0.2 %, 
Fig. 3). 
Time of the day. Foot volume 
increased by 1.2±0.5 % in the 
course of the day and this 
increase was virtually reversed 
by the subsequent 20 min supine 
rest (Fig. 4). 
Exercise. The bicycle exercise 
test itself did not change foot 
v o l u m e ( + 0 . 1 ± 0 . 3 %, 
P>0.10), but the 15 min 
sedentary rest after the test 
resulted in a 0.9±0.2 % 
of foot volume increase 
(P<0.01). 
Menstrual cycle. The premenstrual value of foot volume was 1.2±0.5 % 
higher than the mid-cycle value (P=0.03). 
Day to day variability. Foot volume varied considerably from day to day 
(CV=1.31 %, mean volume 1304 ml). The variation appeared to increase in the 
course of the day, because the subjects measured early in the morning had a 
lower CV (0.97 %) than the subjects measured either in the morning or in the 
afternoon (1.42 %), despite the preceding sedentary rest in the latter group. 
DISCUSSION 
Our new simple method for recording foot volume proved to be accurate with 
a CV of only 0.30 % for repeated measurements. Most recordings could be 
made within one minute in both volunteers and patients who were not acquainted 
with the procedure, without negatively influencing its accuracy. 
The reproducibility of our method cannot be easily compared to other 
methods, either because of insufficient testing of the method2·3,7 or because of 
unusual ways to express reproducibility1,4,6 which do not concur with the 
recently advised approach10. Therefore, we have expressed the reproducibility 
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г 
о 
о 
tl·, 
morning noon evening supine 
rest 
in several other ways to make ^ 
comparisons possible (Table 1). Our g 
method appears to be more accurate 
than the methods of Thulesius6 and 
Christensen5, which determined the 
water level with a photo-electric float-
sensor and a calibrated scale, 
respectively. Winkel4 also used a 
calibrated scale, but reached a higher 
accuracy by reducing the free water 
surface area. However, this method is 
only accurate for short term changes 
because total foot volume was 
measured only once and the 
differences between successive 
recordings were determined by the 
amount of water that had to be added or removed to reach the same mark on the 
calibrated scale. The error induced by refreshing the water was not tested, but 
probably could not be controlled easily. In contrast, refreshment of the water in 
our apparatus will not lead to major experimental errors as indicated by the low 
Figure 4. Relative changes of foot volume 
in the course of a usual week-day in 12 
students, with the last measurement made 
after 20min supine rest. P<0.05 for the 
change from morning value and 
Ρ<0.01 for the change induced by 
supine rest. 
Table 1. Comparison of reproducibility of different volumetrìe methods 
Coefficient of variationA 
Σ | d | /n V(Ed2/n) ANOVA long-termB 
Winkel4 
Thulesius et al6 
Christensen et al3 
van Hamersvelt et al 
37 
48 
9 
49 
0.31 %c 
0.31 % 
1.56 % D 
0.70 %B 
0.38 % 0.30% 
no 
yes 
yes 
yes 
A
 Coefficients of variation were calculated by (SD/mean) χ 100 %, with SD calculated 
according to one of the three methods. %/(Го2/п) and analysis of variance (ANOVA) are the 
preferred approach with two and more than two repeated measurements, respectively. 
B
 suitability of the method for intermittent recordings over prolonged periods of time. 
c
 Winkel measured foot volumes at 21 or 31 °C and reported a CV of 0.16 %. However, he 
omitted the first of three successive recordings at 21 °C because of a supposed "thermal effect". 
The value in the table has included all recordings. 
D
 Thulesius used V(Ed2/2n), so we have multiplied their value of 1.1 % by\f2. 
E
 Christensen did not report the method used to calculate the CV. 
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CV of 0.09 % for the volume of the standard measure with repeated filling of 
the bath. This makes our method also suited for measuring changes over 
prolonged time intervals. Moreover, by linking the Mettler balance to a personal 
computer, our method can also be used for continuous recording of foot volume 
(unpublished observations). 
Foot volume remained stable during immersion in water of room temperature, 
in contrast to the rapid increase in warm water and the slight decrease in colder 
water. These findings allow future measurements in water of room temperature 
and thus obviates the necessity of a heating device. The foot swelling in warm 
water is in agreement with the opinion that a temperature above 34 °C should 
not be used for volumetry12. It has been suggested that the first immersion in 
water of room temperature reduces foot volume by a "thermal effect" ascribed 
to decreased pooling of venous blood4. However, we did not observe such a 
decrease during the 10 min immersion and we did not find a difference between 
the three successive recordings used for testing the reproducibility. We therefore 
doubt the presence of an acute "thermal effect" (see also Table 1). 
Our method was accurate enough to show biological changes that had been 
expected theoretically. Fifteen minutes sedentary rest was followed by a 1 % 
increase of foot volume. Foot volume was also higher at the end of a usual 
week-day in students, comparable to the reported increases of 0.8 % after 
"active" sitting and 2.3 % after "semi-active" sitting13. Such foot swelling in the 
course of the day underscores the well-known advice to buy your shoes in the 
afternoon. Foot volume was higher premenstrually which is in accordance with 
observations on the premenstrual syndrome14. In contrast to our expectation, the 
bicycle exercise did not reduce foot volume, probably because foot volume was 
already minimal before the exercise, as it was measured immediately after 
arrival at the ward. A preceding sedentary rest could have provided us the 
answer whether bicycling reduces foot volume by activation of the calf muscle 
venous-pump, comparable to the effect of several knee-bends8. 
The procedure that we used proved to be reliable in older patients, who are 
more likely to suffer from edematous states such as chronic venous 
insufficiency. Our method is thus suited to study the efficacy of therapeutic 
interventions for these conditions. Our method might also be useful to follow the 
short- and long-term effects of hormonal treatment of acromegaly. In such 
studies, a considerable day to day variability of maximally 5 % (4 χ CV of 
1.31 %) should be taken into account. Moreover, the day to day variability 
could be even larger in patients with edema. In one such patient with a 
nephrotic syndrome we observed an increase of foot volume of 17 % from the 
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morning of one day to the afternoon of the following day. This example 
underscores once more the importance to measure foot volume under 
standardized conditions. Different ambient temperatures could possibly also 
influence foot volume, but were not studied and cannot be controlled easily. 
In conclusion, our new device enables accurate measurements of foot volume 
and can be used to demonstrate small biological changes. This biological 
variability should be taken into account if recordings are made over prolonged 
periods of time. Day to day variability seems acceptable if measurements are 
made at the same time of the day, preferably early in the morning after a 
sedentary rest of at least 15 min. Measurements in the premenstrual period 
should be avoided, unless one is interested in changes during the menstrual 
cycle. 
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Edema formation with the vasodilators nifedipine and diazoxide: 
local effect or sodium retention ? 
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ABSTRACT 
Ankle edema is a common side effect of antihypertensive 
treatment with arteriolar vasodilators such as the calcium entry 
blocker (СЕВ) nifedipine and the potassium channel opener 
(PCO) diazoxide. This edema might be a direct result of 
peripheral vasodilation or a consequence of renal sodium 
retention. 
We therefore studied during three hours the effects of 
nifedipine (20 mg), diazoxide (150 mg i.V.), Captopril (25 mg), 
and placebo on edema formation and sodium excretion in 12 
healthy sedentary volunteers. The degree of edema was 
determined by measuring foot volume with a new accurate 
device. All active drugs decreased diastolic blood pressure 
(Captopril ~9±2 %, nifedipine -4±3 %, and diazoxide -2±2 %, 
all P<0.05 compared to +5±2 % with placebo). Foot volume 
increased acutely after nifedipine (+2.6±0.4 %, P<0.01), 
whereas it remained stable with placebo and the other drugs. 
Captopril and nifedipine induced increases of fractional sodium 
excretion (+20±9 % and +40±20 %, P<0.05 vs. placebo) in 
contrast to the decreases with placebo and diazoxide (-13 ±11 % 
and -24±10 %). Only nifedipine induced significant albeit small 
increases of hemoglobin and serum albumin. 
In conclusion, nifedipine simultaneously induced acute 
increases of foot volume and natriuresis, which supports the 
hypothesis that the development of ankle edema with СЕВ is a 
local phenomenon at the site of vasodilation. The absence of a 
similar increase of foot volume with diazoxide might be 
explained by less vasodilation in these volunteers but could be 
indicative for a different mechanism for edema formation with 
PCO. 
Edema formation with vasodilators 
INTRODUCTION. 
Ankle edema is a common side effect of antihypertensive treatment with 
arteriolar vasodilators, particularly with calcium entry blockers (СЕВ) and 
potassium channel openers (PCO) such as diazoxide1. In the heterogeneous 
group of СЕВ, the incidence of edema formation is higher with dihydropyridines 
such as nifedipine than with drugs such as verapamil and diltiazem2. Most 
likely, this difference is related to the higher vascular selectivity and, 
consequently, the more pronounced vasodilating effect of dihydropyridines3. 
Edema formation with vasodilating drugs might be a direct result of 
vasodilation, but has also been ascribed primarily to renal sodium retention 
following blood pressure reduction4. This latter possibility seems unlikely for 
СЕВ, which do not cause sodium retention5,6 but even induce an acute 
natriuresis and diuresis7. Moreover, СЕВ acutely increase transcapillary fluid 
filtration in skeletal muscles of animals3 and of humans9, which may favour 
edema formation. Dihydropyridine СЕВ also induce an acute increase of 
hematocrit in anephric rats which suggests acute extravasation of fluid to the 
interstitial compartment10. All these findings support the hypothesis that ankle 
edema with СЕВ and possibly also other arteriolar vasodilators is an immediate 
consequence of peripheral vasodilation. We have evaluated this hypothesis in 
humans by studying the acute effects of nifedipine, diazoxide and the ACE 
inhibitor Captopril on foot volume and sodium excretion in healthy sedentary 
volunteers. Foot volumes were used as an exact measure of the degree of edema 
formation and were recorded with a recently developed, accurate, sensitive and 
simple method. 
METHODS 
Subjects 
Twelve healthy volunteers (10 M/2 F), aged 19 to 33 years, were recruited. 
All participants were free of medication and without signs of venous 
insufficiency. The two females did not use oral contraceptives. Blood pressures 
were below 140/90 mm Hg (ranges, systolic 101 to 140 and diastolic 60 to 84 
mm Hg) and all individuals had a normal length (range, 167 to 192 cm) and 
body weight (range, 49 to 95 kg). 
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The study protocol was approved 
by the Hospital Ethics Committee and 
all volunteers gave written informed 
consent. 
Study protocol 
The acute effects of the 
experimental drugs on foot volume 
and natriuresis were studied on four 
different days separated by interval 
periods of at least three days. In a 
randomized, crossover, open manner 
all subjects received oral placebo, 20 
mg of nifedipine (two capsules of 10 
mg bitten and swallowed), 25 mg of 
Captopril (tablet swallowed), and 150 
mg of diazoxide (infused i.v. in 10 
min). The volunteers continued their 
usual diet between experiments. Foot 
volumes were recorded with a 
recently developed, accurate method 
with a coefficient of variation of 
0.30 % for repeated measurements 
(manuscript in preparation). In short, 
a perspex water-bath is placed on a 
sensitive electronic balance (Mettler 
PM 34, Mettler Instrumente AG, Greifensee, Switzerland) and a specially 
constructed stainless steel foot support is suspended in the foot-bath, but rests 
fully on the floor on both sides of the balance (Fig, 1). Immersion of the foot 
will induce water displacement and the downward force needed for this water 
displacement is perceived by the balance as an increase in weight which depends 
only on the immersed volume. The perceived increase in weight in grams 
corresponds to the foot volume in ml, since the relative volume of water closely 
approaches 1 at room temperature (1.00223 ml/g at 22°C). In preliminary 
studies, we observed an increase of foot volume after the first 15 min of 
sedentary rest and at the end of the day. To reduce the influence of such 
a) Foot volume recorder 
foot support 150 
257 
water-
bath 
143 
balance \ 
415 
floor 
b) Bottom of foot support (immersed part) 
143 
left 
<s~ 
330 
* 
elevated support 
with niche 
back 
Figure L Side view (a) and top view (b) 
of foot volume recorder Measures of foot 
support (in mm) are indicated. Perspex 
water-bath measuring 388x208x250 mm 
had a maximal capacity of 20 litres. Left 
foot of the subject is placed on the bottom 
of the foot support with the heel against 
the niche in the back. 
120 
Edema formation with vasodilators 
biological variation, subjects were always studied at the same time of the day 
and baseline levels of foot volume were recorded after 30 minutes of sedentary 
rest. Only volumes of the left foot were recorded. 
Subjects were kept fasting during the last three hours preceding the 
experiments except for an oral water load of 300 ml taken two hours before 
drug administration. After arrival at the ward, the volunteers were seated in 
normal office chairs with their feet resting on the ground. This sedentary rest 
was interrupted only for foot volume recordings and for voiding in an adjacent 
room. After 30 min sedentary rest, baseline levels of blood pressure, heart rate, 
body weight and foot volume were recorded and baseline blood and urine 
samples were collected. Thereafter, one of the four experimental drugs was 
administered and subjects drank 250 ml tap water. An additional oral water load 
of 375 ml was supplied in the following 90 min. Foot volumes, body weights, 
blood pressures and heart rates were recorded 30, 60, 120 and 180 min after 
drug administration, whereas blood and urine samples were collected at 60 and 
180 min. 
Blood pressure and heart rate were recorded in triplicate with a Hawksley 
random zero mercury sphygmomanometer and by pulse counting, respectively. 
In blood and urine samples, creatinine, sodium and chloride concentrations were 
determined by standard (semi)automated techniques. Hemoglobin was 
determined by routine Coulter Counter and serum albumin by an automated 
bromine cresol green method. Fractional sodium and chloride excretions (FENa 
and FE
a
) were calculated using the formula: 
FEX = ( lyPJ χ (Pcre.t/UcrcJ χ 100 % 
with U
x
 and P
x
 representing the urinary and plasma concentrations. 
Statistical analysis 
Statistics were performed with SAS (Statistical Analysis System) software. 
Repeated measures analysis of variance was used to compare baseline values, 
whereas Wilcoxon's rank sum test was used to compare the effects of the 
experimental drugs with placebo. Percentage changes from baseline were used 
for these pairwise comparisons. Correlation coefficients were calculated 
according to Spearman. Probability values below 0.05 were considered 
statistically significant and results are presented as means±SEM. 
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RESULTS 
Two subjects were unable to empty their bladder at the requested time on one 
or more occasions. Therefore, comparisons of fractional excretions were 
restricted to the remaining 10 subjects. 
Baseline levels of all measured parameters were comparable on the four 
experimental days (Table 1). 
In these healthy volunteers, Captopril decreased systolic blood pressure 
(-5+2 % vs. 0±1 % with placebo, P<0.05), whereas neither diazoxide nor 
nifedipine had an effect on this parameter (-1±1 % and -hi±2 %, 
respectively). Therefore, only diastolic blood pressures, which decreased with 
all three active drugs, are shown in Figure 2. The blood pressure lowering 
effects of Captopril and nifedipine were more pronounced than that of diazoxide, 
whereas the effect of Captopril lasted longest. Neither diazoxide nor Captopril 
had an effect on heart rate (-2±2 % and + 1 ± 2 %), whereas nifedipine 
increased it by 7±3 % (-1±2 % with placebo, P<0.05). 
Foot volume remained stable on placebo days and was not changed by either 
Captopril or diazoxide (Fig. 2 and 3). In contrast, foot volume rapidly increased 
with nifedipine and remained elevated until the end of the experiment three 
hours after drug administration (mean increase 2.6±0.4 %, P<0.01, Fig. 2 
and 3). None of the subjects developed visible edema in this period. 
Table 1. Baseline values before drug administration 
Body weight (kg) 
Systolic BP (mm Hg) 
Diastolic BP (mm Hg) 
Heart rate (beats/min) 
Foot volume (ml) 
Hemoglobin (mmol/L) 
Albumin (g/L) 
FE^ (%) 
FEa (%) 
Plac 
75.3 ±3.8 
106±3 
68 ±2 
66+2 
1344±44 
8.4±0.1 
48±1 
0.6 ±0.1 
l.3±0.1 
Capt 
75.4±3.9 
108±2 
72 ±2 
65 ±2 
1335 ±42 
8.5±0.2 
50±1 
0.6 ±0.1 
1.2 ±0.1 
Diaz 
75.2 + 3.8 
104+2 
68±1 
67 ±2 
1335 ±43 
8.5 ±0.2 
49±1 
0.5+0.1 
1.1+0.1 
Nife 
75.1 ±3.8 
105 ±2 
70 ±2 
68 ±2 
1333 ±42 
8.5 ±0.2 
50±1 
0.6 ±0.1 
1.2+0.2 
P* 
0.09 
0.46 
0.13 
0.27 
0.56 
0.59 
0.24 
0.83 
0.50 
Values are means±SEM. Plac=placebo; Capt=Captopril; Diaz=diazoxide; 
Nife=nifedipine; BP=blood pressure. 
P-valu es for comparison of baseline values by repeated measures analysis of variance. 
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Diastolic BP 
+ 5% 
Foot Volume 
+ 3% 
-»-2% 
о Placebo 
• Captopril 
α
 Diazoxide 
• Nifedipine 
Fractional sodium excretion 
gradually decreased on placebo days 
and a similar decrease was observed 
with diazoxide (Fig. 3). In contrast, 
both Captopril and nifedipine induced 
an increase of natriuresis. Changes of 
FEC1 parallelled the changes of FENft 
with decreases after placebo and 
diazoxide(-20± 12 %and-13±13 %) 
and increases after Captopril and 
nifedipine ( + 9 ± 1 9 % and 
+22+13 %). The three active drugs 
did not change serum sodium or urine 
volume in the three hours after drug 
administration (data not shown). 
The only significant change of 
body weight was a minimal decrease 
with Captopril (-0.1 ±0.1 % vs. 
+ 0 . 1 + 0 . 1 % with placebo, 
P<0.05). Body weight did not 
change with either diazoxide or 
nifedipine (both 0 + 0.1 %). 
Hemoglobin decreased slightly on 
placebo days (-1.1+0.6 %) and 
comparable changes were observed 
with diazoxide and Captopril 
(-0.4+0.6 % and-0.1 ±0.5 %). Only 
nifedipine induced a significant, but 
small increase of Hb (+1.7+0.7 %, P<0.01 compared to placebo). Parallel to 
the changes of hemoglobin, serum albumin increased with nifedipine and was 
not changed significantly by either diazoxide or Captopril as compared to 
placebo (Fig. 3). 
Neither the increase of foot volume nor the increase of natriuresis with 
nifedipine was linearly correlated to the increase of serum albumin or of 
hemoglobin with this drug. The increase of foot volume was not correlated to 
the acute blood pressure lowering effect of nifedipine. 
"δ W 60 120 
Time (min) 180 
Figure 2. Relative changes of diastolic 
blood pressure (BP) and foot volume after 
placebo and the three active drugs. 
Ρ<0.05 and **P<0.01 compared to 
placebo (Wilcoxon 's rank sum test). Error 
bars indicate SEM. 
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DISCUSSION 
In the present study in healthy 
sedentary volunteers, the СЕВ 
nifedipine increased sodium excretion 
and at the same time induced an acute 
increase of foot volume, which thus 
cannot be ascribed to sodium 
retention. This observation indicates 
that nifedipine induces a rapid 
increase of volume in the depending 
legs by local changes in the peripheral 
vessels. Our data are thus in line with 
observations in isolated and 
denervated cat skeletal muscles where 
local intra-arterial infusion of 
different types of СЕВ induced an 
acute increase of transcapillary fluid 
filtration8. In this model nifedipine 
also interfered with the increase in 
vascular resistance that normally 
protects capillaries against an 
orthostatic load8, which could explain 
the preference for edema formation in 
the depending legs. In the human 
forearm, systemic administration of a 
dihydropyridine СЕВ also increased 
transcapillary fluid filtration9. Such 
increased fluid filtration could be due to an increase of intracapillary hydrostatic 
pressure following preferential dilation of small precapillary arterioles by 
СЕВ
1 1 , 1 2
. On the other hand, experiments in bilaterally nephrectomized rats have 
suggested that dihydropyridine СЕВ increase capillary permeability, because 
nicardipine but not the benzothiazepine diltiazem acutely increased hematocrit 
more than serum protein10. In these rats, nicardipine induced extravasation of 
Evans blue dye into skeletal muscle which also suggested an increase of 
capillary permeability for proteins10. 
In contrast to the changes with nifedipine, infusion of the PCO diazoxide was 
not followed by an increase of foot volume. This difference with nifedipine is 
-30% 
Figure 3. Mean relative changes of serum 
albumin, foot volume and fractional 
sodium excretion (FE,^) after placebo and 
the three active drugs. Ρ< 0.05 
compared to placebo (Wilcoxon's rank 
sum test). Error bars indicate SEM. 
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rather unexpected, because СЕВ and PCO dilate the same precapillary 
arterioles12,13 and thus should induce similar increases in intracapillary 
hydrostatic pressure. It can be questioned, however, whether this dose of 
diazoxide induced the same degree of peripheral vasodilation as nifedipine, 
because diazoxide hardly changed blood pressure and did not induce reflex 
tachycardia. Thus, it is possible that a higher dose of diazoxide would have led 
to different results. On the other hand, the difference with nifedipine might 
indicate that different mechanisms underlie edema formation with СЕВ and 
PCO, e.g. an increase of capillary permeability with СЕВ10 or primary sodium 
retention with PCO. 
The ACE inhibitor Captopril lowered blood pressure but, like diazoxide, did 
not change foot volume. This is not unexpected since ACE inhibitors do not 
cause edema14. These drugs probably do not induce a rise of hydrostatic 
pressure in the capillaries because of preferential dilation of larger arterioles15. 
Of note, both Captopril and nifedipine induced similar increases of natriuresis, 
but only nifedipine increased hemoglobin and serum albumin. This difference 
could easily be explained by a nifedipine-mediated redistribution of fluid out of 
the intravascular compartment into the interstitium as suggested by the foot 
swelling and in accordance with the aforementioned observations in anephric 
rats10. 
Since ankle edema with dihydropyridine СЕВ is the main long-term side 
effect of these otherwise well-tolerated and highly effective antihypertensive 
agents2, elucidation of the mechanism responsible for the edema could lead to 
successful therapeutic interventions. In a more empirical way, our device might 
be suited for testing such interventions in short term studies. If our method is 
used to study the long-term effect of different vasodilators on foot volume, a 
coefficient of variation of 1.3 % for day to day variability (unpublished 
observations) should be taken into account. 
In conclusion, nifedipine induced parallel increases of foot volume and 
sodium excretion in healthy volunteers, which supports the hypothesis that the 
development of ankle edema with dihydropyridine СЕВ is a local phenomenon 
and a direct consequence of peripheral vasodilation in the depending legs. In 
contrast to nifedipine, diazoxide infusion did not induce acute changes of foot 
volume but also hardly changed blood pressure. This could indicate that 
diazoxide did not induce enough vasodilation in these normal subjects or that 
different mechanisms underlie edema formation with PCO and СЕВ. Further 
studies are needed to elucidate the mechanisms responsible for the edema 
formation with PCO. 
ι?«; 
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Calcium entry blockers (СЕВ) with a dihydropyridine structure such as 
nifedipine and felodipine are potent arteriolar vasodilators with proven 
antihypertensive efficacy. Treatment with СЕВ is largely devoid of the 
compensatory reactions which have limited the use of other potent vasodila­
tors such as minoxidil. Dihydropyridine СЕВ induce only a modest, transient 
activation of the baroreceptor reflex and have a remarkable acute natriuretic 
effect. These properties make monotherapy feasible and СЕВ are nowadays 
one of the first-line choices for patients with hypertension. It is obvious that 
СЕВ owe their position for a considerable part to their natriuretic action 
which prompted us to study this effect in more detail. We have performed 
several renal clearance studies in healthy volunteers in an attempt to elucidate 
the mechanisms that are responsible for this natriuretic effect. Thereafter, we 
studied the natriuretic properties of СЕВ in hypertensive patients with renal 
disease, where such an effect might be of specific value. We also addressed 
the issue whether sodium restriction limits the natriuretic and/or hypotensive 
effects of СЕВ in patients with essential hypertension. Finally, we studied the 
CEB-induced ankle edema which is one of the major side effects of the 
dihydropyridines and a rather surprising phenomenon in view of the natriu­
retic effect of these drugs. 
Mechanisms of the natriuretic effect of СЕВ 
Renal hemodynamic effects. Early attempts to explain the natriuresis with 
СЕВ have concentrated on a possible relation with the renal vasodilating 
effects of these drugs, as reviewed by Romero1. Infusion of low, nonhypoten-
sive doses of vasodilators directly into the renal artery of experimental 
animals usually increases renal blood flow (RBF) and glomerular filtration 
rate (GFR). The increase of GFR increases tubular sodium load and the renal 
vasodilation decreases tubular sodium reabsorption in the proximal tubule or 
Henle's loop2. In this setting, it is not surprising to find an acute natriuresis. 
However, systemic administration of a vasodilator decreases blood pressure 
and, consequently, renal perfusion pressure which counteracts an increase of 
RBF. Under such circumstances, i.e. in the absence of an increase of GFR 
and RBF, СЕВ still induce natriuresis in animals3,4 which strongly supports a 
direct tubular site of action of these drugs. Micropuncture studies have 
localized this natriuretic effect of СЕВ to either the proximal5 or the distal6 
tubule. 
129 
Chapter 10 
In our studies in healthy volunteers, felodipine infusion never induced 
consistent changes of GFR in line with most other observations with СЕВ in 
man
7
. The natriuretic effect in humans must therefore be the consequence of 
reduced tubular sodium reabsorption. In the present studies, our indirect 
estimates of segmental tubular sodium reabsorption indicated decreases of 
both proximal and distal tubular sodium reabsorption with felodipine confir­
ming previous findings. In all our studies, felodipine, also at a relatively low 
dose, induced some renal vasodilation, which could explain part of the 
observed proximal tubular effect. It has been suggested that the CEB-media-
ted decrease in proximal tubular sodium reabsorption in humans can be 
ascribed fully to the renal vasodilation, because a very low oral dose of 
felodipine, which did not induce renal vasodilation, only decreased calculated 
distal tubular sodium reabsorption8. In contrast, however, another dihydro-
pyridine decreased proximal sodium reabsorption at a dose that did not 
induce any noticeable change of RBF9. Therefore, it seems likely that also in 
humans the distal and at least part of the proximal tubular effects of СЕВ are 
explained by factors other than renal hemodynamic changes. The possibility 
of redistribution of RBF to juxtamedullary nephrons favouring natriuresis 
cannot be assessed in humans, but is certainly not firmly supported by the 
available animal data 1 ( U 1. 
Interaction with sodium retaining hormones. Previously, we demonstrated 
that felodipine prevented the sodium retention on exogenous angiotensin II 
(Ang II)12. Thus, the question arose whether the natriuretic effect of СЕВ 
was merely the consequence of inhibition of the renal sodium retaining effect 
of endogenous Ang II. In such a case, СЕВ should no longer induce natriu­
resis if endogenous Ang II were absent. However, to our disappointment, 
powerful suppression of endogenous Ang-II production with the angiotensin 
converting enzyme inhibitor ramipril certainly did not prevent the natriuresis 
caused by felodipine. Our data did not exclude that ramipril slightly inhibited 
the natriuretic effect of felodipine and especially its effect on proximal 
tubular sodium reabsorption, but such an inhibition, if any, was probably due 
to the blood pressure lowering effect of ramipril. Thus, most of the natriure­
tic effect of dihydropyridine СЕВ cannot be ascribed to an interaction with 
endogenous Ang II. How can these data be reconciled with our previous 
study, where the interaction between exogenous Ang II and felodipine had 
been so prominent ? This question prompted us to reevaluate our study with 
exogenous Ang II. As discussed in chapter 2, the clue for the discrepancy 
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might be found in the systemic effects of intravenously administered Ang II 
and especially the rise of systemic blood pressure. This will lead to reflex 
preglomerular vasoconstriction which could be partly responsible for the 
sodium retaining effect of exogenous Ang II. Such a reflex myogenic 
vasoconstriction is very susceptible to СЕВ. Thus, felodipine might have 
prevented sodium retention with exogenous Ang II by its effect on preglo­
merular vasoconstriction and without interfering with the renal tubular effects 
of Ang IL 
Felodipine did not prevent a decrease in urinary sodium excretion induced 
by infusion of exogenous aldosterone. Hence, it is unlikely that the natriure­
tic effect of СЕВ is due to inhibition of the effects of aldosterone. However, 
since СЕВ do not counteract the effects of aldosterone, the absence of a rise 
in aldosterone during treatment with СЕВ could contribute to their natriuretic 
effect. Indeed, the natriuretic effect of felodipine appeared to be slightly 
attenuated in the setting of elevated endogenous aldosterone levels following 
metoclopramide administration (see following section). 
We did not study a possible interaction between norepinephrine and СЕВ, 
but the available animal data do not suggest an important role for such an 
interaction in the natriuretic effect, because СЕВ did not affect the antinatri-
uresis induced by low frequency renal nerve stimulation in normotensive 
rats13·14. 
Distal tubular effects. The natriuretic effect of СЕВ is, in contrast to most 
diuretics, not accompanied by an increase in urinary potassium excretion. 
This beneficial effect could be due to a CEB-mediated inhibition of aldoste­
rone release which is responsible for the generally observed dissociation 
between an elevated plasma renin activity and unchanged plasma aldosterone 
concentration (РАС) during treatment with dihydropyridines. Indeed we 
could clearly demonstrate that infusion of exogenous aldosterone during 
felodipine not only attenuated the natriuretic effect but was followed by a 
major increase of potassium excretion. The kaliuretic effect of aldosterone 
was much more pronounced in the setting of concomitant felodipine infusion 
than during placebo, which can be explained by a felodipine-mediated 
increase of sodium and fluid delivery to distal tubular sites. Although these 
data do not exclude the possibility of another effect of СЕВ on distal tubular 
sodium reabsorption, which is the drive for potassium secretion, they 
certainly indicate that СЕВ will induce urinary potassium losses if sufficient 
amounts of aldosterone are present during treatment. The results of this study 
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could be criticized because of the relatively high, almost supraphysiological 
PAC, but our observations with metoclopramide and felodipine nicely 
confirmed our conclusions. Dopaminergic receptor blockade with metoclop­
ramide induces endogenous aldosterone release and in this setting of a 
physiologic elevation of PAC, infusion of felodipine was followed by an 
immediate increase of urinary potassium excretion. In our hypertensive 
patients, however, the elevated PAC after one week of dietary sodium 
restriction did not lead to kaliuresis (see chapter 7). In this study, PAC 
rapidly fell to normal levels after administration of felodipine in contrast to 
our study with metoclopramide. Therefore, PAC has to remain elevated 
during felodipine in order to induce kaliuresis. 
Interaction with intrarenal natriuretic hormones. Selective administration 
of а СЕВ into the renal artery increases natriuresis4. This suggests that the 
natriuretic effect could be the consequence of an interaction with intrarenal 
natriuretic systems such as the dopaminergic and prostaglandin systems, 
whereas it makes it unlikely that an increased secretion of atrial natriuretic 
peptide plays a major role. In hypertensive rats, blockade of either the 
dopaminergic or the prostaglandin system attenuated the natriuresis with 
СЕВ
15
. However, very high drug doses were used resulting in very large 
changes of blood pressure, which makes it hazardous to translate these data 
to the human situation. Indeed, in our human volunteers, effective dopami­
nergic receptor blockade with metoclopramide did not affect the natriuresis 
with felodipine and in another study in humans, the prostaglandin synthetase 
inhibitor indomethacin did not influence the natriuretic action of oral felodi­
pine16. Moreover, in our volunteers, benserazide, a dopa-decarboxylase 
inhibitor which prevents the intrarenal conversion of inactive dopa to active 
dopamine also failed to attenuate the natriuresis of felodipine17. Taken 
together, these data make it unlikely that, at least in normotensive humans, 
these intrarenal natriuretic systems play any role in the natriuretic action of 
СЕВ. 
Some future perspectives. It is clear from the preceding paragraphs that we 
are still awaiting a satisfactory explanation for the natriuretic effects of СЕВ. 
One of the intriguing questions which remains to be answered is whether the 
natriuretic action of these chemically heterogeneous drugs can be ascribed to 
direct inhibition of tubular sodium reabsorption by blockade of the voltage 
operated calcium channels in tubular cells. The fact that a decrease in 
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cytosolic calcium, such as induced by СЕВ, is expected to enhance instead of 
decrease tubular sodium reabsorption has cast doubt on such a direct link1. 
However, it has been demonstrated recently that TMB-8, an inhibitor of 
intracellular calcium release, also induced natriuresis18. Since most СЕВ are 
chiral compounds with the calcium channel blocking ability residing in one of 
the enantiomers19, comparison of the natriuretic effects of the two enantio-
mers might clarify the relation between calcium channel blockade and 
natriuresis. 
If other effects than calcium channel blockade were responsible for the 
natriuresis with СЕВ, blockade of renal Aj adenosine receptors by СЕВ 
could be considered because the renal effects of A1 receptor antagonists
20 
show much resemblance with the effects of СЕВ. Moreover, dihydropyridine 
СЕВ, albeit at high dose, can displace A{ receptor antagonists from their 
receptors21. 
Natriuretic effects in hypertensive patients 
Effects in patients with renal disease. Felodipine infusion induced natriu­
resis in our hypertensive patients with renal disease, which was quite remar­
kable in view of the large blood pressure reduction in this study. Thus, СЕВ 
also lack sodium retaining effects in this category of patients, which can be 
difficult to treat and often need a vasodilator. However, the natriuretic effect 
was smaller than in our normotensive volunteers and appeared to be less with 
more pronounced renal dysfunction. СЕВ apparently do not correct the 
increased sodium and water retention which is directly involved in inducing 
and sustaining hypertension in many patients with renal disease, especially 
those with severe renal insufficiency. It is therefore unlikely that СЕВ per se 
will reduce the need for diuretics in most of these patients. 
Effects at different salt intakes. It has been suggested that СЕВ reduce 
blood pressure more effectively at higher salt intakes, which might be 
ascribed to a larger natriuretic effect. In our outpatients with essential 
hypertension, felodipine induced a greater acute sodium loss during a salt 
supplemented diet than during moderate sodium restriction, but this did not 
lead to a larger hypotensive response. Moreover, although felodipine appea­
red to neutralize the diet-induced difference in intravascular volume, this 
again was not translated into a larger reduction of blood pressure during the 
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salt supplemented diet. We also demonstrated that the diet-induced 5 mm Hg 
difference in mean arterial pressure was preserved during felodipine and that 
the lowest blood pressure was reached with felodipine during salt restriction, 
in line with other studies. The question thus arises whether the reported 
higher effectiveness of СЕВ at high salt intake is not merely an artificial 
phenomenon, because the studies demonstrating it were performed at extre­
mes of salt intake with large differences in blood pressure before administra­
tion of the СЕВ. The much higher blood pressure with high salt intake thus 
enabled a larger hypotensive response, which is not really surprising since 
the fall in blood pressure with any agent depends directly on the pretreatment 
level. Patients are not likely to benefit from such a larger hypotensive 
response if the final blood pressure remains higher than with а СЕВ and 
sodium restriction. Furthermore, the combination of felodipine and high salt 
intake led to higher foot volumes and visible edema in several patients (see 
next paragraph). We therefore would not advise unrestricted salt intake 
during treatment with а СЕВ. 
Edema formation with СЕВ 
In view of the natriuretic effect of СЕВ, it is surprising that ankle edema is 
one of the main long-term side effects of dihydropyridines. To study the 
process of edema formation in more detail, reliable estimates of foot volume 
were needed. We therefore tested the accuracy of a new simple method, 
which uses a sensitive balance to measure the force needed for immersion of 
the foot in a water-bath. The method proved to be accurate with a coefficient 
of variation of 0.30 % for repeated measurements within a few minutes. 
Biological changes could be demonstrated easily and were probably respon­
sible for the larger day to day variability of foot volume of 1.31 %. With this 
method, we studied the acute effects of several vasodilators on foot volume 
in healthy sedentary volunteers. Diazoxide and Captopril did not change foot 
volume, whereas nifedipine induced an acute increase at the time when 
urinary sodium excretion was also increased. This increase of foot volume 
with nifedipine thus cannot be ascribed to sodium retention which supports 
the hypothesis that ankle edema with СЕВ is a local phenomenon at the site 
of vasodilation. Foot volume apparently increases only when an orthostatic 
load is present, since felodipine did not induce acute changes in our supine 
hypertensive patients (see chapter 7). 
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As ankle edema with СЕВ is not due to sodium retention, it might be 
speculated that treatment with diuretics and dietary sodium restriction are less 
effective than in other edematous states. Indeed, in preliminary studies, 
addition of frusemide to nifedipine did not prevent the acute increase of foot 
volume in our sedentary volunteers. In apparent contrast, less edema was 
observed in our hypertensive patients when felodipine was administered 
during the sodium restricted diet. However, a diet-induced difference in foot 
volume was already present before the start of felodipine. 
It has been suggested that edema formation with a dihydropyridine СЕВ 
can be prevented by an angiotensin converting enzyme (ACE) inhibitor22. 
However, in preliminary studies in sedentary volunteers, we observed only a 
slight insignificant effect of the ACE inhibitor ramipril on the acute increase 
of foot volume with nifedipine. Further long-term studies in patients are 
needed to find effective therapeutic measures for the edema with СЕВ. 
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Samenvatting 
Voor de behandeling van hoge bloeddruk (hypertensie) zijn tegenwoordig 
vele soorten geneesmiddelen beschikbaar. Aangezien hypertensie vrijwel 
steeds gekenmerkt wordt door vernauwing van de weerstandsbloedvaten lijkt 
het logisch de voorkeur te geven aan de zogenaamde vaatverwijders. De 
klassieke vaatverwijders hebben echter als nadeel dat zij een compensatoire 
versnelling van de hartslag en zoutretentie door de nier veroorzaken, waar-
door hun effect althans deels teniet gedaan wordt. Calcium instroom remmers 
(CaIR) zijn een chemisch heterogene groep stoffen die de instroom van 
calcium in de gladde spiercel van de bloedvaten remmen en zodoende 
bloedvatverwijding bewerkstelligen. Vooral CaIR met een dihydropyridine 
structuur zoals nifedipine en felodipine zijn krachtige vaatverwijders die in 
tegenstelling tot de klassieke vaatverwijders slechts een matige, passagère 
versnelling van de hartslag veroorzaken. Bovendien geven CaIR geen 
zoutretentie, maar juist een toegenomen zoutuitscheiding door de nieren 
(natriurese). Door het grotendeels ontbreken van compensatoire reacties zijn 
de CaIR één van de eerstelijns keuzen geworden voor de behandeling van 
hypertensie. In dit proefschrift zijn de natriuretische eigenschappen van 
dihydropyridine CaIR nader bestudeerd. 
Mechanisme van het natriuretische effect van CaIR 
Effecten op de nierdoorstroming. CaIR veroorzaken niet alleen verwijding 
van de weerstandsbloedvaten maar ook van de bloedvaten in de nier. Daar-
door kan toediening van een CaIR in de slagader van de nier de nierdoor-
stroming doen toenemen met natriurese als gevolg. Echter, bij toediening van 
een CaIR in de aders (intraveneus) of in de vorm van tabletten zal tevens de 
bloeddruk dalen waardoor de toename van de nierdoorstroming wordt 
tegengegaan. In dergelijke gevallen veroorzaken CaIR nog steeds natriurese 
zodat het onwaarschijnlijk is dat bloedvatverwijding in de nier de natriureti-
sche eigenschappen van CaIR volledig kan verklaren. 
In overeenstemming met andere onderzoekers vonden wij bij gezonde 
vrijwilligers na toediening van de CaIR felodipine géén toename van filtratie 
van bloed in de nier (glomerulusfiltratie) zodat we moeten aannemen dat het 
natriuretische effect van CaIR berust op verminderde zoutopname (natrium-
reabsorptie) in de nierbuisjes (tubuli). Verder vonden wij aanwijzingen dat de 
natriumreabsorptie zowel in het begin (proximaal) als ook aan het einde 
(distaal) van de tubuli verminderd is. Een deel van het proximale tubulaire 
effect in onze studies zou verklaard kunnen worden door enige toename van 
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de nierdoorstroming, die ook bij toediening van een relatief lage dosis 
felodipine steeds werd waargenomen. 
Interactie met natriumretinerende hormonen. Natriumretinerende hormonen 
zoals angiotensine-II en aldosteron zijn van nature aanwezig en beschermen 
de mens o.a. tegen overmatig zoutverlies via de nieren. Het natriuretische 
effect van CaIR zou kunnen berusten op blokkade van de werking van zo'n 
natriumretinerend hormoon. 
In voorgaand onderzoek op onze afdeling is aangetoond dat felodipine de 
natriumretentie door intraveneus toegediend angiotensine-II voorkomt. Wij 
hebben derhalve onderzocht of felodipine nog steeds natriurese veroorzaakt 
als het natuurlijke angiotensine-II onderdrukt wordt door een zogenaamde 
ACE-remmer, die de omzetting van inactief angiotensine-I in actief angioten-
sine-II blokkeert. Tegen onze verwachting in bleek de ACE-remmer ramipril 
het natriuretische effect van felodipine echter niet te voorkomen, zodat het 
natriuretische effect van CaIR niet verklaard kan worden door een interactie 
met natuurlijk angiotensine-II. De discrepantie met onze eerder studie kan 
mogelijk toegeschreven worden aan het bloeddruk verhogende effect van 
intraveneus toegediend angiotensine-II. Hierdoor kan vernauwing van de 
bloedvaten in de nier ontstaan die zeer gevoelig is voor CaIR. Zodoende 
zouden CaIR de natriumretentie door intraveneus angiotensine-II kunnen 
voorkomen zonder specifieke interactie in de nier. 
Felodipine bleek het natriumretinerende effect van intraveneus toegediend 
aldosteron niet tegen te gaan, waardoor het onwaarschijnlijk is dat het natriu-
retische effect van CaIR berust op een interactie met natuurlijk aldosteron. 
Distale tubulaire effecten. In tegenstelling tot de bevindingen met de 
meeste plaspillen (diuretica) wordt het natriuretische effect van CaIR niet 
begeleid door een toename van kaliumuitscheiding. Dit op zich gunstige 
effect van CaIR zou een gevolg kunnen zijn van remming van aldosteronaf-
gifte uit de bijnier door CaIR. Wij konden inderdaad aantonen dat intrave-
neus aldosteron niet alleen het natriuretische effect van felodipine remde 
maar tevens een belangrijke toename van de kaliumuitscheiding veroorzaakte. 
Deze bevindingen werden vervolgens bevestigd door onze studie met meto-
clopramide en felodipine. Metoclopramide blokkeert de dopamine receptor 
(zie volgende paragraaf) in o.a. de bijnier en veroorzaakt daardoor een 
verhoogde afgifte van natuurlijk aldosteron. Onder deze omstandigheden 
bleek felodipine ook een toename van de kaliumuitscheiding te bewerkstelli-
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gen. Alhoewel het niet uitgesloten is dat CaIR nog andere effecten hebben op 
de distale natriumreabsorptie en kaliumuitscheiding tonen onze onderzoeken 
aan dat CaIR kaliumverlies via de nier zullen veroorzaken als er voldoende 
aldosteron aanwezig is. De remming van aldosteronafgifte uit de bijnier door 
CaIR draagt derhalve in belangrijke mate bij aan de gunstige combinatie van 
natriurese zonder toegenomen kaliumuitscheiding tijdens gebruik van CaIR. 
Interactie met natriuretische hormonen. Natriuretische hormonen zoals 
dopamine zijn van nature in de nier aanwezig en dragen bij aan de verhoogde 
zoutuitscheiding die bijvoorbeeld volgt op een verhoogde zoutinname via de 
voeding. Het natriuretische effect van CaIR zou kunnen berusten op stimula-
tie van de dopamine produktie of versterking van het dopamine effect. 
Blokkade van de dopamine receptor met metoclopramide bleek echter de 
natriurese door felodipine niet te beïnvloeden, zodat het onwaarschijnlijk is 
dat het dopamine systeem een belangrijke rol speelt bij de natriuretische 
werking van CaIR. 
Natriuretische effecten bij patiënten met hypertensie 
Effecten bij hypertensieve patiënten met nierziekten. In deze groep patiën-
ten wordt de hypertensie veelal veroorzaakt door toegenomen zout- en 
waterretentie, vooral bij slechte nierfunctie. Felodipine bleek ook bij deze 
patiënten een toename van de zoutuitscheiding te veroorzaken ondanks een 
gelijktijdige sterke daling van de bloeddruk. CaIR missen dus ook hier het 
zoutretinerende effect van andere vaatverwijders, hetgeen van groot belang is 
aangezien dit soort patiënten vaak een vaatverwijder nodig heeft voor hun 
veelal moeilijk te behandelen hypertensie. Het natriuretische effect van 
felodipine bleek echter geringer dan in onze vrijwilligers, vooral bij patiënten 
met slechte nierfunctie. Het is dan ook onwaarschijnlijk dat CaIR de toege-
nomen zout- en waterretentie bij deze patiënten corrigeren en daarmee de 
behoefte aan diuretica zouden verminderen. 
Effecten bij verschillende zoutinname. Enkele onderzoekers hebben gesug-
gereerd dat CaIR de bloeddruk sterker doen dalen bij verhoogde zoutinname 
via de voeding. Een dergelijke eigenschap van CaIR zou toegeschreven 
kunnen worden aan een sterker natriuretisch effect in deze situatie. In onze 
poliklinische patiënten met hypertensie bleek felodipine weliswaar acuut een 
groter zoutverlies te geven bij hogere zoutinname, maar dit werd niet gevolgd 
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door een sterkere bloeddrukdaling. Ook het bloeddruk verlagende effect van 
een week behandeling met felodipine was vergelijkbaar bij hoge en lage 
zoutinname. Het gunstige bloeddrukverlagende effect van zoutbeperking 
bleek aldus behouden te blijven tijdens felodipine zodat de laagste bloeddruk 
gevonden werd tijdens felodipine en een zoutbeperkt dieet. Bovendien kregen 
enkele patiënten alleen in de periode met hoge zoutinname dikke enkels 
(oedeem) na het gebruik van felodipine (zie volgende paragraaf). Op basis 
van deze gegevens zouden wij dan ook willen adviseren om overmatige 
zoutinname tijdens behandeling met een CaIR te vermijden. 
Oedeemvorming tijdens behandeling met CaIR. 
In veel gevallen is oedeemvorming aan de enkels een gevolg van toege-
nomen zout- en vochtretentie door de nieren. Ondanks de evidente natriure-
tische eigenschappen van CaIR blijkt enkeloedeem verrassend genoeg een van 
de belangrijkste bijwerkingen van behandeling met dihydropyridine CaIR 
zoals nifedipine. Om het proces van oedeemvorming nader te bestuderen rees 
de behoefte aan een betrouwbare maat voor de hoeveelheid oedeem. Wij 
hebben derhalve een nieuwe, simpele methode voor de bepaling van het 
voetvolume uitgetest. Hierbij wordt gebruik gemaakt van een gevoelige 
weegschaal die de kracht meet die nodig is voor onderdompeling van de voet 
in een waterbak. Deze methode bleek nauwkeurig het voetvolume te bepalen 
met een variatiecoëfficient van 0.30 % voor herhaalde metingen. Biologische 
veranderingen van het voetvolume konden gemakkelijk aangetoond worden 
en waren waarschijnlijk verantwoordelijk voor de grotere dag tot dag variatie 
van 1.31 %. 
In gezonde, zittende vrijwilligers hebben wij met de bovenstaande methode 
het acute effect van enkele vaatverwijders op het voetvolume bestudeerd. De 
klassieke vaatverwijder diazoxide had in de door ons gebruikte dosering géén 
acuut effect op het voetvolume. Nifedipine daarentegen bleek het voetvolume 
acuut te vergroten in de fase dat er sprake was van een verhoogde zoutuit-
scheiding door de nier. Deze bevindingen passen bij de veronderstelling dat 
oedeemvorming tijdens het gebruik van dihydropyridine CaIR berust op een 
lokaal effect en een direkt gevolg is van de vaatverwijding. In de bovenge-
noemde patiënten met hypertensie bleek oedeemvorming na felodipine 
weliswaar alleen op te treden in de periode met hoge zoutinname, maar dit 
hield verband met de verschillen in voetvolume die door het dieet veroor-
zaakt waren vóór de start van de behandeling met felodipine. 
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1. Het natriuretische effect van dihydropyridine calcium instroom remmers 
kan niet verklaard worden uit een interactie met endogeen angiotensine II 
of het dopaminerge systeem. 
2. Omdat dihydropyridine calcium instroom remmers een stijging van de 
aldosteronspiegel voorkomen gaat het natriuretische effect van deze mid-
delen niet gepaard met overmatig kaliumverlies via de urine. 
3. Mede dankzij hun natriuretische effect zijn calcium instroom remmers een 
goede keus voor de behandeling van hypertensie bij patiënten met nier-
insufficiëntie. 
4. Met het oog op de uiteindelijk te bereiken bloeddruk en de kans op oe-
deemvorming is onbeperkte zoutinname tijdens behandeling met een 
dihydropyridine calcium instroom remmer af te raden. 
5. Oedeemvorming tijdens behandeling met een dihydropyridine calcium 
instroom remmer berust op een lokaal fenomeen in de afhangende onder-
ste extremiteiten. 
6. Gezien de toename van het voetvolume in de loop van de dag is het 
raadzaam om schoenen pas 's middags aan te schaffen. 
7. Bij niertransplantatiepatiënten, bij wie de eigen nieren verwijderd zijn, is 
het weinig zinvol om een jS-blokker te gebruiken voor de behandeling van 
hypertensie. 
8. Bij onbegrepen natriumretentie bij een niertransplantatiepatient dient niet 
alleen een sténose in de transplantaatarterie maar ook een Stenose in de 
arteria iliaca, proximaal van de anastomose, uitgesloten te worden. 
9. "Science is always wrong: it never solves a problem without creating ten 
more". (G.B. Shaw, 1856-1950) 
10. De gezinssamenstelling van een promovendus kan men veelal afleiden uil 
de personen aan wie het proefschrift opgedragen is. 
11. Er bestaat waarschijnlijk een sterke positieve correlatie tussen de prijs in 
een bepaalde winkel en het aantal creditcards waarmee men daar kan 
betalen. 
12. Het opschrift "vertrouwelijk" op verzamelbakken voor oud papier maakt 
het riskant om werkelijk vertrouwelijke informatie, die vernietigd moet 
worden, daarin te verzamelen. 



